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ABSTRACT 
Whole transcriptome analysis of the human genome has revealed that the majority of the genome 
gives rise to non-protein-encoding or simply non-coding RNAs (ncRNAs). Long non-coding RNAs 
(lncRNAs) ranging from 200 nt to >100 kb represent a large subgroup of ncRNAs. They have emerged 
as critical players for not only regulating various physiological and developmental processes but also 
various cancers including liver cancer. Global cancer statistics report of 2018 has shown liver cancer 
to be the fourth leading cause of cancer-related deaths worldwide and has predicted it to be the 
sixth most commonly diagnosed cancer. Notably, advanced stage liver cancer has a poor overall 
survival rate of less than 20 % - thus warranting further investigations into the understanding of 
molecular mechanisms driving hepatocarcinogenesis, contributing to the discovery of improved 
diagnostic, prognostic and  treatment modalities. 
Here, I performed a transcriptome-wide profiling of lncRNAs in liver cancer and identified a novel 
lncRNA, which I named lincNMR (long intergenic non-coding RNA - Nucleotide Metabolism 
Regulator). LincNMR was induced six-fold in hepatocellular carcinoma compared to normal liver 
tissue. Depletion of lincNMR in multiple liver cancer cell lines invoked a strong proliferation defect 
and lead to an induction of senescence. This phenotype was also observed in multiple breast and 
lung cancer cell lines suggesting cancer-wide role of lincNMR. Silencing of lincNMR caused a strong 
depletion of the key dNTP synthesizing enzymes RRM2, TK1 and TYMS implicating lincNMR in 
regulation of nucleotide metabolism. Notably, dNTP levels were significantly decreased in liver 
cancer cells upon the loss of lincNMR. Importantly, the proliferation defect induced by 
downregulation of lincNMR could be rescued by bathing the cells in exogenous pools of extracellular 
dNTPs. An in vivo RNA Antisense Purification combined with mass spectrometry (RAP-MS) approach 
identified YBX1 as a direct interaction partner of lincNMR. Furthermore, I show YBX1 as a regulator 
of RRM2, TK1 and TYMS gene expression and found lincNMR to control the transactivational activity 
of YBX1 as measured in luciferase assays. Lastly, I established the relevance of lincNMR for tumor 
growth in vivo using the Chick Chorioallantoic Membrane (CAM) model. LincNMR-depleted tumors 
were significantly smaller in size and weight. In summary, I discovered a novel lncRNA, lincNMR, 
which regulates tumor cell proliferation through a YBX1-RRM2-TK1-TYMS axis governing nucleotide 
metabolism. 
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ZUSAMMENFASSUNG 
Die vollständige Transkriptomanalyse des menschlichen Genoms erwies, dass ein Großteil des 
Genoms zu nicht-proteinkodierenden beziehungsweise nicht-kodierenden RNAs (ncRNAs) 
umgeschrieben wird. Lange, nicht-kodierende RNAs (lncRNAs) im Bereich von 200 nt bis >100 kb 
stellen eine große Untergruppe von ncRNAs dar. Sie sind nicht nur wichtige Akteure in 
verschiedenen physiologischen und entwicklungsbezogenen Prozessen, sondern auch Regulatoren 
verschiedener Krebsarten, wie Leberkrebs. Der globale Krebsstatistikbericht von 2018 hat gezeigt, 
dass Leberkrebs die vierthäufigste Ursache für krebsbedingte Todesfälle weltweit, sowie die 
sechsthäufigste diagnostizierte Krebsart ist. Zudem weist Leberkrebs im fortgeschrittenen Stadium 
eine sehr niedrige Gesamtüberlebensrate von weniger als 20 % auf. Dies rechtfertigt weitere 
Untersuchungen zum Verständnis der molekularen Mechanismen, welche die Hepatokarzinogenese 
antreiben. Die daraus gewonnenen Erkenntnisse tragen zur Entdeckung verbesserter Diagnose- 
Prognose- und Behandlungsmethoden bei.  
In der vorliegenden Arbeit habe ich eine Transkriptomprofilierung von lncRNAs in Leberkrebs 
durchgeführt und eine neue lncRNA identifiziert, die ich lincNMR (long intergenic non-coding RNA-
Nucleotide Metabolism Regulator) genannt habe. LincNMR lag im hepatozellulären Karzinom im 
Vergleich zu normalem Lebergewebe sechsfach induziert vor. Die Depletion von lincNMR 
verursachte einen starken Proliferationsdefekt in diversen Leberkrebszelllinien und führte zu einer 
Induktion der Seneszenz. Dieser Phänotyp wurde auch in mehreren Brust- und Lungenkrebszelllinien 
beobachtet, was auf eine krebsweite Rolle von lincNMR hindeutet. Die Stilllegung von lincNMR 
führte zu einer starken Abnahme der wichtigsten dNTP-synthetisierenden Enzyme RRM2, TK1 und 
TYMS. Dies impliziert eine Regulation des Nukleotidstoffwechsels durch lincNMR. Insbesondere 
waren die dNTP-Spiegel in Leberkrebszellen nach dem Verlust von lincNMR signifikant gesenkt. 
Hervorzuheben ist, dass der durch die Runterregulierung von lincNMR induzierte 
Proliferationsdefekt durch Zugabe von extrazellulären dNTPs zu den Zellen aufgehoben werden 
konnte. Eine Kombination aus in vivo RNA Antisense Aufreinigung und Massenspektrometrie (RAP-
MS) identifizierte YBX1 als direkten Interaktionspartner von lincNMR. Zudem zeige ich, dass YBX1 die 
Genexpression von RRM2, TK1 und TYMS reguliert. Dass wiederum lincNMR die 
Transaktivierungsaktivität von YBX1 steuert, erwies die Durchführung eines Luciferase-Assays. 
Schließlich untersuchte ich die Relevanz von lincNMR für das Tumorwachstum in vivo mittels eines 
Hühnerei-Chorion-Allantoic-Membran (CAM)-Tests. Größe und Gewicht von lincNMR-depletierten 
Tumoren waren im Vergleich zu nicht-depletierten Tumoren signifikant reduziert. Zusammenfassend 
 xiv 
 
habe ich eine neuartige lncRNA, lincNMR, entdeckt, welche die Proliferation von Tumorzellen über 
die nukleotidstoffwechselsteuernde YBX1-RRM2-TK1-TYMS-Achse reguliert.  
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1. INTRODUCTION 
Since this project mainly investigates liver cancer, I start by introducing this disease with a focus on risk 
factors, pathology including current diagnostic, prognostic and treatment modalities. As the second 
major topic of this project is the function of non-coding RNAs, I delve into our understanding of their 
role and relevance in health and diseases including in liver cancer and their potential to regulate 
multiple hallmarks of cancer including cell proliferation. Lastly, I provide an overview of nucleotide 
metabolism pathways in the context of cancer cell proliferation and cellular senescence.  
1.1 Liver Cancer 
1.1.1 Epidemiology 
Liver cancer is the fourth leading cause of cancer related deaths worldwide and is predicted to be the 
sixth most commonly diagnosed cancer in 2018 [1]. Almost 800,000 new cases are being reported every 
year making it the fifth most commonly diagnosed cancer in men and ninth in women. It  is more 
prevalent in males as compared to females due to a more pronounced inflammatory response [2]. Liver 
cancer comprises of multiple malignancies like hepatocellular carcinoma (HCC), cholangiocarcinoma 
(intrahepatic bile duct sarcoma) and hepatoblastoma [3, 4]. Of all liver cancers diagnosed, HCC accounts 
for 75 % - 85 % of the cases followed by cholangiocarcinoma. Although the five year overall survival of 
HCC patients has improved over the last years, it is still not better than 20% [2, 5].  
1.1.2 Risk factors  
Major risk factors contributing to hepatocarcinogenesis include increased alcohol intake, liver cirrhosis, 
obesity, diabetes, infection with hepatitis B and C viruses (HBV and HCV) and exposure to aflatoxins. In 
80 % – 90 % of patients, chronic liver disease and cirrhosis are the underlying causes of progression to 
hepatocarcinogenesis [2]. Over a half of the reported global HCC cases are attributed to an HBV 
infection with a prevalence in Asia and Africa whereas about 30% of global HCC cases are due to only 
HCV infection with highest incidences in northern and middle Africa [6]. Obesity and type-2 diabetes are 
strongly associated with development of non-alcoholic fatty liver disease (NAFLD) which can progress 
into Nonalcoholic steatohepatitis (NASH) and cirrhosis which eventually progresses into HCC [7]. In 
western countries, up to 50 % of the reported HCC cases are attributed to alcohol abuse where up to 38 
% are due to NAFLD [7, 8]. Other reported risk factors for HCC include hemochromatosis, α-1 antitrypsin 
deficiency and Wilson’s disease [9].  
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1.1.3 Pathogenesis 
Hepatocarcinogenesis is a complex multistep process in which a chronic liver injury leads to 
development of cirrhotic liver which further eventually progresses into liver cancer. Cirrhotic liver 
consists of dead tissue incapable of regeneration, which is a major factor in hepatocyte turnover in 
otherwise healthy liver [6]. Continuous liver damage as a result of increased deposition of fibrous tissue 
contributes to disturbed liver architecture as well as function [10]. Overall, malignant transformation is a 
long process that takes up to 30 years or more from cirrhotic liver to formation of dysplastic nodules and 
eventually to HCC.  
1.1.4 Diagnosis, prognosis and treatment 
As per the American Association for the Study of Liver Diseases (AASLD) guidelines, initial diagnosis of 
HCC is based on elevated serum levels of α-fetoprotein (AFP), radiological tests and a biopsy. Recent 
studies have shown insufficiency of AFP levels for HCC diagnosis because AFP levels are also elevated in 
intrahepatic cholangiocarcinoma as well as in some cases of metastasized colon cancer [11, 12]. Due to 
limitations in diagnostic modalities, HCC is often diagnosed in advanced stage when patients are already 
symptomatic and liver function is significantly impaired, which strongly contributes to a poor five year 
overall survival rate of less than 20%. Treatment of HCC is decided based on the tumor grade, number of 
nodules and the degree of liver function impairment. Most well established systemic strategies for 
cancer treatment fail to be effective in the terminal stage of HCC and are primarily used as a palliative 
course of treatment. Due to the challenges discussed above, course of treatment for HCC remains 
limited to loco-regional procedures such as partial liver resection, tumor ablation and liver 
transplantation [13, 14]. At the moment, the only FDA approved primary line of treatment for terminal 
stage HCC is a multi-kinase inhibitor Sorafenib (Nexavar) which improves average survival of patients 
from 7.9 to 10.7 months with manageable side-effects [15, 16]. Sorafenib functions by inhibiting 
angiogenesis, proliferation, migration and resistance to apoptosis by targeting the Ras-Raf-MAP2K-
MAPK pathway [16]. Recently, a multi-kinase inhibitor Regorafenib, normally used for the treatment of 
gastrointestinal and colorectal cancer, demonstrated a survival benefit in HCC patients and thus was 
approved as a second line of therapy for HCC [17, 18].  
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1.2 Non-coding RNAs 
1.2.1 Background and discovery 
In 1958, Francis Crick proposed that genetic information flows from DNA to RNA, which serves as a 
template for translation into proteins [19]. This was defined to be the central dogma of molecular 
biology. Later in 1961, Jacob and Monod demonstrated the need of an RNA intermediate which was 
termed messenger RNA or mRNA. Although according to central dogma of molecular biology, RNA was 
simply a messenger molecule translating genetic information from DNA to proteins, it quickly became 
evident that not all RNA molecules acted as messenger RNAs and coded for proteins. Early work from 
the Zamenick lab demonstrated that RNA was involved in protein synthesis not as a messenger molecule 
but as an adaptor molecule for amino acids which were later called transfer RNAs (tRNAs) [20]. Similarly, 
a link between rRNAs and ribosomes was also established around the same time [21]. These were the 
first RNA molecules with non-protein-coding functions. Following the discovery of rRNAs and tRNAs, 
several other groups of small RNAs such as small nuclear RNAs (snRNAs) and small nucleolar RNAs 
(snoRNAs) were discovered. snRNAs play a role in RNA splicing [22, 23] whereas snoRNAs are involved in 
rRNA processing [24]. After the discovery of ribozymes it was abundantly clear that RNAs were 
functionally involved in roles other than protein synthesis [25, 26].  Subsequently, next generation 
sequencing (NGS) technologies revealed that the majority of the genome gave rise to non-protein-
coding transcriptome or simply non-coding RNAs (ncRNAs) [27]. These non-coding RNAs could be 
divided into two major groups by virtue of their length - small and long RNA non-coding RNAs. The most 
extensively studied group of small non-coding RNA molecules are microRNAs (miRNAs), which are 20 - 
22 nt in length and depending on the degree of complementarity to their miRNA binding site regulate 
the expression of their target RNA through the RNA-induced silencing complex (RISC) by either 
degrading the RNA or by inhibiting their translation into proteins, thus regulating post transcriptional 
gene expression using the RNA interference mechanism (RNAi) [28, 29]. In contrast to miRNAs, long non-
coding RNAs (lncRNAs) are a highly heterogeneous class of biomolecules and function via different 
mechanisms upon interaction with not only RNA but also with DNA and proteins.  
1.2.2 Long non-coding RNAs – classification 
Long non-coding RNAs are defined as RNA molecules longer than 200 bases in length with minimal or no 
protein coding potential and more aptly can be defined as RNA transcripts that are functional as RNAs 
beyond translation and do not belong to any other non-coding RNA groups such as small (miRNA, piRNA, 
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snoRNA), functional or structural RNAs (tRNA, rRNA, snRNA) [27]. Other than being classified by length, 
lncRNAs can also further be grouped into sense, antisense, bidirectional, intergenic or intronic 
transcripts based on the genomic orientation of the nearest protein-coding gene [27, 30-32]. LncRNAs 
transcribed from intergenic regions are called long intergenic non-coding RNAs (lincRNAs) whereas 
intragenic transcripts overlap with a protein-coding gene. Almost 60 % of lncRNA transcripts fall into the 
intergenic category where they arise from independent promoters or divergently from a bidirectional 
promoter [33]. Intragenic lncRNAs can further be classified as sense or anti-sense transcripts depending 
on their orientation with respect to the protein-coding gene. They can either arise from external 
promoters or internal promoters of the genes they overlap. Transcripts arising from internal promoters 
are the second largest group of lncRNAs accounting for 30 % of total annotated transcripts [34]. 
Additionally lncRNAs are further classified based on the functional roles in cancer, like proto-oncogenic 
[35, 36] or tumor suppressive [37, 38].  
1.2.3 Long non-coding RNA – characterization and expression regulation 
Similar to mRNAs, expression of lncRNAs is subjected to epigenetic and transcriptional regulation [39-
42]. Active (H3K4me3 and H3K36me3) and repressive (H3K27me3) histone marks around the 
transcription start site (TSS) define the transcription status of a lncRNA. LncRNAs are also shown to 
display a much denser methylation status as compared to their mRNA counterparts [42]. LncRNAs are 
transcribed by RNA polymerase II and subjected to subsequent post-transcriptional processing involving 
5’-capping and 3’-polyadenylation [34, 43]. In comparison to the mRNA counterparts, lncRNAs are less 
expressed in general but display high tissue specificity [27, 44, 45] and can localize to a specific 
compartment in the cell depending on the biological function [46, 47]. Nuclear lncRNAs can act on 
transcriptions factors [35] or as guides for chromatin modifying complexes [48] whereas cytoplasmic 
lncRNAs often play a role in post-transcriptional gene expression regulation by either acting as 
competing endogenous RNAs (ceRNAs) / microRNA sponges [49] or regulating the stability of mRNAs 
[50]. Being a heterogeneous class of molecules, lncRNAs play diverse functional roles by either 
interacting with DNA, RNA or proteins in recruitment of chromatin modifying complexes [36] or 
transcription factors [35], controlling mRNA stability [50] or acting as competing endogenous RNAs [49]. 
Irrespective of limited sequence conservation across different organisms, diverse expression patterns 
and complexity, lncRNAs have been shown to help us understand developmental complexities of higher 
evolved organisms due to their significant functional roles in regulating multiple biological processes [30, 
51, 52].  
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1.2.4 Long non-coding RNAs – in regulation of hallmarks of cancer 
A growing number of publications emphasizes the importance of the role of lncRNAs in a multitude of 
physiological and pathological processes [47, 53, 54]. Although lncRNAs were initially viewed as 
background noise, it is now evident that they play an important role in the regulation of various 
biological processes and their deregulation has been linked to multiple cancers [47, 55].  
LncRNAs act as drivers of carcinogenesis by regulating one or multiple hallmarks of cancer [56-58]. 
Several well investigated examples include lncRNAs regulating viability (GAS5 and PANDA) [59-61], 
proliferation (CTBP1-AS, PVT1) [62-64], growth suppression (MIR31HG and NKILA) [65, 66], migration 
(LincRNA-p21, BANCR and MALAT1) [67-69], angiogenesis (HULC and MALAT1) [70, 71], and cellular 
immortality (NBAT1, TERRA and TINCR) [72-74].  
1.2.5 Long non-coding RNAs – as drivers of hepatocarcinogenesis  
Due to their frequent association with deregulation of hallmarks processes in cancer, lncRNAs have 
gained and maintained special attention also in liver cancer research.  
LncRNA HOTAIR is expressed not only in HepG2 cells but also induced in HCC tumor tissues where 
upregulation of HOTAIR is also associated with earlier relapse and tumor progression [75-77]. LncRNAs 
LINC00152, ZEB-AS1 and LINC01225 function as oncogenes by accelerating motility and invasiveness in 
HCC cells [78-80]. LncRNAs such as TUC338 [81] and MALAT1 [82] also modulate drug resistance and 
sensitivity in HCC cells through pathways involving cell cycle arrest, apoptosis and DNA repair.  
Frequent deregulation, up- or downregulation, tissue- and cancer-specific expression of lncRNAs make 
them attractive targets for a multitude of clinical applications like diagnosis, prognosis or treatment of 
cancer. Using expression as an attribute, lncRNAs such as PVT1, uc002mbe.2, CCHE1 and CRNDE 
distinguish tumor tissues from the normal tissue [83-86]. Additionally, some lncRNAs such as JPX, XIST, 
SNHG15, SNHG20, GAS5, CARLo-5 and SNHG3 have potential to be used as prognostic markers due to 
their correlation with overall survival and difference between low and high risk HCC [84, 87-92].   
1.2.6 Long non-coding RNAs – molecular mechanisms in HCC 
LncRNAs modulate gene expression in HCC through complex regulatory networks. LncRNA GIHCG 
promotes progression of HCC through upregulation of DNA methylation and H3K27me3 levels [93] 
whereas lncRNA ZNFX1-AS1 [94] suppresses cell growth in HCC by modulation of miR-9 methylation. 
Linc00441 promotes HCC progression through H3K27 modifications [95]. Some lncRNAs such as CCAT2 
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[96] and HOTAIR [97] function as transcriptional regulators and promote EMT via modulation of 
transcription factors Slug and Snail in HCC. LncRNA uc.338 accelerates growth in HCC via transcriptional 
modulation of CDKN1A [98].  
LncRNAs regulate hepatocarcinogenesis by interacting with plethora of biomolecules due to their 
heterogeneous nature. LncRNA-protein and lncRNA-RNA interactions play a key role in lncRNA functions 
in HCC. LncRNA HNF1A-AS1 promotes HCC upon repressing p21 on its interaction with EZH2 whereas 
lncRNA SNHG12 - miR-199a/b-5p - MLK3 - NF-κB signaling promotes tumorigenesis and metastasis in 
HCC cells [99]. LncRNA HULC and MALAT1 work together to promote CSC proliferation in HCC cells [100].  
1.3 Cell Proliferation, Senescence and Nucleotide Metabolism 
Normal cells and tissues control cell proliferation by modulation of growth promoting signals that 
regulate the entry into the cell cycle thereby ensuring the maintenance of tissue homeostasis, 
architecture and function. Cell cycle is a complex cascade of events resulting in a division of a cell into 
two daughter cells. The eukaryotic cell cycle is divided into two phases: interphase and mitosis or M 
phase. Interphase is the longest phase of the cell cycle consisting of three steps G1, S and G2 phase. G1 
phase is the first gap phase where the cell grows in size and organelles are duplicated whereas in S 
phase (also called as synthesis phase), cell synthesizes a new copy of the cell’s DNA using the DNA 
replication machinery. In G2 phase (a second gap phase), cell prepares for M phase / cell division by 
reorganizing its contents. Continuously proliferating cells complete G2 phase and undergo cell division in 
M phase whereas cells that don’t divide exit enter a non-dividing phase called G0.  
In sections below, I further discuss the aspects important for the regulation and deregulation of cell 
cycle in normal liver and in HCC. 
1.3.1 Cell cycle regulation in normal liver 
Under normal conditions, hepatocytes are fully differentiated and do not proliferate. But upon injury, 
they are able to exit G0 state and enter the cell cycle to undergo cell division. Progression of 
hepatocytes through different cell cycle phases is controlled by the expression and activity of cyclin-CDK 
complexes. Additionally, CDK inhibitors bind to cyclins to regulate their activity in a specific cell cycle 
phase. Cell cycle inhibitors are divided into two families Cip/Kip and Ink4. Members of Cip/Kip families 
p21, p27 and p57 bind to the ATP binding pocket of all CDKs and inhibit CDK/cyclin complex function 
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whereas INK4 inhibitors p16, p15, p18 and p19 bind and alter the conformation of the CDK4/6 complex 
and in result impair cyclin D binding [101].  
Upregulation of CDK inhibitors results in a cell cycle arrest. In the absence of external growth stimuli, 
p27 maintains hepatocytes in the quiescent state by restricting cyclin/CDK activity [102-104]. In this 
state, hepatocytes still express membrane receptors which could be activated by cytokines or growth 
factors resulting in expression of early phase genes and cell cycle re-entry through cyclin D expression 
and consecutive phosphorylation of pRb by the cyclin D / CDK4 complex.  
1.3.2 Deregulation of proliferation and cell cycle in HCC 
Deregulation of the cell cycle plays a central role in various cancers including hepatocarcinogenesis 
through uncontrolled cell proliferation, resistance to cell death, evasion of growth suppressors and 
genomic instability. Development of HCC is a multi-step process in which different risk factors contribute 
to multiple cycles of hepatocyte damage, death and regeneration which leads to accumulation of 
collagen in the tissue leading to liver fibrosis [105]. Over a period of time, fibrotic liver turns cirrhotic 
and eventually transforms into pre-cancerous and cancerous lesions. WNT, MET or AKT pathways are 
most frequently deregulated individually or in combination in up to 20 % - 80 % of HCC cases [106, 107]. 
Most often, the first and most common cellular alteration observed in HCC is telomere shortening. 
Telomere shortening affects cell cycle checkpoint regulation thus affecting hepatocyte proliferation 
[108]; the limited replication potential due to shortening of telomeres is known as replicative 
senescence (RS). 
1.3.3 Cellular Senescence 
Cellular senescence was first described by Hayflick and Moorehead in context of human primary 
fibroblasts as cells having limited lifespan in cell culture [109]. Cellular senescence can be triggered by 
diverse stimuli such as oncogene induction, oxidative stress and DNA damage [110]. Though the 
senescent cells do not divide, they display pronounced characteristics such as a change in cell shape to 
flattened morphology, increase in cell size, induction of expression of cell cycle inhibitors and increased 
senescence-associated β-galactosidase activity detectable at low pH. Most senescent cells display 
compaction of heterochromatin known as Senescence Associated Heterochromatic Foci (SAHF). As an 
additional marker, senescent cells display a Senescence Associated Secretary Phenotype (SASP), 
characterized by production and secretion of regulatory factors including interleukins, angiogenic 
factors, cytokines, growth factors and matrix metalloproteinases [111, 112]. SASP regulates the 
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functions of tissues and organs by recruiting immune cells and remodeling of extracellular matrix [113, 
114]. Induction of senescence is an attractive therapeutic modality due to its potential in regulating 
cancer cell proliferation by irreversible cell cycle arrest [115-118].  
The onset of cellular senescence leads to the deregulation of genes associated with G1 phase 
progression inducing a cell cycle arrest in G1 phase and failure to progress into the S phase. Among 
other bona fide proliferation markers, negatively regulated G1/S phase transition genes include the 
genes driving dNTP biosynthesis [119-123]. As characterized by multiple markers listed above, senescent 
cells remain metabolically active and undergo cellular alterations including but not limited to pathways 
of nucleotide, glucose, mitochondrial and lipid metabolism [124].  
1.3.4 Nucleotide Metabolism 
Cellular deoxyribonucleotide triphosphates (dNTPs) are essential for a wide variety of biological 
processes [125]. Disturbance of dNTP synthesis results in genotoxicity impacting genome integrity and 
stability, mutagenesis, mitochondrial health and disorders of purine and pyrimidine metabolism (DPPM) 
[126-128]. On the other hand, increased dNTP pools have been associated with uncontrolled DNA 
replication with reduced fidelity and deregulation of cell cycle [129, 130]. This implies that a balance of 
intracellular levels of dNTP pools is essential to prevent multiple diseases associated with DPPM like 
obesity, diabetes and cancer [128, 130, 131].  
1.3.5 Nucleotide metabolism in cell proliferation 
Highly proliferative cells increase DNA and RNA biosynthesis to maintain the pace with accelerated cell 
division [132, 133]. This is supported by increased synthesis of nucleotide biosynthesis genes in late G1 
phase of the cell cycle [134] using either of the two pathways: de novo nucleotide biosynthesis pathway 
and salvage pathway [135].  
The de novo biosynthesis pathway is highly energy-intensive and generates purine and pyrimidines from 
raw materials like glucose, glutamine, aspartate and HCO3− [136]. Due to high energy requirements, 
cells have developed a more energy-efficient route to synthesize dNTPs, called nucleoside salvage 
pathway [137]. The salvage pathway essentially recycles nitrogen bases and nucleosides arising from 
nucleotide breakdown and diet to synthesize dNTPs [136]. 
Ribonucleotides obtained from either pathway are reduced to dNTPs with the help of a key enzyme 
called ribonucleotide reductase (RNR) [138, 139]. RNR consists of a tetrameric complex with two 
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catalytic subunits (RRM1) and two small regulatory subunits (RRM2) [139]. Of note, RRM2 subunits 
regulate and are rate limiting enzymes for dNTP synthesis during S phase whereas RRM1 is present 
throughout the cell cycle [140].  
Both pathways of dNTP biosynthesis are utilized for thymidine biosynthesis in cells. The salvage pathway 
involves usage of the enzyme Thymidine Kinase 1 (TK1) for thymidine triphosphate formation which is 
critical for the process of DNA replication. Expression of TK1 is significantly reduced in senescent cells 
[141]. TK1 phosphorylates thymidine to generate dTMP, a precursor of thymidine triphosphate (dTTP) 
pools [142]. dTTP synthesis using the salvage pathway is not sufficient to sustain mitochondrial DNA 
replication [143] and thus de novo dTMP synthesis pathway is often utilized for thymidine nucleotide 
biosynthesis. This involves the conversion of dUMP to dTMP catalyzed by tetrahydrofolate (THF)-
dependent enzymes including Thymidylate Synthetase (TYMS) [144]. TYMS catalyzes the methylation of 
deoxyuridylate to deoxythymidylate using 10-methylenetetradehydrofolate as a cofactor, which 
maintains dTMP pools essential for DNA replication and repair. Depletion of TYMS results in 
deoxyuridine misincorporation into nuclear DNA leading to genome instability [145]. 
1.3.6 Long non coding RNAs – Senescence and Nucleotide Metabolism 
Expression of a multitude of lncRNAs have been reported to be deregulated in senescence but only a 
handful have been functionally linked to the pathways driving senescence.  
Some examples of lncRNAs modulating senescence include ANRIL, MIR31HG, FAL‐1, PANDA, VAD, 
SALNR, UCA1, HOTAIR and 7SL. Overall, it has been reported that nuclear lncRNAs (ANRIL, MIR31HG, 
FAL‐1, PANDA, VAD and SALNR) function through transcriptional repression / transcriptional activation / 
modulating protein localization / telomere remodeling pathways whereas cytoplasmic lncRNAs (UCA1, 
HOTAIR and 7SL) modulate the senescence pathways by regulation of mRNA stability and translation 
turnover of its targets. 
ANRIL has been identified to interact with SUZ12 and CBX7 (components of PRC2 and PRC1 complexes) 
to promote epigenetic silencing of CDKN2A/CDKN2B loci and thereby impair senescence. 
Downregulation of ANRIL has been associated with induction of cell cycle inhibitors p14, p15 and p16 
further aiding to support its role in senescence [146-148]. MIR31HG has been shown to transcriptionally 
repress p16INK4A by interacting with both the PRC1 and PRC2 complexes [149]. Focally amplified lncRNA 
on chromosome 1 (FAL‐1) interacted with and stabilized BMl1 (a PRC1 component) while repressing p21 
expression and promoting senescence [150]. PANDA has been shown to act as a scaffold between SAFA 
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(transcriptional regulator scaffold attachment factor A), PRC1 and PRC2 interactions in proliferating cells 
whereas, in senescent cells, SAFA-PRC complex disruptions promoted the expression of PANDA where 
PANDA interacted with transcription NF-YA and suppressed the expression of proliferation genes thus 
playing a dual role in regulation of cell proliferation and senescence [61]. LncRNA VAD has been shown 
to be induced in OIS and to activate transcription of CDKN2B locus contributing to senescent phenotype 
[151]. SALNR was found to be over expressed in RS and OIS has been shown to interact with NF90 
(nuclear factor 90) to prevent biogenesis of senescence-associated miRNAs [152-154]. Overexpression of 
UCA1 has been attributed with stabilizing p16 mRNA by sequestering hnRNPA1 in RAS induced 
senescence [155]. Depletion of HOTAIR has been reported to suppress senescence in cancer [156] 
whereas 7SL has been reported to enhance the translation turnover of p53 by binding to 3’ UTR of p53 
mRNA leading to cell cycle arrest and senescence by competing with HuR [157, 158]. 
While there have been multiple reports of lncRNAs regulating pathways governing senescence, there are 
no reports of lncRNAs in the context of regulation of nucleotide metabolism pathways so far. 
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2. AIMS OF MY DOCTORAL PROJECT 
HCC has been reported to cause more than 740,000 deaths annually and is the fourth leading cause of 
cancer-related deaths worldwide. The treatment options for HCC are limited with a poor overall survival 
of less than 20 %, thus warranting further investigations into molecular mechanisms underlying 
hepatocarcinogenesis. The era of high-throughput sequencing has aided in the discovery of lncRNAs 
regulating hallmarks of cancer, but there are no reported studies of lncRNAs so far investigating the 
regulation of cancer cell proliferation through nucleotide metabolism pathways.  
Thus the aim of my doctoral research project is to investigate and uncover novel mechanisms driving 
hepatocarcinogenesis from a lncRNA perspective.  
The aims of this project can be sub-divided into the following objectives:  
 to identify novel lncRNAs induced and regulated in hepatocellular carcinoma 
 to screen for an impact on cell viability after depletion of selected lncRNAs 
 to select a novel lncRNA candidate for further investigation based on the strength of phenotype 
 to perform in-depth characterization of the selected novel lncRNA in terms of -  
o basic characterization: coding potential, gene boundaries and subcellular localization 
o cellular function 
o  and molecular function
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3. MATERIALS 
Parts of the text and figures presented in this chapter are revised versions of the figures and text 
submitted for publication as an original research article: 
Gandhi et al., “lincNMR regulates Nucleotide Metabolism via a YBX1 - RRM2 Axis in Cancer” 
Nature Communications (manuscript under review) 
3.1 Reagents and chemicals 
Table 1. List of reagents and chemicals used in this study 
Reagent/ Chemical Supplier Catalogue Number 
4,4,5,5-D4 L-Lysine-2hcl Fisher Scientific  11305402 
Acetic Acid Lager 12847 
Acetone Sigma-Aldrich 32201-1L 
Ampicilin Sodium Crystalline Sigma A9518-25G 
Anti-FLAG M2 Magnetic Beads Sigma  M8823 
Anti-Mouse Igg For IP (HRP) Abcam ab131368 
Benzonase Santa Cruz sc-202391 
Beta-Mercaptoethanol Sigma-Aldrich M6250  
Bovine Serum Albumin (Bsa) Sigma A9418-10G 
Bp Clonase Ii Enzyme Thermofisher 11789020 
Bromphenol Blue Serva 15375.02 
Chlorofom Lager 12938 
Chloroform : Isoamylalcohol 24:1 Th. Geyer SA/00025666/000100 
Crystal Violet Serva 27335.01 
Dialyzed FBS Life Technologies 88212 
Dimethyl Sulphoxide Applichem A3672,0100 
Dmem (High Glucose Medium) Life Technologies 41965062 
Dnase I Recombinant, Solution Roche 4716728001 
Dntp Set, 100 Mm Solutions Thermo Fisher R0182 
Dream Taq Dna-Polymerase Fermentas EP0702 
Dtt Roche 10708984001 
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Dynabeads Streptavidin Beads Life Technologies 65002 
Ecl(Tm) Prime  Ge Life Science GERPN2236 
Edta Gebru 10341000 
Ethanol Dkfz Catalogue 873 
Ethidium Bromide Carl Roth 2218.1 
Fcs Life Technologies 10270106 
Formaldehyde Sigma-Aldrich F8775-4X25ML 
Generule 100 Bp DNA Ladder Fermentas SM0241 
Generuler 100 Bp Plus DNA Ladder Fermentas SM0322 
Glutaraldehyde Serva 23116.01 
Glycerol Sigma-Aldrich G9012 
Glycine Gerbu 1023 
Glycogen Carl Roth HP51.1 
Hydrogen Peroxide 30%  Sigma-Aldrich H1009-100ML 
Isopropanol Lager 13404 
L-Arginine-Hcl, 13C6   Life Technologies 88210 
L-Arginine-Hcl, 13C6, 15N4 Life Technologies 89990 
Le Agarose Biozym 840004 
Lipofectamine 2000 Life Technologies 11668019 
Lipofectamine Rnaimax Invitrogen 13778150 
L-Lysine-2hcl, 13C6, 15N2 Thermo Fisher  88209 
L-Proline Thermo Fisher   88211 
Magnesium Chloride Roth KK36.3 
Matrigel Matrix High Conc. A75(Hc) Corning 354262 
Methanol Lager 12693 
N, N'-Dimethylformamide Th.Geyer 39756.02 
N-Dodecyl B-D-Maltoside Sigma-Aldrich D4641 
Np - 40 Applichem A1694,0250 
Opti-Mem Reduced Serum Medium Invitrogen 31985047 
Pageruler Prestained Protein Ladder Fermentas  26616 
Pbs Sigma D8537-6X500ML 
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Penicilin-Streptomycin Solution Sigma P0781-100ML 
Phos-Stop Roche 4906837001 
Pierce Bca Protein Assay Reagent B Thermo Fisher 23224 
Pmsf  Sigma Aldrich  78830-5G  
Potassium Chloride 13096 Lager 
Powersybr Green PCR MM, 5ml Life Technologies 4367659 
Propidium Iodide  Sigma-Aldrich P4170  
Protease Inhibitor Roche Diagnostics 11873580001 
Protein G Magnetic Beads Cell Signaling  9006S 
Proteinase K Solution Life Technologies AM2546 
Random Hexamer Primer Fermentas SO142 
Revertaid Reverse Transcriptase Fermentas EP0442 
Ribolock Rnase Inhibitor Thermo Scientific EO0381 
Ribolock Rnase Inhibitor (40 U/µl) Thermo Fischer EO0384 
Riboruler High Range Thermo Fisher 11893993 
Riboruler Low Range Thermo Fisher SM1821 
Rnase A Sigma/Roche 10109169001 
Roti-Phenol / Chlorofom / Isoamyl Lager 13294 
Rotiphorese® Gel Acrylamide Solution Carl Roth 3029.1 
Rpmi 1640 Medium Life Technologies 21875091 
Sds (Sodium Dodecyl Sulphate) Roth 2326.2 
Silac Rpmi 1640 Medium Life Technologies A2494401  
Skim Milk Powder Sigma-Aldrich 70166-500G 
Sodium Acetate Solution (3 M), Ph 5.2 Thermo Scientific R1181 
Sodium Chloride  12781 
Sodium Deoxycholate Sigma-Aldrich D6750-10G  
Superase In (20 U/Μl) Life Technologies AM2696 
Supersignal West Picosubstrate Fisher Scientific 34580X4 
Tcep Sigma 646547 
Temed Carl Roth 2367.3 
Thymidine Sigma-Aldrich T9250 
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Tri Reagent Sigma T9424-200ML 
Trisma Base Lager 12681 
Triton X-100 Gerbu 2000, 1000 
Trypsin 0.05% Life Technologies 25300054 
Trypsin 0.25 % Life Technologies 25200056 
TURBO DNA-Free™ Kit Thermo AM1907 
TURBO Dnase (2 U / µl) Life Technologies AM2238 
Turbofect Transfection Reagent  Fisher Scientific 15325016 
Tween 20 Mp Biomedicals M4904 
Ultrapure Distilled Water Invitrogen 10977049 
Urea Th. Geyer SA/U0631/000500 
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3.2 Kits and consumables 
3.2.1 Kits 
Table 2. List of kits used in this study 
Kit Supplier Catalogue Number 
Axyprep Plasmid Miniprep Kit Axygen AP-MN-P-250 
Celltiter Glo Luminescent Cell Viability Assay Promega G7572 
Dual Luciferase Reporter Assay System Promega E1910 
Genejet Gel Extraction Kit  Thermo Scientific K0691 
Genelute Genomic DNA Kit  Sigma-Aldrich G1N10 
Pcr Mycoplasma Test Kit Promocell PK-CA91-1048 
Pierce Silac Protein Quantitation  Thermo Fisher 89982 
Purelink Hipure Plasmid Midiprep Life Technologies K210005 
Qiagen Mirneasy Mini Kit   DKFZ Lager 217004 
Silac Protein Quantitation Kit – Rpmi 1640 Life Technologies  89982  
Smarter RACE Cdna Amplication  Clontech 634859 
Topo Ta Cloning Kit, Dual Promoter Life Technologies 450640 
 
3.2.2 Consumables 
Table 3. List of consumables used in this study 
Item Company Catalogue Number 
10 cm Dishes, 96 X 20mm TPP Multiple 
15 cm Dishes, 146x21 Mm TPP Multiple 
15 ml, 50 Ml Falcon Tubes TPP Multiple 
2 ml Cryotubes Greiner Bio-One 126278 
6-, 12-, 24 - Well Plates  TPP Multiple 
96 - Well Plate Greiner Bio-One 650101 
96 - Well Plate, Black Clear Bottom Greiner Bio-One 655076 
Combitips Advanced, 0.2 ml  NeoLab E-6401 
Cover Glass  VWR  HECH1001/12 
Cryo Vials Greiner Bio-One 122263 
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GeneJet PCR Purification Kit Thermo Fisher K0702 
GenElute Mammalian Genomic DNA Miniprep Kit Sigma-Aldrich G1N350 
MicroAmp Fast Optical 96-Well Reaction Plate ABI 4346907 
MicroAmp Optical Adhesive Film Life Technologies 4311971 
Millex-HV 0.45 μm Neolab SLHV033RS 
Nitrocellulose Membrane 0.45 μm VWR  10600002 
NucleoSpin Plasmid Macherey-Nagel 740588.25 
Parafilm DKFZ-Lager 12728 
PCR Tubes 0.2 mL Biozym 710980 
Reaction Tube 1.5 mL Eppendorf 12682 
Reaction Tube 2 mL Eppendorf 12776 
Scalpels DKFZ-Lager 13493 
Sterile Filter Tips (1-50 mL) Nerbe Plus Multiple 
Sterile Filter Tips (1-1000 μL) Nerbe Plus Multiple 
 
3.3 Buffers and solutions 
Table 4. Buffers and solutions recipes used in this study 
Buffer Recipe 
1.5X Hybridisation Buffer 15 mM Tris-HCL pH 7.5, 7.5 mM EDTA, 750 mM LiCl, 
0.75% DDM, 0.3% SDS, 0.15% Sodium Deoxycholate, 6M 
Urea, 3.75 mM TCEP  
1X Wash Buffer (RAP-MS) 10 mM Tris-HCL pH 7.5, 5 mM EDTA, 500 mM LiCl, 0.5% 
DDM, 0.2% SDS, 0.1% Sodium Deoxycholate, 4M Urea, 
2.5mM TCEP 
200X DNase Salt Solution 500 mM MgCl2, 100mM CaCl2 
Medium for Breast and Lung cell lines DMEM, 10% FCS, no P/S 
Cell culture medium for CAM experiment RPMI-1640, 10% FCS, 1% P/S 
Cell culture medium for Liver cell lines RPMI-1640, 10% FCS, no P/S 
dNTP mix 10 mM dATP, 10 mM dGTP, 10 mM dCTP, 10 mM dTTP 
High Salt Wash Buffer (CLIP) 0.1% SDS, 0.5% Sodium Deoxycholate, 0.5% NP-40, 0.05 
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M Nacl, 0.010 M KCl, 0.005 M Na2HPO4, 0.0005 M 
KH2PO4 
Hypotonic Lysis Buffer (HLB) 10 mM Tris (pH 7.5), 10 mM NaCl, 3 mM MgCl2, 0.3% 
(vol/vol) NP-40, 10% (vol/vol) Glycerol 
LB Agar 2.5% Luria Broth Base, 1.5% agar 
LB Medium 2.5% Luria Broth Base 
Low Salt Wash Buffer (CLIP) 0.1% SDS, 0.5% Sodium Deoxycholate, 0.5% NP-40, 0.01 
M Nacl, 0.002 M KCl, 0.001 M Na2HPO4, 0.0001 M 
KH2PO4 
Modified Wuarin-Schibler Buffer (MWS) 10 mM Tris-HCl (pH 7.0), 4 mM EDTA, 0.3 M NaCl, 1 M 
Urea, 1% (vol/vol) NP-40 
Proteinase K Buffer (CLIP) 125 mM Tris-Cl pH 7.8, 62.5 mM NaCl, 12.5 mM EDTA 
RIPA Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 
0.5% Na-Deoxycholate, 0.1% SDS, 1% DTT 
RNA Elution Buffer (RAP-MS) 20 mM Tris-HCL pH 8.0, 10mM EDTA , 2% NLS, 2.5mM 
TCEP,  
RNA Loading Dye 95% Formamide, 0.05% SDS, 0.05% Bromphenol blue, 
4.9% TE-buffer 
RNA Precipitation Solution (RPS) 3 M Sodium Acetate (pH 5.5),  9.5 ml of Ethanol 
SDS PAGE Running Buffer (10X) 0.25 M Tris-base, 1.92 M Glycine, 1% SDS 
SDS PAGE Solution B 1.5 M Tris-base, 0.4% SDS 
SDS PAGE Solution C 0.5 M Tris-base, 0.4% SDS 
TBE Buffer 0.89 M Tris, 0.89 M Boric acid, 0.5 M EDTA (pH 8.0) 
TBS Buffer 247 mM Tris, 1.37 M NaCl, 26.8 mM KCl, 0.05% Tween-20 
Total Cell Lysis buffer (CLIP and RAP-MS) 10 mM Tris HCL pH 7.5, 500 mM Lithium Chloride, 0.5% 
Dodecyl Maltoside, 0.2% SDS, 0.1% Sodium Deoxycholate 
Western Blot Loading Buffer (6X) 58% SDS PAGE Solution C, 25% Glycerol, 8% SDS, 0.01% 
Bromphenol Blue, 0.6 M DTT 
Western Blot Transfer Buffer (10X) 0.25 M Tris-base. 1.92 M Glycine, fresh 1X buffer contains 
20% Methanol 
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3.4 Equipments and devices 
Table 5. List of equipments and devices used in this study 
Equipment Name 
Company 
Applied Biosystems StepOnePlus Cycler Applied Biosystems 
BD FACSCantoTM II  Beckton Dickinson 
BioPhotometer Plus Eppendorf 
Cell Counter Neubauer Roth 
Cell Incubator Labotect C200 Labotect 
Dynamag 15 Life Technologies 
Dynamag 2  Life Technologies 
Fluoroskan Ascent FL  Thermo Scientific 
FLUOstar Omega Microplate Reader BMG Labtech 
Gilson Pipetman Pipette Set  Gilson 
Heraeus B5042H Heater  Heraeus 
Heraeus Fresco 17 Centrifuge  Thermo Scientific 
Heraeus Labofuge 400  Thermo Scientific 
Heraeus Megafuge 16R Centrifuge  Thermo Scientific 
Heraeus Pico 17 Centrifuge  Thermo Scientific 
INFORS HT - Ecotron (Bacterial Shaker)  INFORS HAT 
INTAS UV Gel Imager  INTAS 
Intelli – Mixer NeoLab 
Isotemp 202 (Waterbath)  Thermo Scientific 
Kisker Maxigel (20x20 cm) Electrophoresis System Kisker 
Leica DM IRB Microscope Leica 
LTQ Orbitrap XL Mass Spectrometer Thermo Scientific 
Metal – Block - Thermostate MBT - 250 Kleinfeld 
Mini Trans - Blot Electrophoretic Transfer Cell  Bio-Rad 
Mini - Protean Minigel System Bio - Rad Bio-Rad 
Multistep Pipette (Multipette stream) Eppendorf 
MultiSUB Choice Tray (15x15 cm) Kisker 
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Multiwell Pipette (pipet lite) Rainin 
Nalgene 5100-0036 Cryo 1°C Thermo Fisher 
NanoDrop 2000 Spectrophotometer  Thermo Scientific 
Olympus CellR Microscope  Olympus 
Orbital Shaker DOS-10L  NeoLab 
PCR Thermal Cycler PTC-200  Bio-Rad 
PowerPac Basic, Power Supply  Bio-Rad 
PowerPac HC, Power Supply  Bio-Rad 
Research Pipette 100 – 1000 μl Eppendorf 
Research Pipette 2 – 20 μl Eppendorf 
Research Pipette 20 – 200 μl Eppendorf 
Rocking Shaker Kisker 
Sartorius pH Meter PB - 11  Sartorius 
Spectra Max M5e Molecular Devices 
SterilGARD III Advance Cell Culture Hood  The Baker Company 
Thermo Scientific Savant DNA120 Thermo 
UV Stratalinker 1800  Stratagene 
Vortex Mixer  NeoLab 
Whatman Nitrocellulose Blotting Membrane  Whatman 
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3.5 Nucleic acid sequences 
3.5.1 siPOOL sequences 
Table 6. List of siPOOLs used in this study 
siPOOL Name siRNA No. Sense sequence Antisense sequence 
si
P
O
O
L-
N
C
 
1 UGUACGCGUCUCGCGAUUU  AAAUCGCGAGACGCGUACA 
2 UAUACGCGGUACGAUCGUU  AACGAUCGUACCGCGUAUA 
3 UUCGCGUAAUAGCGAUCGU  ACGAUCGCUAUUACGCGAA 
4 UCGGCGUAGUUUCGACGAU  AUCGUCGAAACUACGCCGA 
5 UCGCGUAAGGUUCGCGUAU  AUACGCGAACCUUACGCGA 
6 UCGCGAUUUUAGCGCGUAU  AUACGCGCUAAAAUCGCGA 
7 UCGCGUAUAUACGCUACGU  ACGUAGCGUAUAUACGCGA 
8 UUUCGCGAACGCGCGUAAU  AUUACGCGCGUUCGCGAAA 
9 UCGUAUCGUAUCGUACCGU  ACGGUACGAUACGAUACGA 
10 UUAUCGCGCGUUAUCGCGU  ACGCGAUAACGCGCGAUAA 
11 UCUCGUAGGUACGCGAUCU  AGAUCGCGUACCUACGAGA 
12 UCGUACUCGAUAGCGCAAU  AUUGCGCUAUCGAGUACGA 
13 UUUGCGAUACCGUAACGCU  AGCGUUACGGUAUCGCAAA 
14 UGCGUAAGGCAUGUCGUAU  AUACGACAUGCCUUACGCA 
15 UUAUCGGCAGUUCGCCGUU AACGGCGAACUGCCGAUAA 
16 UAGCGCGACAUCUAUCGCU  AGCGAUAGAUGUCGCGCUA 
17 UCGUCGUAUCAGCGCGUUU  AAACGCGCUGAUACGACGA 
18 UACGCGAAACUGCGUUCGU  ACGAACGCAGUUUCGCGUA 
19 UCGACGAUAGCUAUCGCGU  ACGCGAUAGCUAUCGUCGA 
20 UCGCGUAAUACGCGAUCGU  ACGAUCGCGUAUUACGCGA 
21 UCGCGAUAAUGUUACGCGU  ACGCGUAACAUUAUCGCGA 
22 UUAACGCGCUACGCGUAUU  AAUACGCGUAGCGCGUUAA 
23 UCGCGUAUAGGUAACGCGU  ACGCGUUACCUAUACGCGA 
24 UUACGCGAUCACGUAACGU  ACGUUACGUGAUCGCGUAA 
25 UUAUCGCGCGUCGCGUAAU  AUUACGCGACGCGCGAUAA 
26 UUACGUACUAGUGCGUACU  AGUACGCACUAGUACGUAA 
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27 UAUACGCCGGUUGCGUAGU  ACUACGCAACCGGCGUAUA 
28 UUCGCGUGCAUAGCGUAAU  AUUACGCUAUGCACGCGAA 
29 UACGCGACCUAAUCGCGAU  AUCGCGAUUAGGUCGCGUA 
30 UCGUACGCUGAACGCGUAU  AUACGCGUUCAGCGUACGA 
si
-l
in
cN
M
R
-A
 
1 GACAATCCTTAGACTTCTT AAGAAGTCTAAGGATTGTC 
2 CGCCCACTCTCACCCGGAA TTCCGGGTGAGAGTGGGCG 
3 CAGCAATTATCACCAATCT AGATTGGTGATAATTGCTG 
4 CGAGATAGGAGGCCCATAA TTATGGGCCTCCTATCTCG 
5 GACAAAGAAGGACAAATAT ATATTTGTCCTTCTTTGTC 
6 GGGAACGCTGCCATGAATT AATTCATGGCAGCGTTCCC 
7 GCTATACCCTGCGTTTTGA TCAAAACGCAGGGTATAGC 
8 CCCATTGGGATGTTCATTA TAATGAACATCCCAATGGG 
9 CAAACAGATCCAATCACAA TTGTGATTGGATCTGTTTG 
10 GAGCCTTCATTCAAACTAA TTAGTTTGAATGAAGGCTC 
11 GTGAAAAGCATATGGTAAT ATTACCATATGCTTTTCAC 
12 GCTTGATTTAACCACGCCA TGGCGTGGTTAAATCAAGC 
13 GCAGCACCGGTGTTCTTCA TGAAGAACACCGGTGCTGC 
14 GTACACCATGGTCAATATA TATATTGACCATGGTGTAC 
15 GATAAATGAAAGAGTAGTA TACTACTCTTTCATTTATC 
16 CTCTCCTGGGTTCCGGTAA TTACCGGAACCCAGGAGAG 
17 CGCCACAGTGCATACATAT ATATGTATGCACTGTGGCG 
18 GACCTAGAGGGATCAGCTT AAGCTGATCCCTCTAGGTC 
19 GAACATTAAGGACGAGATA TATCTCGTCCTTAATGTTC 
20 CCGTCCAGGACCTCAAACA TGTTTGAGGTCCTGGACGG 
21 CCCGATGCTGAGTTCACGA TCGTGAACTCAGCATCGGG 
22 CCAGTAAGAAAGCCTGGTT AACCAGGCTTTCTTACTGG 
23 CACCTTACTGAGCTTCAAA TTTGAAGCTCAGTAAGGTG 
24 CCTGTTGGAATTACACCTT AAGGTGTAATTCCAACAGG 
25 CCCTCTTGGATCTGGCTCT AGAGCCAGATCCAAGAGGG 
26 GGATCGTGGCGAAGTCTAT ATAGACTTCGCCACGATCC 
27 CAGATTAAGAAGAACCAAA TTTGGTTCTTCTTAATCTG 
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28 GGACTTCGTCCAAGCCTTT AAAGGCTTGGACGAAGTCC 
29 GTCAATTTTAAACAGGTTA TAACCTGTTTAAAATTGAC 
30 CATGTTATTGTTGATAATT AATTATCAACAATAACATG 
si
-l
in
cN
M
R
-B
 
1 CCAATCTAGATTATGAGAT ATCTCATAATCTAGATTGG 
2 GGACGACCTCTTCCTATAT ATATAGGAAGAGGTCGTCC 
3 GTTCATTAGAACTCTGAAA TTTCAGAGTTCTAATGAAC 
4 CCTCAAACAGATCCAATCA TGATTGGATCTGTTTGAGG 
5 GCCTTTCCGTCCAGGACCT AGGTCCTGGACGGAAAGGC 
6 CCACCTTACTGAGCTTCAA TTGAAGCTCAGTAAGGTGG 
7 CGGTAAGAAGAGATTCCAA TTGGAATCTCTTCTTACCG 
8 GAGATTTCAGGAAAGAGAA TTCTCTTTCCTGAAATCTC 
9 CCTCTCCTGGGTTCCGGTA TACCGGAACCCAGGAGAGG 
10 GTGTACAGTATAATGATAA TTATCATTATACTGTACAC 
11 GTCCGACCTAGAGGGATCA TGATCCCTCTAGGTCGGAC 
12 CCATGGGACAGCCCTCTGA TCAGAGGGCTGTCCCATGG 
13 CTCTCACTCTCTTATGGAA TTCCATAAGAGAGTGAGAG 
14 CAGTGCATACATATGTCAA TTGACATATGTATGCACTG 
15 GCTGGGAACGCTGCCATGA TCATGGCAGCGTTCCCAGC 
16 CGGAACCTTTCATCTCTTA TAAGAGATGAAAGGTTCCG 
17 GAATAGTACGTTAGACAAA TTTGTCTAACGTACTATTC 
18 GGCAACGTTGACTTCCAGT ACTGGAAGTCAACGTTGCC 
19 CTGCAAGGACTTCGTCCAA TTGGACGAAGTCCTTGCAG 
20 CTGCTTACAACCATGCTGA TCAGCATGGTTGTAAGCAG 
21 GATGGTTACCAGTTAGAAA TTTCTAACTGGTAACCATC 
22 GCCTGTTGGAATTACACCT AGGTGTAATTCCAACAGGC 
23 GAGATAGGAGGCCCATAAT ATTATGGGCCTCCTATCTC 
24 GCCATGAATTGGGCTTGGT ACCAAGCCCAATTCATGGC 
25 GAAGAACCAAAGCAGAATA TATTCTGCTTTGGTTCTTC 
26 CACCATGGTCAATATAGTT AACTATATTGACCATGGTG 
27 CAGATCTTGTGGAATCTAA TTAGATTCCACAAGATCTG 
28 CACCTTGGATCGTGGCGAA TTCGCCACGATCCAAGGTG 
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29 GCGAAGTCTATAGAGGTCA TGACCTCTATAGACTTCGC 
30 GCCCATTGGGATGTTCATT AATGAACATCCCAATGGGC 
si
-Y
B
X
1
 
1 GGATATGGTTTCATCAACA TGTTGATGAAACCATATCC 
2 CCAGTTCAAGGCAGTAAAT ATTTACTGCCTTGAACTGG 
3 CTGAGTAAATGCCGGCTTA TAAGCCGGCATTTACTCAG 
4 GCCTAGAGAGGACGGCAAT ATTGCCGTCCTCTCTAGGC 
5 CCTGTTAATAAAGGTCTTA TAAGACCTTTATTAACAGG 
6 CCCAACAACGCCGGCCCTA TAGGGCCGGCGTTGTTGGG 
7 GAAATTCCAGCAATAAGAA TTCTTATTGCTGGAATTTC 
8 CCCTCCTGTGCAGGGAGAA TTCTCCCTGCACAGGAGGG 
9 GAGATGAGACCCAAGGTCA TGACCTTGGGTCTCATCTC 
10 GGCTTACCATCTCTACCAT ATGGTAGAGATGGTAAGCC 
11 GGTAATAACAAACGTGTTT AAACACGTTTGTTATTACC 
12 GCCCTCCTCGCCAAAGACA TGTCTTTGGCGAGGAGGGC 
13 GCCCGTTGACCAGATAAAT ATTTATCTGGTCAACGGGC 
14 GGCGAAGGTTCCCACCTTA TAAGGTGGGAACCTTCGCC 
15 GGGCGTCGACCACAGTATT AATACTGTGGTCGACGCCC 
16 GATTGGAGCTGAAGACCTA TAGGTCTTCAGCTCCAATC 
17 CCACGCAATTACCAGCAAA TTTGCTGGTAATTGCGTGG 
18 GCGGAGGCAGCAAATGTTA TAACATTTGCTGCCTCCGC 
19 CTAAACCACAAGATGGCAA TTGCCATCTTGTGGTTTAG 
20 GCCGATCCACCAGCTGAGA TCTCAGCTGGTGGATCGGC 
21 GGTAGACCAGTGAGGCAGA TCTGCCTCACTGGTCTACC 
22 CAATGTAAGGAACGGATAT ATATCCGTTCCTTACATTG 
23 CACCAAGGAAGATGTATTT AAATACATCTTCCTTGGTG 
24 GCAGACCGTAACCATTATA TATAATGGTTACGGTCTGC 
25 CGACGCAGACGCCCAGAAA TTTCTGGGCGTCTGCGTCG 
26 GGTACCGCCGCAACTTCAA TTGAAGTTGCGGCGGTACC 
27 GACCTAAAGTGCTTGCTTT AAAGCAAGCACTTTAGGTC 
28 CCAGGGTGCAGGAGAACAA TTGTTCTCCTGCACCCTGG 
29 CCATCATCCGGTTTAGTCA TGACTAAACCGGATGATGG 
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30 GTCATCCAACAAGAAGAAA TTTCTTCTTGTTGGATGAC 
si
-R
R
M
2 
1 CATTAAAATGAAAGGCTTT AAAGCCTTTCATTTTAATG 
2 GCCAGATAGAAGACAGGTT AACCTGTCTTCTATCTGGC 
3 GGCACTTTACAAACAAATA TATTTGTTTGTAAAGTGCC 
4 GTGTTACCAACTAGCCACA TGTGGCTAGTTGGTAACAC 
5 GTTATTGTTACCTAAAGTT AACTTTAGGTAACAATAAC 
6 CAATGGCAGTCTTGGCTTT AAAGCCAAGACTGCCATTG 
7 CTGTCTCTCATTAGCTGAA TTCAGCTAATGAGAGACAG 
8 CTACAAGTTGTTCATTCTA TAGAATGAACAACTTGTAG 
9 GCCGTTTCATTTTATTTCT AGAAATAAAATGAAACGGC 
10 GTGCTGGTAGTATCACCTT AAGGTGATACTACCAGCAC 
11 CAAGTATTTCAGTCTCAAA TTTGAGACTGAAATACTTG 
12 GCCCTTACTTGGCTGATTT AAATCAGCCAAGTAAGGGC 
13 GAATAATGCACAAGTCTTA TAAGACTTGTGCATTATTC 
14 CACAAGGCGATAATAGCTT AAGCTATTATCGCCTTGTG 
15 GCCTCACTGCTTCAACGCA TGCGTTGAAGCAGTGAGGC 
16 CTCTGTAATATGATACATT AATGTATCATATTACAGAG 
17 CTTAAACTTTAGTAGGAAA TTTCCTACTAAAGTTTAAG 
18 CCCTTTAGTGAGCTTAGCA TGCTAAGCTCACTAAAGGG 
19 GAAAGGGAAACAAGTATTT AAATACTTGTTTCCCTTTC 
20 CACCATGAATTGTCCGTAA TTACGGACAATTCATGGTG 
21 GGGATTAAACAGTCCTTTA TAAAGGACTGTTTAATCCC 
22 GGGAAACAAGTATTTCAGT ACTGAAATACTTGTTTCCC 
23 GGGATAAAGGAATCTCTCA TGAGAGATTCCTTTATCCC 
24 CACTAAGTGACTAAAGTAA TTACTTTAGTCACTTAGTG 
25 GCTAAGGTAGTATTGTAAA TTTACAATACTACCTTAGC 
26 CATTTATTGTATAGACAAT ATTGTCTATACAATAAATG 
27 GAGAAGCCGTTTCATTTTA TAAAATGAAACGGCTTCTC 
28 GTGAGGTACAGGCGGAAGT ACTTCCGCCTGTACCTCAC 
29 CTGCAGCTCTCGCCGCTGA TCAGCGGCGAGAGCTGCAG 
30 GCTTGGTCGACAAGGAGAA TTCTCCTTGTCGACCAAGC 
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si
-T
K
1 
1 CCGGGAAGACCGTAATTGT ACAATTACGGTCTTCCCGG 
2 CCGAGAGCGTGGTGAAGCT AGCTTCACCACGCTCTCGG 
3 CCCAGCCACTCCAGGAGGA TCCTCCTGGAGTGGCTGGG 
4 CCGTAATTGTGGCTGCACT AGTGCAGCCACAATTACGG 
5 GCTTCCGGGAAGCCGCCTA TAGGCGGCTTCCCGGAAGC 
6 GGCTTAGGCCTCTCTGCCT AGGCAGAGAGGCCTAAGCC 
7 CCATGGCCAACGCCGGGAA TTCCCGGCGTTGGCCATGG 
8 GGTGATCAAGTATGCCAAA TTTGGCATACTTGATCACC 
9 GGATTCACGCCCTCTTGTT AACAAGAGGGCGTGAATCC 
10 GAGCCTTGGCCCACACTGA TCAGTGTGGGCCAAGGCTC 
11 GGAACAACAGCATCTTTCA TGAAAGATGCTGTTGTTCC 
12 CTGCGGCTTTCACTGCTGA TCAGCAGTGAAAGCCGCAG 
13 GCCTACTGGACGCTGCCCT AGGGCAGCGTCCAGTAGGC 
14 GCATTAACCTGCCCACTGT ACAGTGGGCAGGTTAATGC 
15 GGCTTTCACTGCTGAGTTT AAACTCAGCAGTGAAAGCC 
16 CCGCTTGGTGGCCTGGGAT ATCCCAGGCCACCAAGCGG 
17 CCAACTGAGGGACCTGCGA TCGCAGGTCCCTCAGTTGG 
18 GGGAAGCCGCCTATACCAA TTGGTATAGGCGGCTTCCC 
19 CCTTCCTACCTCTGGTGAT ATCACCAGAGGTAGGAAGG 
20 GCCTTCTGGGAACTCTCCT AGGAGAGTTCCCAGAAGGC 
21 GTGCCTGGTGATCAAGTAT ATACTTGATCACCAGGCAC 
22 CTGCTTAAAGCTTCCCTCT AGAGGGAAGCTTTAAGCAG 
23 CGGTGTGCATGGAGTGCTT AAGCACTCCATGCACACCG 
24 GGCAGATCCAGGTGATTCT AGAATCACCTGGATCTGCC 
25 CTACCCACTGGTCTGCTTA TAAGCAGACCAGTGGGTAG 
26 CACCAACCTTGCTGGGACT AGTCCCAGCAAGGTTGGTG 
27 CACGCCCTCTTGTTTCCTT AAGGAAACAAGAGGGCGTG 
28 CCTGCATGCTGCCCAGCCA TGGCTGGGCAGCATGCAGG 
29 GCTTATGAAATTAACTAAT ATTAGTTAATTTCATAAGC 
30 GGAACACCATGGAGGCACT AGTGCCTCCATGGTGTTCC 
si
-
TY
M S 1 TGCCAGTTCTTTCCATAAT ATTATGGAAAGAACTGGCA 
 28 
 
2 GCTATTCCCTCAAATCTGA TCAGATTTGAGGGAATAGC 
3 CCCACGTACTTATAAAGAA TTCTTTATAAGTACGTGGG 
4 CGGGCCTGAAGCCAGGTGA TCACCTGGCTTCAGGCCCG 
5 GGTTATGAACTTTAAAGTT AACTTTAAAGTTCATAACC 
6 CCTGAAGCCAGGTGACTTT AAAGTCACCTGGCTTCAGG 
7 GGCAAATGTAACTGTGCCA TGGCACAGTTACATTTGCC 
8 GGGAGCTGAGTAACACCAT ATGGTGTTACTCAGCTCCC 
9 TGCATTTCAATCCCACGTA TACGTGGGATTGAAATGCA 
10 CATGATGTAGAGTGTGGTT AACCACACTCTACATCATG 
11 GTCCGTGACCTATCAGTTA TAACTGATAGGTCACGGAC 
12 GAGTAACACCATCGATCAT ATGATCGATGGTGTTACTC 
13 GTTAACTCACTGAGGGTAT ATACCCTCAGTGAGTTAAC 
14 GGTGAATTTCACAAGCTAT ATAGCTTGTGAAATTCACC 
15 TTCCATAATAAAAGGCTTT AAAGCCTTTTATTATGGAA 
16 CAATCCCACGTACTTATAA TTATAAGTACGTGGGATTG 
17 ACTGAGGGTATCTGACAAT ATTGTCAGATACCCTCAGT 
18 CACAAGCTATTCCCTCAAA TTTGAGGGAATAGCTTGTG 
19 CTGAGGGAGCTGAGTAACA TGTTACTCAGCTCCCTCAG 
20 TGTAGAGTGTGGTTATGAA TTCATAACCACACTCTACA 
21 GAACTTTAAAGTTATAGTT AACTATAACTTTAAAGTTC 
22 GGATGTTGCCACTGGCAAA TTTGCCAGTGGCAACATCC 
23 GGCTTTGAGTTAACTCACT AGTGAGTTAACTCAAAGCC 
24 TGTATGTGCTCTTAGCAAA TTTGCTAAGAGCACATACA 
25 GCCACTGGCAAATGTAACT AGTTACATTTGCCAGTGGC 
26 GCTGAGTAACACCATCGAT ATCGATGGTGTTACTCAGC 
27 AGGAGAATGAAATGTATGT ACATACATTTCATTCTCCT 
28 GGGTATCTGACAATGCTGA TCAGCATTGTCAGATACCC 
29 CGCTACAGCCTGAGAGATT AATCTCTCAGGCTGTAGCG 
30 CGATCATGATGTAGAGTGT ACACTCTACATCATGATCG 
si
-H
U
LC
 
1 CATATGTATCTTTGGAAGA TCTTCCAAAGATACATATG 
2 GGAATTGGAGCCTTTACAA TTGTAAAGGCTCCAATTCC 
 29 
 
3 GACCATGCAGGAACTCTGA TCAGAGTTCCTGCATGGTC 
4 GGTGGAACTCATGATGGAA TTCCATCATGAGTTCCACC 
5 GCAAGAAGTTTCCTGGCAA TTGCCAGGAAACTTCTTGC 
6 CTGAAGTAAAGGCCGGAAT ATTCCGGCCTTTACTTCAG 
7 GACATTTCAACCTCCAGAA TTCTGGAGGTTGAAATGTC 
8 CTGAATTATGTTGTTATCA TGATAACAACATAATTCAG 
9 GCCTTTACAAGGGAATGAA TTCATTCCCTTGTAAAGGC 
10 GTACTTTCTCCCTGAATTA TAATTCAGGGAGAAAGTAC 
11 GAGACAAGAGCTCTCTTTA TAAAGAGAGCTCTTGTCTC 
12 GGAAGAAACTCTGAAGTAA TTACTTCAGAGTTTCTTCC 
13 CAGACCAAAGCATCAAGCA TGCTTGATGCTTTGGTCTG 
14 GCCGGAATATTCTTTGTTT AAACAAAGAATATTCCGGC 
15 CCTGGCAATAAACTAAGCA TGCTTAGTTTATTGCCAGG 
16 CTGTGGCAAATTTGTACTT AAGTACAAATTTGCCACAG 
17 GGAACACAAATTAAGTGTT AACACTTAATTTGTGTTCC 
18 GGAAGAGTCGTCACGAGAA TTCTCGTGACGACTCTTCC 
19 GGAACTCTGATCGTGGACA TGTCCACGATCAGAGTTCC 
20 GTGTTCAACCTGTGGCAAA TTTGCCACAGGTTGAACAC 
21 CCAATCTGCAAGCCAGGAA TTCCTGGCTTGCAGATTGG 
22 CTGAAACTAGAATTAAACA TGTTTAATTCTAGTTTCAG 
23 GTCACGAGAACCAGACCAT ATGGTCTGGTTCTCGTGAC 
24 CCACGTGAGGATACAGCAA TTGCTGTATCCTCACGTGG 
si
-P
LK
1
 
1 GGCAACCAAAGTCGAATAT ATATTCGACTTTGGTTGCC 
2 CCGAAACCGAGTTATTCAT ATGAATAACTCGGTTTCGG 
3 GACTTCGTGTTCGTGGTGT ACACCACGAACACGAAGTC 
4 CCCGCACTATGGTGGACAA TTGTCCACCATAGTGCGGG 
5 CCATGGAAATATCCATTCA TGAATGGATATTTCCATGG 
6 CGGCCAGCAACCGTCTCAA TTGAGACGGTTGCTGGCCG 
7 CCGTGAGTTCCCATCCCAA TTGGGATGGGAACTCACGG 
8 GGTCGACTGCCACCTCAGT ACTGAGGTGGCAGTCGACC 
9 GGGTATCAGCTCTGTGATA TATCACAGAGCTGATACCC 
 30 
 
10 GGGCCCATACTGGTTGGCT AGCCAACCAGTATGGGCCC 
11 GACCATTCCACCAAGGTTT AAACCTTGGTGGAATGGTC 
12 CCCAACTCCTTGATGAAGA TCTTCATCAAGGAGTTGGG 
13 CGGGCAAGATTGTGCCTAA TTAGGCACAATCTTGCCCG 
14 GGGTTGCTGTGTAAGTTAT ATAACTTACACAGCAACCC 
15 GGCACTGAGTCCTACCTCA TGAGGTAGGACTCAGTGCC 
16 CCCTCACAGTCCTCAATAA TTATTGAGGACTGTGAGGG 
17 GGCAGCGTGCAGATCAACT AGTTGATCTGCACGCTGCC 
18 CCATATGAATTGTACAGAA TTCTGTACAATTCATATGG 
19 GCCAGTACCTGCACCGAAA TTTCGGTGCAGGTACTGGC 
20 CCCTGTGTGGGACTCCTAA TTAGGAGTCCCACACAGGG 
21 CCATTAACGAGCTGCTTAA TTAAGCAGCTCGTTAATGG 
22 GCCTCATCCTCTACAATGA TCATTGTAGAGGATGAGGC 
23 CACTGCCCGCCCAACCATT AATGGTTGGGCGGGCAGTG 
24 CTGAGCCTGAGGCCCGATA TATCGGGCCTCAGGCTCAG 
25 CGATACTACCTACGGCAAA TTTGCCGTAGGTAGTATCG 
26 CTTAATGACGAGTTCTTTA TAAAGAACTCGTCATTAAG 
27 GCTGCACAAGAGGAGGAAA TTTCCTCCTCTTGTGCAGC 
28 CCATCTTCTGGGTCAGCAA TTGCTGACCCAGAAGATGG 
29 CACCAGCACGTCGTAGGAT ATCCTACGACGTGCTGGTG 
30 GGATCAAGAAGAATGAATA TATTCATTCTTCTTGATCC 
 
3.5.2 RT - qPCR primer sequences 
Table 7. List of RT - qPCR primers used in this study 
Gene Name Sequence (5'-3' direction) 
DANCR.F GCGCCACTATGTAGCGGGTT 
DANCR.R TCAATGGCTTGTGCCTGTAGTT 
GAPDH.F CTGGTAAAGTGGATATTGTTGCCAT 
GAPDH.R TGGAATCATATTGGAACATGTAAACC 
IL-1a.F AGTAGCAACCAACGGGAAGG 
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IL-1a.R AAGGTGCTGACCTAGGCTTG 
IL-1b.F GCCATGGACAAGCTGAGGAA 
IL-1b.R TCGTTATCCCATGTGTCGAAGA 
lincNMR-amp#1.F CATGGGACAGCCCTCTGAAA 
lincNMR-amp#1.R CTGTTTGAGGTCCTGGACGG 
lincNMR-amp#2.F TGCTTTAATCCTGTCGTGGC 
lincNMR-amp#2.R CGGAAAGGCTTGGACGAAGT 
lincNMR-amp#3.F TTATGAGGACTGCACCACAGC 
lincNMR-amp#3.R GTTTGAGGTCCTGGACGGAA 
MALAT1 1787 F GAATTGCGTCATTTAAAGCCTAGTT 
MALAT1 1871R GTTTCATCCTACCACTCCCAATTAAT 
NEAT1.F GTCTTTCCATCCACTCACGTCT 
NEAT1.R GGACAACTAGATGCCGAGGTAG 
PPIA.F CTGCTGTCTTTGGGACCTTGT 
PPIA.R GTCAACCCCACCGTGTTCTT 
RNU1-1.F TTATCCATTGCACTCCGGATGT 
RNU1-1.R CCCCACTACCACAAATTATGCAG 
RRM2.F  AGGACATTCAGCACTGGGAA 
RRM2.R TTCTTGGCTAAATCGCTCCA 
SRSF4.F TGCAGCTGGCAAGACCTAAA 
SRSF4.R TTTTTGCGTCCCTTGTGAGC 
TK1.F TGCCAAAGACACTCGCTACA 
TK1.R CGATGCCTATGACAGCCAC 
TYMS.F TTCTGGAAGGGTGTTTTGGA 
TYMS.R TGGCATCCCAGATTTTCACT 
YBX1.F AGGGTGCAGGAGAACAAGGT 
YBX1.R TCATTGCCGTCCTCTCTAGG 
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3.5.3 Sequences of 5’ and 3’ RACE primer 
Table 8. List of primers used for 5’ and 3’ RACE experiments 
RACE GSP Name Sequence (5'-3' direction) 
5'RACE 5'RACE_GSP_001 ACGTTGCCACGACAGGATTAAAGC 
3'RACE 3'RACE_GSP_e1 CGAGTGAGGACGACCTCTTCCTATATGC 
 
3.5.4 Sequences of biotinylated DNA oligos 
Table 9. Sequences of biotinylated DNA oligos used for lincNMR RAP-MS 
Name Bases Modification Sequence 
lincNMR_2 90 /5Biosg/ /5Biosg/TGGGCGTGGGCGAAGCTGATCCCTCTAGGTCGGACTAAGG
CAGAGCCAGATCCAAGAGGGAGAATCCAACTGTAAAAGGGATCTGG
GGAA 
lincNMR_3 90 /5Biosg/ /5Biosg/AAAGGGGAGAACTGTAGTTTTCAGAGTTCTAATGAACATCC
CAATGGGCCTAAAAGGCTTCAATAAGAGATGAAAGGTTCCGGGTGA
GAG 
lincNMR_4 90 /5Biosg/ /5Biosg/TCTTGCCTTTCTGAATTCTGAAAAAAGAGTGGTATTGGAAT
CTCTTCTTACCGGAACCCAGGAGAGGGCGAGCTGTGGTGCAGTCCT
CAT 
lincNMR_5 90 /5Biosg/ /5Biosg/GGATTGTCGAAAAGGTGGCTCCCTTCAGACAGACCAAGCC
CAATTCATGGCAGCGTTCCCAGCCCCAGTTTGAAGCTCAGTAAGGTG
GTC 
lincNMR_6 90 /5Biosg/ /5Biosg/ACGTTTATTCTGCTTTGGTTCTTCTTAATCTGACCTCTATAGA
CTTCGCCACGATCCAAGGTGTAATTCCAACAGGCAAAAGAAGTCTAA 
lincNMR_7 90 /5Biosg/ /5Biosg/TCCTATCTCGTCCTTAATGTTCAAAACGCAGGGTATAGCAA
AGCATATAGGAAGAGGTCGTCCTCACTCGTGAACTCAGCATCGGGTT
CT 
lincNMR_8 90 /5Biosg/ /5Biosg/TCAGAGGGCTGTCCCATGGGCTCACTCTGCAACCAGGTGG
AAGTCAACGTTGCCACGACAGGATTAAAGCAAGAAGAAACATTATG
GGCC 
lincNMR_9 90 /5Biosg/ /5Biosg/TCTTCTTGTGATTGGATCTGTTTGAGGTCCTGGACGGAAAG
GCTTGGACGAAGTCCTTGCAGACTCAGCATGGTTGTAAGCAGTATAA
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TT 
lincNMR_10 90 /5Biosg/ /5Biosg/TTTTTCCACTTAACATGATTATTTTCCCAGTCATTTCATGTTC
TTCAAAAACCCCGATGATAGGAATAATTTTCTCTTTCCTGAAATCTC 
 
3.6 Biological material 
3.6.1 Human cancer cell lines  
Table 10. Cell line, origin, growth medium and biosafety level 
Organ Cell line   Description Medium Biosafety 
Lung A549 Human lung adenocarcinoma cell line DMEM 1 
Lung NCI-H1299 Human NSCLC epithelial cell line DMEM 1 
Lung NCI-H460 Human large cell lung cancer epithelial cells  DMEM 1 
Liver FLC-4 Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver Hep3B Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver HepG2 Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver HLE Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver HLF Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver Huh6 Hepatoblastoma RPMI-1640 1 
Liver Huh-7 Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver PLC Human hepatocellular carcinoma cell line RPMI-1640 2 
Liver SK-HEP1 Adenocarcinoma RPMI-1640 1 
Liver SNU-182 Human hepatocellular carcinoma cell line RPMI-1640 1 
Liver SNU-387 Human hepatocellular carcinoma cell line RPMI-1640 1 
Breast MCF7 Human mammary ADC epithelial cell line DMEM 1 
Breast KPL-1 Human mammary carcinoma cell line DMEM 1 
Breast T47D Human mammary Invasive ductal cancer DMEM 1 
 
3.6.2 Antibodies 
Table 11. List of antibodies used in this study 
Antibody Name Host Company Catalogue No. MW (kDa) Dilution 
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anti-Flag-M2 Mouse Sigma 1804 - 1:1000 
anti-HA.11 Mouse Covance MMS-101P - 1:1000 
GAPDH Mouse Millipore MAB374 37 1:20000 
Goat Anti-Mouse  Goat Abcam ab6789 - 1:2500 
Goat Anti-Rabbit  Goat Abcam ab6721 - 1:2500 
RRM2 Mouse Abcam ab57653 30/45 1:1000  
TK1 Rabbit Abcam ab76495 25 1:5000  
TYMS Rabbit Abcam ab168853 36 1:2000 
Vinculin Mouse  Santa Cruz sc-25336 116 1:1000 
YBX1 Mouse Abcam ab12148 36 1:1000  
3.6.3 Plasmids 
Table 12. List of plasmids used in this study 
Plasmid  Source 
pFRT-Flag-HA-ΔCmR-ΔccdB From Sandeep Dukare 
pFRT-Flag/HA-YBX1 Gene and clone repository DKFZ 
pRL-TK From Sven Diederichs 
pRL-SV40 From Sven Diederichs 
Y-Box-TATA-Luc Gift from Prof. Birgit Schittek group 
 
3.7 Softwares 
Table 13. List of softwares used in this study 
Software Provider 
Adobe Illustrator Adobe 
Flow Jo FlowJo, LLC 
GraphPad Prism 8 GraphPad Software, San Diego, USA 
GSEA Broad Institute, Cambridge, USA 
Image J NIH and the Laboratory for Optical and Computational Instrumentation, USA 
Ingenuity  Qiagen, USA 
MS Office Microsoft 
Perseus Max Planck Institute of Biochemistry, Munich, Germany 
StepOne v2.3 Applied Biosystems, Darmstadt, Germany 
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3.8 Online tools and databases used in this study 
Table 14. List of web tools used in this study 
Name 
ENCODE – Accessed through tracks in the UCSC genome browser 
KM Plotter – http://kmplot.com/analysis/ 
Panther Database – http://www.pantherdb.org/ 
PhyloCSF - Accessed through tracks in the UCSC genome browser 
Primer-Blast – https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
Switchgear TSS – Accessed through tracks in the UCSC genome browser  
TANRIC – https://ibl.mdanderson.org/tanric/_design/basic/index.html 
UCSC Genome Browser – https://genome.ucsc.edu/ 
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4. METHODS 
Parts of the text and figures presented in this chapter are revised versions of the figures and text 
submitted for publication as an original research article: 
Gandhi et al., “lincNMR regulates Nucleotide Metabolism via a YBX1 - RRM2 Axis in Cancer” 
Nature Communications (manuscript under review) 
Unless otherwise indicated, all commercially available reagents and kits were used according to 
manufacturer’s instructions. 
4.1 Human cancer cell lines 
4.1.1 Growth and propagation of human cancer cell lines 
Details on the cell lines, growth medium used in this study are provided in Table 10 
All cell lines were cultured in a cell culture incubator at 37°C and 5 % CO2 without the addition of any 
antibiotics. Liver cancer cell lines (HLE, HLF, FLC - 4 and SNU - 387) used in this study were a kind gift 
from PD Dr. Kai Breuhahn (Institute of Pathology, University Heidelberg, Heidelberg Germany). Lung 
(A549, NCI - H1299 and NCI - H460) and breast cancer cell lines (MCF - 7, KPL - 1 and T47D) were 
purchased from ATCC. Liver cancer cell lines were grown in RPMI - 1640 medium supplemented with 10 
% FBS whereas lung and breast cancer cell lines were grown in DMEM (high glucose) and supplemented 
with 10 % FBS.  
For the cell culture, 1 X PBS and respective culture medium were pre-warmed in a water bath at 37°C. 
Cells were washed once with 1 X PBS and incubated with 0.05 % trypsin at 37°C until cells were 
detached from the surface. Detachment time varied depending on the cell line used. Two volumes of 
respective growth medium was added to the plate and cells were pipetted to ensure complete mixing in 
order to inactivate the trypsin as well as to completely detach the cells from the surface. 10 µL of cell 
suspension was used to calculate cell number using the hemocytometer (Neubauer). After counting, 
required number of cells were diluted as per experimental requirement and either used for further 
downstream assays, further seeded and frozen. 
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4.1.2 Cryopreservation of cells lines 
For long term storage of cell lines, growth medium was removed, cells were washed twice with 1 X PBS 
and trypsinized using 0.05% Trypsin-EDTA for 2 - 8 minutes depending on cell line used. Trypsin was 
deactivated using complete growth medium and cells in suspension were centrifuged at 200 g for 5 
minutes to pellet the cells. Cell pellet was re - suspended in cryo - medium (10 % DMSO and 20 % FCS in 
complete growth medium) in cryo vials. Freezing container called Mr. Frosty was used to store the cryo 
vials to attain cooling rate of -1°C / min in - 80°C freezer. For long term storage, vials were transferred to 
the liquid nitrogen tank.  
4.1.3 Thawing of cryo - preserved cells 
To thaw cryo-preserved cells, respective complete growth medium was warmed to a temperature of 
37°C in a water bath. 1 ml of warmed medium was added to the cryo vials and mixture was re-
suspended in growth medium. Cells were centrifuged at 200 g for 5 minutes in order to remove freezing 
medium and then plated on a 10 cm dish. 
4.1.4 Cell line authentication and mycoplasma test 
As a quality control measure, all cell lines used in this study were periodically tested at a 3-month 
interval for mycoplasma contamination using a PCR based detection kit. Genomic DNA was isolated from 
the cell lines to be tested and sent for authentication by using cell authentication services from 
Multiplexion, Heidelberg, Germany [159]. 
4.2 Transfections 
4.2.1 siPOOL transfections 
siPOOL sequences used in this study are provided in Table 6 
For RNAi mediated knockdowns, siPOOLs were used [160]. siPOOLs were reverse transfected onto the 
cells using Lipofectamine RNAiMAX as a transfection reagent in serum free RPMI-1640 medium to a final 
concentration of 10 nM. 
4.2.2 Plasmid transfections 
Details of plasmids used in this study are provided in Table 12 
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For plasmids transfections, required number of cells were seeded on day 1 into 6 well plates and 
transfected with plasmids on day 2. For all plasmid transfections in this study, TurboFect transfection 
reagent together with serum free medium opti-MEM was used. Two reaction mixtures were prepared, 
master mix 1 (DNA and opti-MEM) and master mix 2 (TurboFect and opti-MEM) in such a way that DNA: 
TurboFect ratio was in the range of 1:2-1:2.5 for all transfections.  Both master mixes were combined 
and incubated at room temperature for 15 minutes. After the incubation, master mix was added 
dropwise on the cells. Cell plate was swirled to ensure proper mixing of reagents.  
4.3 RNA isolation, reverse transcription and quantitative PCR 
4.3.1 RNA isolation using TRIzol 
Cells were prepared for RNA isolation by washing with pre-warmed 1 X PBS. 1 ml of TRIzol was added to 
the cells and shaken on a rotor for 5 minutes at room temperature to ensure complete denaturation of 
cells. Lysate was then transferred to fresh tubes and stored at – 20°C for up to a week until ready for 
RNA isolation. For isolating RNA, frozen TRIzol lysates were thawed at room temperature and 200 µL of 
chloroform was added to the tubes. Tubes were incubated for 2 - 3 minutes at room temperature after 
shaking for 30 s. Tubes were then further centrifuged at 10,000 g for 15 minutes at 4°C. Next, about 230 
μl of aqueous phase was transferred into a new tube containing 500 μl of isopropanol. Tubes were 
mixed by inverting multiple times. Next, RNA was precipitated for at least 1 h at -20°C after subsequent 
centrifugation at 4°C at a speed of 12,000 g. Pelleted RNA was washed twice with 1 ml of 70 % ethanol 
and centrifuged at 8000 g for 5 minutes at 4°C. Supernatant was then carefully removed, pellet was 
partially air dried to ensure complete removal of ethanol and then re-suspended in pre-heated nuclease 
free water. 
4.3.2 RNA isolation using kits 
Isolation of RNA from RAP-MS and UV-RIP-qPCR samples was performed as per manufacturer’s protocol 
using miRNeasy Mini kit.  
4.3.3 DNase digestion of total RNA 
DNase digestion was performed in a 50 µL reaction with up to 50 µg of RNA, 5 µL of 10X buffer (Roche), 
1 µL of DNase I. This mix was incubated for 30 min at 37°C. After incubation, 150 µL of nuclease free 
water was added to the reaction. Further samples were shaken for 15 s after addition of 200 µL of Roti-
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Aqua-P/C/I for RNA extraction and incubated for 2 minutes at room temperature. Next, samples were 
centrifuged for 2 minutes at a speed of 13,000 rpm. Upper phase was transferred into the new tubes 
containing 200 µL of chloroform. At this step, RNA was treated as per the RNA isolation procedure and 
upper aqueous phase was transferred in to new tube containing 1 μl of 10 μg/μl of glycogen (Carl Roth) 
and 19 μl of 3 M sodium acetate (pH5.2, Carl Roth). Next, 500 μl of ice cold ethanol was added to the 
tube and contents were mixed by inverting multiple times. Tubes were stored at -80°C for at least 2 h to 
precipitate RNA. After the incubation, tubes were centrifuged at 16,000 g minutes at 4°C and pellet 
washed twice with 70% ethanol. RNA pellet was re-suspended in pre warmed nuclease free water after 
complete removal of ethanol and stored at 80°C until further downstream applications.  
4.3.4 DNase digestion of RNA isolated using kits 
DNAse digestion was performed as per manufacturer’s instruction using TURBO DNA free kit. 
4.3.5 Reverse transcription 
1 µg of RNA was mixed in a reaction with 2 μL of 10 mM dNTPs, 1 μL random hexamer primer to the 
total volume of 15 μL with ultra-pure water. Sample was mixed by vortexing and heated to 65°C for 5 
minutes to denature RNA. Sample tubes were immediately transferred to ice where 4 μL of 5 X reverse 
transcriptase buffer and 1 μL of Revert Aid reverse transcriptase was added to the reaction. Samples 
were incubated using thermal cycler at room temperature for 10 min and later at 42°C for 1 h. Reaction 
was terminated by heating the sample to 70°C for 10 minutes. 
4.3.6 qPCR primer design 
All the primers used in this study were designed by Primer-Blast tool based on Primer3 algorithm. 
Following parameters were considered while designing: PCR product between of 70 – 150 bp, primer 
length of 20 – 27 bp and melting temperature in the range of 59 – 61°C. Primers were synthesized and 
delivered by Sigma-Aldrich. 
4.3.7 qPCR 
Sequences for primers used in this study are provided in Table 7 
This method was used to determine the relative expression of the genes. cDNA was diluted to 1:40 with 
DNAse and RNAse free water and 4 µL of diluted cDNA was used in a qPCR reaction.  RT - qPCR was 
performed using Power SYBR Green PCR Master Mix on Applied Biosystems StepOne Plus thermal cycler 
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with holding stage of 95°C for 10 min followed by a 40 cycles of 95°C for 15 sec and 60°C for 30 sec. 
Normalization of the obtained data was performed with PPIA, GAPDH and/or SRSF4 as internal 
reference controls. Data was analyzed using StepOne Software v2.3.  
4.4 Protein isolation, quantitation, western blot 
4.4.1 Protein lysate preparation 
For preparing protein lysates, cells were washed with 1 X PBS to ensure complete removal of growth 
medium and the plates were transferred to ice. Cells were washed again with 2 ml of ice cold PBS and 
complete PBS was removed. Every use, RIPA buffer was freshly supplemented with protease and 
phosphatase inhibitor cocktail. 200 µL of RIPA buffer supplemented with 1 X Protease (Roche) and 
Phosphatase Inhibitors was added in each well and incubated on ice with intermittent mixing for 30 
minutes. After incubation, cell lysate was collected from the well and centrifuged at 17000 g for 10 mins 
at 4°C. Next, supernatant was transferred to a new Eppendorf tube and protein quantification was 
performed using Pierce BCA Protein Assay Kit.  
4.4.2 Bicinchoninic Acid (BCA) assay 
For BCA assay, first a BSA standard curve was prepared from Bovine Serum Albumin (BSA) Fraction V in 
the range of 0 - 1.4 mg/ml in technical duplicates using the same aliquot of supplemented RIPA buffer. 
Depending on the experiment schematic in terms of number of cells used for cell lysis, samples were 
either undiluted or diluted up to 1: 50 in the same RIPA buffer in duplicates. 10 μl of each sample was 
transferred to a new tube and 200 μl of BCA reagent mixture in the ratio of 50: 1 for BCA: Copper (II) 
sulfate solutions was added. Samples were next incubated for 30 minutes at 37°C on a mixer. After 
incubation, 80 μl of sample was transferred to a cuvette and absorbance was measured at 550 nm using 
the BioPhotometer Plus. 
4.4.3 Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The recipe for buffers used is provided in Table 4. 
In this study, sample concentration used for loading on to SDS-PAGE gel was 10 - 20 μg per sample. 
Required volume of samples were boiled for 10 mins at 95°C in 4 X laemmli buffer before loading onto 
10 % gel. SDS mini gels were cast in-house using 4 % gel stacking layer. Gels were run at room 
temperature at up to 160 V using a power pack from Bio-Rad. 5 μl pre-stained PAGE ruler was used as a 
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size marker on each gel to assist in size analysis of the blotted proteins. SDS - PAGE was performed using 
Mini-Protean system. 
4.4.4 Western Blot 
After the electrophoresis, proteins were transferred to nitrocellulose membrane using transfer buffer 
(0.25 M Tris-base, 1.92 M Glycine, 1 % SDS with 20 % Methanol) at 120 V for 90 minutes. Membrane 
was blocked with 5% Milk in 1 X TBS-T (1 X TBS, 0.1 % Tween-20) for 30 minutes. Blots were incubated in 
5 % skimmed milk solution containing the respective dilutions of primary antibody overnight at 4°C. 
Details on antibodies used and their respective dilutions is available in Table 11. After the overnight 
incubation, blots were washed 5 times with 1 X TBS-T to ensure complete removal of primary antibody 
solution. Blots were then incubated in respective secondary antibody for 1 h at room temperature at a 
concentration of 1: 2500. After incubation with secondary antibodies, membranes were washed 5 times 
with 1 X TBS-T to remove the unbound antibodies. Membranes were incubated in 1: 1 Super Signal West 
Pico Stable Peroxidase Solution and the Luminol Enhancer Solution for 5 min. After incubation, images 
were acquired for detection of specific bands using ChemoCam Imager and quantification of the signal 
was done using LabImage 1D software.  
4.5 Plasmid isolation, purification and sequencing 
4.5.1 Generation of plasmids in Gateway vector system 
Respective gateway entry vectors were obtained from DKFZ plasmids and clone repository. LR reaction 
was performed with 50 - 150 ng of entry vector using LR Clonase II as per manufacturers instructions 
into the gateway destination vector pFRT-Flag/HA. Mach-1 cells were used for transformation. Mini Prep 
was performed using NucleoSpin® Plasmid kit. Midi Prep was done using PureLink™ HiPure Plasmid kit. 
Services from Eurofins genomics/ GATC were used for sequencing with CMV.for 
CGCAAATGGGCGGTAGGCGTG and BGH.rev TAGAAGGCACAGTCGAGG primers. Finally, cells were 
transfected with respective plasmid of interest and empty vector pFRT-Flag-HA-ΔCmR-ΔccdB as a control 
plasmid. Overexpression was confirmed by western blot using anti-Flag-M2 or anti-HA antibody (Table 
11). 
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4.5.2 Genomic DNA isolation 
GenElute Mammalian Genomic DNA Miniprep kit was used to isolate genomic DNA from cultured cells. 
From respective cells, 6*106 were harvested and pelleted after centrifugation at 300 g for 5 minutes. 
Cell pellet was re-suspended in 200 µL of resuspension solution with 20 µL of RNAse A. Mix was 
incubated for 2 minutes at room temperature. 200 µL of cell lysis solution containing 20 µL of proteinase 
K was added to the mix and vortexed for 15 s vigorously. Sample was incubated at 70°C for 10 minutes. 
500 μl of column preparation solution was used to equilibrate the columns and then centrifuged for 1 
minutes at 12,000 g. 200 μl of ethanol was added to the lysate and vortexed to homogenize the 
solution. Next, the lysate was loaded onto the column and centrifuged for 1 minutes at 6500 g. 
Supernatant/ flow through was discarded and 500 μl of wash solution was added to the column and 
centrifuged for 1 minutes at 6500 g. The column was washed for the second time and centrifuged for 3 
minutes at a maximum speed. Columns were then incubated for 5 minutes with 200 μl of elution buffer 
at room temperature. The DNA was eluted by centrifugation at 6500 g for 1 min. 
4.5.3 Transformation of bacteria 
Chemically competent E.coli (Mach 1) cells were used in this study. 50 µL of Mach 1 cells were incubated 
with approximately 1 µL of plasmid DNA. The sample was mixed gently by pipetting up and down using a 
sterile cut tip and incubated on ice for 15 minutes. The sample was then at incubated at 42°C for 40 s in 
a thermocycler for a heat-shock. Next, samples were immediately transferred to ice and 200 µL of LB 
media without antibiotics was added. 100 μl of reaction mix was then pipetted on to pre-warmed 
selective LB-plates after incubation at 900 rpm at 37°C for 45 min and distributed with the help of sterile 
glass balls/ spreader. Plates were then incubated overnight at 37°C and single clones were picked the 
next morning and inoculated into about 80 ml of LB medium with 100 μg / mL ampicillin for plasmid 
DNA preparation.  
4.5.4 Plasmid DNA isolation 
NucleoSpin plasmid kit was used to perform mini prep as per manufacturer’s instruction. Sequences 
were confirmed using sanger sequencing services from Eurofins genomics/GATC Biotech. Nanodrop 
2000 was used to check the DNA concentrations. Plasmids were stored at -20°C until further use. 
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4.6 Basic characterization of lincNMR 
4.6.1 Subcellular fractionation  
Recipes for buffers used for this protocol are provided in Table 4. All buffers used in this protocol were 
supplemented with RNase inhibitor cocktail SUPERase-In. Fraction specific controls were used to assess 
the quality of fractions obtained (chromatin fraction: NEAT1, MALAT1, nucleoplasmic fraction: RNU-1, 
cytoplasmic fraction: DANCR).Primer sequences are provided in Table 7. 
Subcellular fractionation was performed in HLE cells to separate chromatin associated, nucleoplasmic 
and cytoplasmic fractions as per the previously described protocol [161]. HLE cells were grown on a 15-
cm dishes and allowed to achieve 80 % - 90 % confluency. 10*106 cells were harvested, pelleted and 
used for each replicate for a fractionation experiment. Pellets was carefully washed twice with 1 X ice 
cold PBS to ensure complete removal of growth medium. Cells were centrifuged at 500 x g and kept on 
ice in order to avoid any RNA degradation. Cell pellet was then re-suspended in 380 μl of hypotonic lysis 
buffer (HLB) and incubated for 10 mins on ice. The samples were vortexed to ensure complete mixing 
and then centrifuged at 4°C for 3 min at 1000 x g. The supernatant fraction = cytoplasmic fraction was 
transferred carefully to a fresh tube and mixed with 1 mL of RNA precipitation solution (RPS) and kept at 
-20°C for at least 1 h. The remaining cell pellet= nuclei were washed thrice with 1 mL of ice-cold HLB and 
centrifuged at 4°C for 2 mins at a speed of 500 x g. Next, 380 μl Modified Wuarin - Schibler buffer 
(MWS) was added to the pellet and carefully vortexed for 30 s and later incubated on ice for 5 min. 
Nuclei were incubated on ice for 10 min after vortexing for 30 s. Later, at 4°C sample was centrifuged for 
3 min at 1000 x g and the supernatant = nucleoplasmic fraction was transferred to a fresh tube. 1 mL of 
RPS was then added and the fraction was stored for at least 1 h at -20°C. The remaining pellet, now 
chromatin fraction was carefully washed thrice using 1 mL of cold MWS to remove any leftover 
nucleoplasmic fraction and centrifuged at 4°C for 2 min at a speed of 500 x g. Sample was stored at 20°C 
after adding of 1 mL of TRIzol. The stored cytoplasmic and nucleoplasmic fractions were vortexed and 
centrifuged at a high speed of 18000 x g at 4°C for 15 min. The pellet was washed with ice-cold 70% 
ethanol after discarding the supernatant and centrifuged at 18000 x g at 4°C for 15 min. 1 mL of TRIzol 
was added to the pellets and stored at -20°C. Now as next steps, 10 μl 0.5 M EDTA was added, samples 
were mixed by vortexing and heated to 65°C until the pellet was completely dissolved. Samples were 
then cooled to room temperature and 200 μl of chloroform: isoamyl alcohol was added, samples were 
vortexed and immediately centrifuged at 18000 x g at RT for 10 min. The supernatant was then 
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transferred to a fresh tube and 1 volume of isopropanol was added and precipitated overnight at -20°C. 
After centrifugation at high speed of 18000 x g at 4°C for 5 min, the supernatant was discarded, and the 
now RNA was re-suspended in DNase, RNase free ultra-pure H2O. Nanodrop 2000 was used to measure 
the RNA concentration. DNase digestion of 5 μg of RNA was performed by adding 5 μL of 0.5 μL 
Ribolock, 10X DNase buffer, 0.5 μL DNAse for a total reaction volume of 50 μL with ultra-pure H2O. 
Further steps, reverse transcription and quantitative real time polymerase chain reaction were 
performed as described in the section 4.3. 
4.6.2 Rapid Amplification of cDNA ends (RACE) 
The SMARTer RACE cDNA Amplification Kit was used to perform 5’ and 3’ RACE analysis according to the 
manufacturer’s instructions. The gene-specific primers used are listed in Table 8. 
Total RNA (DNAse I treated) from HLE cells was used for first strand cDNA synthesis. PCR reaction was 
performed in Bio-Rad DNA Engine PTC200 thermal cycler using Advantage 2 polymerase mix. Obtained 
PCR products were resolved on 1% agarose gel and visible bands were extracted using GeneJET Gel 
Extraction kit.  Extracted bands were eluted in 30 μl of nuclease free water. Purified fragments were 
cloned into pCR2.1 TOPO TA vector backbone and Mach1 E-coli cells were transformed. Plasmids were 
isolated using Axyprep Plasmid Mini Prep Kit after picking the colonies the next day. Gene specific 
primers were used for sequencing using services from GATC Biotech. 
4.7 Cellular function of lincNMR 
4.7.1 Cell viability assay 
CellTiter-Glo Luminescent Cell Viability Assay was performed 72 h after knockdown with the respective 
siPOOLs. At the time point for the assay, growth medium was removed from the cells using multi-
channel pipette and 60 µL of 1:4 CellTiter-Glo reagent: 1X PBS was added to the cells. Plate was 
incubated for 15 minutes at room temperature in the dark using an orbital shaker. After the incubation, 
chemiluminescence was measure using luminometer.  
4.7.2 Cell proliferation assay 
Cell Proliferation Assay kit was used to assess the impact of knockdown on proliferative capacity of cells. 
For the assay, at respective time point, the BrdU reagent was added to the final concentration of 10 µM 
to each well and the cells were allowed to grow for 6 h. Next, the medium was removed and the plate 
 46 
 
was further incubated for 30 minutes at room temperature after the addition of 200 µL of FixDenat 
solution. After the incubation, the FixDenat solution was removed and 100 µL of 1:100 dilution of BrdU 
antibody-POD solution was added and plate was incubated for 90 minutes on an orbital shaker in dark. 
Next, the cells were washed thrice with washing buffer at room temperature on a shaker for 5 minutes 
each. After washing steps, 100 µL of Luminol substrate was added and plate was incubated for 3 
minutes. After the incubation, chemiluminescence was measure using luminometer. 
4.7.3 Cell cycle analysis 
72 h post treatment with siPOOLs, cells were trypsinized and fixed in 70 % Ethanol overnight at -20°C. 
Fixed cells were pelleted and washed with 1 X PBS. After washing step, cells were re-suspended in 1 X 
PBS containing 100 µg/ml RNAse A and incubated at 37°C for 30 minutes. Post RNAse treatment, cells 
were stained with 100 µg/ml Propidium Iodide (PI). 10000 cells were acquired on BD FACSCanto II Flow 
Cytometer and data analysis was performed using FlowJo v10 software.  
4.7.4 Senescence associated β-GAL assay  
Cell were reverse transfected with respective siPOOLs on a 6-well plates and 96 h post transfection SA-
β-GAL activity was detected. Cells were washed with 1 X PBS and fixed at room temperature with 0.5% 
Glutaraldehyde for 20 mins. Cells were washed twice with 1 X PBS supplemented with 1 mM MgCl2 (pH 
6.0) for 10 min on a rocker. 2 ml X-Gal staining solution (1X PBS containing 1 mM MgCl2, 41 mg 
potassium hexacyanoferrate (III), 52.5 mg potassium hexacyanoferrate (II) trihydrate, 1 mg / ml X-Gal (5-
bromo-4-chloro-3-indolyl-beta-D-galacto-pyranoside), pH 6.0) was added and the dishes were sealed 
with parafilm and incubated overnight at 37°C. Next day, the cells were washed 3 X with distilled water 
and microscopy pictures were taken using 10x objective of a Zeiss Cell Observer microscope. For 
analysis, 100 cells were manually counted per condition in 3 independent experiments. 
4.8 Molecular Function 
4.8.1 Triple label SILAC-MS   
- Generation of HLE cell lines with light (Lys0, Arg 0), medium (Lys4, Arg 6) and heavy (Lys8, Arg 10) 
metabolic labels 
SILAC Protein Quantitation Kit RPMI 1640 was used to generate light and heavy labelled HLE cells. For 
generation of medium labelled cells 4, 4, 5, 5-D4 L-Lysine-2HCL (Fischer Scientific) and L-Arginine-HCL 
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13C6 (Life technologies) were individually purchased. Cells were grown in respective medium 
supplemented with 200 µg/ml of L-Proline for at least 8-10 passages in a humidified incubator at 37°C 
with 5 % CO2 for achieving > 99 % incorporation of each respective labels.  
- Cell Culture, transfections, lysate preparation, protein quantification, LC-MS/MS 
After confirmation of label incorporation, respective HLE cells were grown to 80% confluency. Cells were 
reverse transfected with respective siPOOLs targeting gene of interest. Lysates were harvested 48 h post 
transfection. Cells were lysed in 200 µL RIPA buffer supplemented with protease and phosphatase 
inhibitors. Additionally 0.1 % Benzonase was added to digest nucleic acids. After incubation on ice for 1 
h, cell lysates were cleared by centrifuging at 15000 g, for 30 minutes at 4°C. 2-D Quant Kit was used to 
quantify proteins. 
4.8.2 In vivo RNA Antisense Purification - Mass Spectrometry (In vivo RAP - MS) 
This experiment was performed in collaboration with Lander Lab at Broad Institute based in Cambridge 
MA USA. Biotinylated DNA oligo’s complementary to lincNMR sequence were ordered from IDT, 
sequences available in Table 9. 1 billion HLE cells were used per pulldown/condition per biological 
replicate. In vivo RAP-MS was performed as per the protocol described [162]. 
4.8.3 Crosslinking RNA Immunoprecipitation (UV - RIP) 
- Cell seeding, transfection, UV crosslinking and harvesting of cell lysates 
On day 1, 4x106 HLE cells were seeded onto 15-cm dish. On day 2, 2 µg of respective constructs (Empty 
vector plasmid pFRT-Flag-HA-ΔCmR-ΔccdB and pFRT-Flag/HA-YBX1) were transfected using Turbofect 
transfection reagent with a forward transfection protocol. On day 4, cells were UV crosslinked at a 
wavelength of 254 nm using 8000 J energy settings and then lysed in high strength cell lysis buffer 
supplemented with inhibitors cocktail containing SUPERase-In, protease and phosphatase inhibitors. 
Lysate was passed through syringe to break up the pellet and DNAse digestion was performed as per 
manufacturer’s instruction using Turbo DNA-free Kit. Protein quantification was done using BCA reagent 
and overexpression YBX1 was confirmed by probing with anti-HA antibody using western blot.  
- Pulldown   
1.5 µg of cell lysate was used to perform UV - RIP using anti-Flag magnetic beads and IP was confirmed 
by probing for anti-HA using western blot. For UV - RIP protocol, 150 µL of anti-Flag magnetic beads 
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were used per pulldown. Beads were prewashed 5 X using 1 X TBS and re-suspended in supplemented 
cell lysis buffer. 5% lysate was removed each for Input fraction and 150 µL of prewashed beads were 
added to cell lysate and incubated for 1 h at 4°C with rotation. After the incubation, beads were 
magnetically separated. 50 µL of flow through was saved to confirm depletion of YBX1 and remaining 
flow through was discarded. Beads were washed 2X first with low salt wash buffer and then with high 
salt wash buffer with rotation for 5 mins per wash. Beads were magnetically separated and re-
suspended in 500 µL of RNAse free pure water. Beads were then separated into fractions of 20 % (for 
protein extraction) and 80 % (RNA isolation) to confirm the IP and lincNMR interaction respectively. 
-Elution of RNA 
RNA was eluted from the beads by reversal of UV crosslinking in high salt buffer combined with 
Proteinase K digestion. 160 µL of Proteinase K buffer and 40 µL of Proteinase K were added to the eluted 
beads and incubated with shaking at 37° C for 30 mins at 1000 rpm. 500 µL of Trizol was added, tube 
was vortexed for 10 seconds and stored at -20 C until ready for RNA isolation. RNA isolation, reverse 
transcription and qPCR was performed as described above in section 4.3. 
-Elution of Proteins 
Captured, washed beads were boiled with 1 X SDS Loading buffer at 95° C for 10 mins and western blot 
was performed with input and flow through samples to confirm the pulldown. 10 % IP was loaded onto 
10 % SDS-PAGE gel. 
4.8.4 dNTP measurement assay  
This experiment was performed in collaboration with Prof. Kim Baek Lab at Emory University in Atlanta, 
GA USA. Cellular dNTPs were extracted from cells (HLE and FLC-4) transfected with respective siPOOLs 
72 h post transfection as per previously published protocol [163]. The dried dNTPs were re-suspended to 
proper volumes of water and added to the HIV-1 RT mediated single dNTP incorporation reactions. The 
percent of primer extension were converted to the incorporated dNTP amounts and the determined 
dNTP amounts were normalized by 1 million cells for comparison. Further, data was normalized to 
negative control siPOOLs. 
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4.8.5 dNTP bathing assay 
1250 cells were reverse transfected with respective siPOOLs in a clear bottom 96 well plate. Desired 
concentration of extracellular dNTPs were added to the cells 24 h later. Cell proliferation assay was 
performed at 96 h post siPOOL transfection to assess proliferation potential of the cells. 
4.8.6 Luciferase reporter assay 
HLE and FLC-4 cells were reverse transfected with 10 nM of control siPOOL and siPOOLs targeting 
lincNMR on day 1. Control pRL-TK / pRL-SV40 reporter constructs and Y-Box-TATA-Luc were co-
transfected using a forward transfection protocol on day 2. Cell culture medium was changed on day 3. 
Luciferase reporter assay was performed using a Dual Luciferase Reporter Assay System kit on day 4 as 
per manufacturer’s instruction and luminescence was measured on Spectra Max M5e.  
4.8.7 Chick Chorioallantoic Membrane (CAM) Assay 
Pathogen free, fertilized eggs were purchased from Valo Biomedia GmbH and incubated in an incubation 
oven with 60 % humidity at 37°C. On day 8, lincNMR was knocked down with 10 nM siPOOLs using a 
forward transfection protocol described before in HLE cells. On day 9, eggs were windowed with an 
electric drilling tool. On the same day, in parallel, 1x106 of respective HLE cells were re-suspended in 10 
µL growth media, mixed with 10 µL Matrigel and incubated for 10 min at 37°C and 5 % CO2.  Cell-
matrigel mix was seeded onto the CAM and window was further sealed for 5 days and incubated at 37°C 
with 60% humidity. Next days, eggs were observed and dead or injured embryos were excluded from 
further experiments. On day 6, Chicken embryos were euthanized by a quick decapitation and tumors 
were harvested from the CAM. Harvested tumors were processed, cleaned and collected in ice-cold 1 X 
PBS. Images of tumors from HLE cells transfected with negative control siPOOL and two independent 
siPOOLs targeting lincNMR were taken. Tumors were weighed on a micro-scale. 
4.9 Statistical analysis, softwares, databases and online tools 
4.9.1 T-TEST 
For calculation of statistical significance, Microsoft Excel function TTEST was used. P-values were 
calculated using a two-tailed distribution with either hetero/homoscedasticity. All data are shown as 
mean ± standard error mean from at least three independent biological replicates. * = P < 0.05; ** = P < 
0.01; *** = P < 0.001  
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4.9.2 Software, databases and online tools 
LncRNA expression data for transcriptome-wide profiling was downloaded from TANRIC platform. 
Correlation plots were also obtained from TANRIC portal. Kaplan Meier survival plots were generated 
using KM plotter. UCSC genome browser interface was used to study genomic orientation, gene 
neighborhoods etc. Coding potential of LncRNA was determined using PhyloCSF and CPC tools. Primers 
were designed using Primer3 interface on NCBI. Proteomics data obtained from Triple label SILAC 
experiment was analyzed using Perseus and Ingenuity Pathway Analysis platform. Gene set enrichment 
analysis was performed using Broad Institute’s GSEA platform.  GraphPad Prism 8 and Adobe Illustrator 
were used to prepare figures. All the softwares and tools were used as per the usage guidelines 
provided. List of softwares, online databases, tools and resources used in this study is provided in Table 
No. 13 and Table No. 14. 
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5. RESULTS 
Parts of the text and figures presented in this chapter are revised versions of the figures and text 
submitted for publication as an original research article: 
Gandhi et al., “lincNMR regulates Nucleotide Metabolism via a YBX1 - RRM2 Axis in Cancer” 
Nature Communications (manuscript under review) 
5.1 Transcriptome-wide expression analysis of lncRNAs in liver cancer 
In order to identify novel lncRNAs deregulated in liver cancer, I performed a transcriptome-wide 
expression profiling of lncRNAs using publicly available sequencing datasets from liver cancer patients. 
Upon further investigation of existing databases with lncRNA annotation, I chose to use the TANRIC 
database [164] where the patient dataset was derived from the TCGA data portal. The TANRIC dataset 
was chosen primarily due to the sample size, recent updates to the database and availability of 
associated clinical information. Next, expression data of liver cancer patients (tumor = 200 samples, 
normal = 50 samples) with 12727 lncRNAs annotations was downloaded and subjected to selection as 
per the outlined matrix (Fig. 1). As a first step, lncRNAs were selected primarily based on high expression 
and strength of induction in liver cancer compared to normal samples.  
Out of 12727 annotated lncRNAs, 217 lncRNAs were strongly and significantly induced by at least 5-fold 
(median tumor / median normal) and selected for further analysis (List available as Table 15 in the 
appendix section). Out of 217 lncRNAs, 49 lncRNAs were further chosen based on their genomic 
orientation, gene neighborhoods, low content of repeats or pseudogenes, CAGE tags and clinical 
attributes like subtype differentiation. Primarily goal behind second selection was to filter out lncRNAs 
with repeats, reported pseudogenes and to select for cancer-relevant locus by examining genes up and 
downstream of reported transcription start site. Next, the expression of selected 49 lncRNAs was 
validated in nine liver cancer cell lines to further select the candidates and identify suitable cell line 
models for further experiments (List of 49 lncRNAs available as Table 16 in the appendix section). 
Candidates were ranked for their abundance based on raw CT values obtained from RT-qPCR (data 
available as Table 16 in the appendix section) and nine lncRNAs were selected based on their expression 
in cell lines of interest, novelty and non-coding potential for further RNAi-based cellular function and 
phenotypic analysis.  
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Figure 1: Schematic: Transcriptome-wide lncRNA profiling in liver cancer 
Flow chart detailing selection steps performed for transcriptome-wide lncRNA profiling in 
RNA sequencing dataset (data derived from TANRIC data portal). Funnel-down approach was 
employed with indicated multiple parameters of selection to select lincNMR for further in-
depth characterization from initial 12727 lncRNAs. 
 
In order to circumvent off-target effects caused by single siRNAs, a more specific approach called 
siPOOLs was used. siPOOLs consist of a pool of 30 single siRNAs targeting one gene of interest and are 
used at much lower concentrations, thereby attenuating potential off-target effects conferred by 
individual siRNAs [160].  
Next, the candidates were subjected to cellular function analysis using cell viability assay in HLE cells. 
Among the candidates screened, the uncharacterized transcript RP6-65G23.3 showed the strongest 
 53 
 
decrease of cell viability in liver cancer cells where siPOOLs targeting PLK1 [165] and HULC [166] were 
used as a positive control (Fig. 2a).  
 
Figure 2: lincNMR emerged as a candidate with the strongest impact on cell viability 
a. Cell viability screen to assess the impact of depletion of selected lncRNAs with 10 nM siPOOLs at 72 h 
in HLE cells (n=4). si-HULC and si-PLK1 were used as positive controls. Data represents mean and error 
bars represent SEM. Significance was calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 
0.01; ***, P < 0.001 b. Knockdown efficiency for selected siPOOLs targeting lncRNAs in HLE cells at 24 h 
post depletion (n=1). a, b: Data shown was normalized to negative control siPOOL. 
The knockdown efficiency of siPOOLs (sequences available in Table 6) targeting nine lncRNAs was 
between 60 % – 90 % as determined by RT-qPCR (primer sequences available in Table 7) in HLE cells (Fig. 
2b). For reasons described in further sections in this thesis, this transcript RP6-65G23.3 was named 
lincNMR (long intergenic non-coding RNA Nucleotide Metabolism Regulator).  
  
 54 
 
5.2 Basic characterization of lincNMR 
LincNMR is a lncRNA transcribed from a bidirectional promoter in a head-to-head orientation with 
MAP3K9 on chromosome 14. Since the lincNMR transcript had never been studied before, I first 
performed Rapid Amplification of cDNA ends (RACE) experiment to define its gene boundaries. By using 
5‘RACE, I identified a new transcription start site (TSS) upstream of the current GENCODE annotation 
(Fig. 3a). This finding is supported by RNA-Pol II ChIP and switchgear TSS datasets corroborating the 
extended transcript identified in our 5'-RACE (Fig. 3b). I further performed 3'-RACE and not only 
confirmed the previously annotated 3'-end of lincNMR, but also identified a second, less abundant 
isoform of lincNMR including an additional internal exon (Fig. 3c). Both isoforms have been deposited 
into Genbank with the accession numbers MK652436 and MK652437. 5’- and 3’-RACE results are 
supported by ENCODE / Cold Spring Harbor long RNA - Seq tracks from the ENCODE consortium [167] 
(Fig. 3a, b, c).  
5.2.1 lincNMR is a long non-coding RNA 
Next, I analyzed the coding potential of lincNMR using coding potential scores from widely used online 
tools phyloCSF [168] (Fig. 3d) and the Coding Potential Calculator [169] (Fig. 4a) and found both 
algorithms to classify lincNMR as a non-coding transcript.  
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Figure 3: Basic characterization of lincNMR 
a. lincNMR genomic orientation from UCSC genome browser derived from GENCODE gene 
annotation tracks. Black bar depicts the blat sequence search representing 5’ RACE data. 
Additionally, subcellular fraction-specific HepG2 RNA-Seq data from ENCODE/CSHL tracks 
confirming the further upstream transcription start site of the lincNMR transcript and predominant 
cytoplasmic localization of lincNMR. b. UCSC genome browser tracks depicting data from 
Switchgear transcription start site (TSS) annotation supporting longer lincNMR exon with another 
TSS. Also shown is a grey bar depicting RNA Pol II binding site from Transcription factor binding site 
ChiP-Seq data set from ENCODE/HAIB supporting the new TSS. c. lincNMR genomic orientation 
from UCSC genome browser derived from comprehensive gene annotation set GENCODE tracks. 
Black bar depicts the blat sequence search representing 3’ RACE data.  Two different gene specific 
primers (GSP) were used for 3’RACE, 3RACE_GSP.e1 and 3RACE_GSP.e2. d. PhyloCSF tracks 
indicate the lack of coding potential of lincNMR in all three translation frames. 
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5.2.2 lincNMR is a predominantly cytoplasmic lncRNA 
Since subcellular localization maybe linked to the biological function of non-coding RNAs [32, 170], I 
further performed subcellular fractionation with fraction-specific controls NEAT1 (chromatin fraction), 
RNU-1 (nucleoplasmic fraction) and DANCR (cytoplasmic fraction). lincNMR localized predominantly 60 
% - 70 % to the cytoplasmic fraction, but also showed considerable presence in the nucleoplasmic 
fraction (Fig. 4b). 
 
Figure 4: lincNMR is non-coding and predominantly cytoplasmic 
a. Coding Potential Calculator: Bar graph representing coding potential scores for a set of 
coding (RRM2, TK1 and TYMS) and non-coding (lincNMR, HOTAIR, DANCR and MALAT1) 
genes where positive scores indicate a gene coding for proteins and negative scores confirm 
the non-coding potential of lncRNAs b. Subcellular fractionation of HLE cells and subsequent 
RT-qPCR confirms the cytoplasmic and partially nucleoplasmic localization of lincNMR. 
Fraction-specific controls are included to ensure fraction quality (Chromatin: NEAT1, 
MALAT1; Nucleoplasm: RNU1; Cytoplasm: DANCR). Data represent mean and error bars 
represent SEM (n=4). Significance was calculated by unpaired, two-tailed t-test with *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
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5.3 Cellular function of lincNMR 
5.3.1 Depletion of lincNMR invokes a strong proliferation defect in multiple cancer cell lines 
To elucidate the cellular function of lincNMR, I silenced lincNMR using two independent siPOOLs for 
additional specificity and to exclude any off-target effects observed with single siRNAs [160] in multiple 
cancer cell lines.  
Since lincNMR knockdown decreased cell viability in liver cancer cells (Fig. 2a), I investigated whether 
depletion of lincNMR would impact cancer cell proliferation using a BrdU incorporation assay. lincNMR 
silencing with two independent siPOOLs resulted in 30 % - 80 % decrease in cell proliferation in four liver 
cancer cell lines (HLE, HLF, SNU-387 and FLC-4) (Fig. 5a).  
Additionally, depletion of lincNMR also invoked a proliferation defect in three breast (MCF-7, KPL-1 and 
T47D) (Fig. 5b) and three lung (A549, NCI-H460 and NCI-H1299) cancer cell lines (Fig. 5c) suggesting a 
broader function of lincNMR in cancer.  
As a quality control to ensure the functioning of siPOOLs, I also tested the knockdown efficiency of both 
siPOOLs targeting lincNMR. Both siPOOLs silenced lincNMR expression efficiently in multiple liver (Fig. 
5d), breast (Fig. 5e) and lung (Fig. 5f) cancer cell lines with an efficiency of 85 % - 98 %.  
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Figure 5: Depletion of lincNMR invokes a proliferation defect in multiple cancer cell lines 
a. Depletion of lincNMR with 10 nM of two independent siPOOLs invokes a strong proliferation 
defect in four liver cancer cell lines (HLE, HLF, FLC-4 and SNU-387) 72 h post transfection (n=3) 
b. Depletion of lincNMR with 10 nM siPOOLs invokes a proliferation decrease in multiple 
breast cancer cell lines (MCF7, KPL-1 and T47D) 72 h post transfection (n=3) c. Depletion of 
lincNMR with 10 nM siPOOLs invokes a proliferation decrease in multiple lung cancer cell lines 
(A549, NCI-H460 and NCI-H1299) 72 h post transfection (n=3). d. LincNMR knockdown with 10 
nM of two independent siPOOLs (si-lincNMR-A and si-lincNMR-B) leads to 80 % – 94 % 
silencing at 24 h post knockdown in multiple liver cancer cell lines (HLE, HLF, FLC4, and SNU-
387) e. LincNMR knockdown with 10 nM of two independent siPOOLs (si-lincNMR-A and si-
lincNMR-B) leads to 75 % – 99 % silencing at 72 h post knockdown in multiple breast cancer 
cell lines (MCF-7, KPL-1, and T47D) f. LincNMR knockdown with 10 nM of two independent 
siPOOLs (si-lincNMR-A and si-lincNMR-B) leads to 80 % – 93 % silencing of lincNMR at 72 h post 
knockdown in multiple lung cancer cell lines (A549, NCI-H460 and NCI-H1299). a – f: Data 
represents mean and error bars represent SEM (n=4). Significance was calculated by unpaired, 
two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data shown was normalized to 
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negative control siPOOL. 
 
5.3.2 Silencing of lincNMR causes a cell cycle arrest in G0/G1 phase of cell cycle 
After investigating the effect of lincNMR depletion on cell proliferation, cell cycle analysis was 
performed using flow cytometry and where I found an increase in the number of lincNMR depleted cells 
in the G0/G1 phase of the cell cycle in multiple cancer cell lines (Fig. 6 a, b, c). 
 
Figure 6: Silencing of lincNMR caused a cell cycle arrest in G0/G1 phase  
a. Silencing of lincNMR with 10 nM siPOOLs induces cell cycle arrest in G0/G1 phase as shown by flow 
cytometry 72 h post transfection in HLE (n=3). b. Silencing of lincNMR with 10 nM siPOOLs induces cell 
cycle arrest in  G0/G1 phase  at 72 h post transfection in FLC-4 (n=3) c. Silencing of lincNMR with 10 
nM siPOOLs induces cell cycle arrest in G0/G1 phase at 72 h post transfection in MCF-7 (n=3). a – c: 
Analysis was performed using FlowJo v10. Data represents mean and error bars represent SEM (n=4). 
Significance was calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Data shown was normalized to negative control siPOOL. 
5.3.3 Loss of lincNMR triggers an induction of senescence in multiple cancer cell lines 
The arrest of cells in the G0/G1 phase prompted me to evaluate whether there was an induction of 
senescence in lincNMR depleted cells. Indeed, depletion of lincNMR triggered an induction of 
senescence in multiple liver cancer cell lines with two independent siPOOLs as evident by β-GAL-positive 
blue cells in SA-β-GAL assay (Fig. 7a, b). The induction of senescence was supported by the increased 
expression of the pro-inflammatory cytokines IL-1a and IL-1b, which have been known to be the bona 
fide markers of senescence-associated secretary phenotype (SASP) (Fig. 7c). 
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Figure 7: Loss of lincNMR triggers an induction of senescence and SASP  
a. Representative microscopic images showing increased β-Gal activity indicating senescent cells 
in HLE, 96 h post lincNMR knockdown with 10 nM siPOOLs b. Bar graph representing the percent 
β-Gal-positive cells in multiple liver cancer cell lines after lincNMR depletion c. Induction of 
senescence associated secretary phenotype (SASP) markers IL-1a and IL-1b determined by RT-
qPCR at 72 h after lincNMR knockdown in HLE with 10 nM siPOOLs (n=3); b, c: Data represents 
mean and error bars represent SEM. Significance was calculated by unpaired, two-tailed t-test 
with *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data shown was normalized to negative control 
siPOOL 
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5.4 Molecular function of lincNMR 
5.4.1 RAP-MS to identify direct protein binding partners of lincNMR 
I performed an in vivo RNA Antisense Purification (RAP-MS) in order to identify protein interaction 
partners and gain insight into the molecular function of lincNMR [162, 171] in collaboration with the lab 
of Eric Lander at the Broad Institute in Cambridge, MA, USA, where I spent two weeks to learn this 
important technique. I used biotinylated DNA oligos (sequences available in Table 9) complementary to 
the sequence of lincNMR to pulldown lincNMR and associated direct protein binding partners 
(schematic Fig. 8a).  
 
Figure 8: Schematic: LincNMR in vivo RNA Antisense Purification (RAP-MS) 
a. Schematic of lincNMR RAP-MS, used to identify direct protein interaction partner b. lincNMR 
RAP-MS pulldown efficiency: data represent log10 fold change normalized to reference gene PPIA 
and input in HLE with three different lincNMR amplicons and GAPDH as additional negative 
control (n=2) c. Volcano plot depicting total proteins (n = 701) identified by lincNMR RAP-MS. 48 
candidates highlighted in red were selected for fold enrichment and significance: (FC > 2) and 
adjusted p-value of enrichment (P < 0.001) 
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Pulldown efficiency of lincNMR was confirmed by RT-qPCR with three different lincNMR amplicons 
where PPIA and GAPDH mRNAs were used as negative controls (Fig. 8b). Mass spectrometry of lincNMR 
RAP-MS from crosslinked compared to non-crosslinked lysates identified 701 proteins in total (Fig. 8c) 
with 48 proteins enriched at least two fold with strong significance of adjusted p-value < 0.001 (List 
available as Table 17).  
5.4.2 lincNMR directly binds to YBX1 protein, which regulates cell survival 
To further select relevant lincNMR binding partners linked to HCC, I analyzed their correlation to survival 
in HCC using a web-based tool called KM Plotter, based on patient dataset from the TCGA liver cancer 
cohort (Fig. 9a).  
 
Figure 9: YBX1 has a strongest association with survival in liver cancer patients 
a. Interaction partners identified by lincNMR RAP-MS are selected for fold enrichment in crosslinked 
over non-crosslinked samples (FC > 2), adjusted p-value of enrichment (P < 0.001), and sorted for 
logrank p-value in liver cancer survival (based on TCGA data) b. Kaplan-Meier plot correlating high YBX1 
expression to poor survival in liver cancer patients (TCGA survival data accessed through web-based 
tool KM Plotter) 
Upon ranking, the candidates using logrank survival p-value, 22 candidates were found to be 
significantly associated with the overall survival of liver cancer patients (highlighted in bold in Table 18). 
Moreover, YBX1 emerged as a direct binding partner with strongest significant correlation to survival in 
liver cancer (Fig. 9a, b). Additionally, to further support lincNMR - YBX1 interaction, I also searched for 
predicted RBP binding sites in the lincNMR transcript using RBPmap [172] and found three YBX1 and two 
SRSF3 sites (p < 0.001) consolidating the results obtained from the RAP-MS experiment. 
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5.4.3 Validation of  lincNMR - YBX1 interaction using UV - RIP 
In order to further validate lincNMR - YBX1 interaction identified by RAP - MS, I performed crosslinking 
RNA Immuno-precipitation (UV – RIP) in HLE cells. After immunoprecipitation of Flag-HA tagged YBX1 
(Fig. 10a), lincNMR was found to be significantly enriched in the YBX1 pulldown as compared to the 
negative control (Fig. 10b) thus confirming the direct interaction between the lincNMR transcript and 
YBX1 protein.  
 
Figure 10: Direct interaction between lincNMR - YBX1 validated by UV – RIP 
a. Representative western blot for YBX1 UV – RIP validating YBX1 pulldown using anti-HA antibody in 
HLE cells. Input, supernatant and IP fractions are loaded onto 10% SDS-PAGE gel b. Determination of 
RNA pulldown efficiency in UV - RIP by RT-qPCR validating the interaction between YBX1 and 
lincNMR in HLE cells (n = 4). Data represents mean and error bars represent SEM. Significance was 
calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data shown is 
normalized to SRSF4 as negative control gene and to control vector. 
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5.4.4 Silencing of YBX1 mimics the phenotype induced by lincNMR depletion 
Depletion of YBX1 also impaired the cell proliferation by 50% (Fig. 11a), resembling the effect of 
lincNMR knockdown. I also found significant positive correlation between lincNMR and YBX1 mRNA in 
HCC patient samples (Fig. 11b). Additionally, lincNMR levels were found to be decreased by 49 % after 
YBX1 silencing (Fig. 11c); vice versa we found that YBX1 protein levels were only marginally decreased by 
about 20% when lincNMR was silenced by two independent siPOOLs (Fig. 11d, e).  
 
Figure 11:  Depletion of YBX1 mimics phenotype induced by lincNMR depletion 
a. Silencing of YBX1 with 10 nM siPOOL imparts a proliferative disadvantage to HLE cells determined 
at 72 h post transfection. Data shown is normalized to negative control siPOOL (n = 3). b. LincNMR 
expression levels significantly correlate with YBX1 mRNA with a correlation coefficient of R = 0.44 in 
hepatocellular carcinoma patients (data derived from TCGA through TANRIC platform) [164] c. 
Depletion of YBX1 using 10 nM siPOOLs in HLE cells is effective and leads to downregulation of 
lincNMR expression at 72 h in HLE cells. LincNMR and YBX1 RNA were measured by RT-qPCR and the 
data was normalized to SRSF4 and negative control siPOOL. d. Western blot image of YBX1 expression 
upon lincNMR depletion in HLE using 10 nM YBX1 siPOOLs (n = 3) e. Depletion of lincNMR using 10 
nM siPOOLs in HLE cells leads to marginal, but significant downregulation of YBX1 protein at 72 h. 
Protein fold change was calculated by normalizing the YBX1 signal to loading control GAPDH and 
negative control siPOOL. a, c, e: Data represent mean and error bars represent SEM. Significance was 
calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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5.4.5 LincNMR directly binds to YBX1 and regulates its transactivational activity 
The direct interaction of lincNMR and YBX1 protein prompted us to assess whether there was change in 
activity of YBX1 upon lincNMR depletion. Dual luciferase assay was performed where lincNMR depleted 
cells were transfected with control or YBX1 reporter plasmids together with renilla luciferase reporter 
construct for in-experiment normalization. Depletion of lincNMR significantly decreased the YBX1 
activity in two independent liver cancer cell lines HLE and FLC - 4 (Fig. 12).  
 
Figure 12: LincNMR regulated the transactivation activity of YBX1 in liver 
Dual Luciferase assay for the transactivational activity of YBX1 unravels the inhibition of YBX1 
by lincNMR silencing. Data shown is the ratio of YBX1-dependent Firefly luciferase activity 
divided by Renilla luciferase used for standardization after depletion of lincNMR with 10 nM 
siPOOLs in HLE and FLC-4 cells (n = 3). 
Taken together, this data concludes that lincNMR directly interacts with and regulates YBX1 (section 
5.4.1 – 5.4.3), YBX1 mimics the impact of lincNMR on cell proliferation and the regulation of lincNMR by 
YBX1 generates a feedforward loop leading to the correlation of expression in liver cancer (section 
5.4.5). 
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5.4.6 Total cellular proteome after lincNMR depletion using triple-label SILAC approach 
To investigate the impact of lincNMR depletion on the cellular proteome and identify the target genes, I 
optimized and established a triple-label stable isotope labelling by amino acids in cell culture (SILAC) 
approach in the lab (Fig. 13a). SILAC ratios were used for analysis comparing lysates from cells treated 
with siPOOLs targeting lincNMR to cells treated withthe negative control siPOOL (si-lincNMR-A / si-Neg 
Ctrl = M/L and si-lincNMR-B/si-Neg Ctrl = H/L). A correlation analysis depicted by multi-scatter plot 
served as a quality control for the complete dataset: a significant correlation was observed across three 
biological replicates (individual correlation coefficients displayed on the plot) and in between both 
siPOOLs targeting lincNMR with an average correlation coefficient of R = 0.74 (Fig. 13b).  
 
Figure 13: Schematic overview and reproducibility of triple-label SILAC experiment 
a. Schematic of triple-label SILAC-MS experiment to identify proteins deregulated upon lincNMR loss. 
b. Multi-scatter plot depicting all deregulated proteins identified within and across three biological 
replicates using two independent siPOOLs (si-lincNMR-A = Medium (M), si-lincNMR-B = Heavy (H), vs. 
control siPOOL = Light (L)) in triple-label SILAC-MS. HLE cell lysates were harvested at 48 h after 
depletion of lincNMR with 10 nM siPOOLs (n = 3). Data represents fold change normalized to 
negative control siPOOLs. A total of 2088 proteins were identified across biological replicates and 
only candidates deregulated with both siPOOLs were selected for further analysis. Pearson 
correlation coefficient is displayed on the multi-scatter plot. 
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Further, stringent analysis with a significance filter of adjusted p-value < 0.001 led to the identification of 
242 candidates deregulated by both lincNMR-targeting siPOOLs. Panther overrepresentation analysis 
was performed using Fisher test with Bonferroni correction on these selected 242 candidates. This 
revealed a significant enrichment of key reactome pathway terms - G1/S transition, cell cycle 
checkpoints, and metabolism of RNA etc. corroborating the phenotype observed after lincNMR 
depletion (Fig. 14).  
 
Figure 14: Panther overrepresentation analysis reveals enrichment of key cell cycle terms 
Panther overrepresentation test: Fisher test was performed on 242 deregulated candidates (P < 
0.001) with Bonferroni correction on a dataset obtained from triple-label SILAC-MS experiment after 
depletion of lincNMR in HLE cells. Depicted is the fold enrichment of key terms associated with 
these deregulated hits from SILAC-MS. 
5.4.7 Loss of lincNMR causes downregulation of key enzymes in nucleotide metabolism  
Upon further in-depth analysis of strongly deregulated candidates after lincNMR depletion, I identified 
RRM2 (si-lincNMR-A = - 68%, si-lincNMR-B = - 67%), TK1 (si-lincNMR-A = - 52%, si-lincNMR-B = - 58%) 
and TYMS (si-lincNMR-A = - 43%, si-lincNMR-B = - 57%) as strongly downregulated proteins among other 
key enzymes implicated in nucleotide metabolism pathways (Fig. 15a). This decrease of RRM2, TK1 and 
TYMS proteins after lincNMR depletion was validated by western blotting in HLE cells (Fig. 15b) in good 
accordance with the independent triple-label SILAC-MS approach (Fig. 15c). Additionally, a decrease of 
RRM2, TK1 and TYMS mRNA was also observed after lincNMR depletion with both siPOOLs (Fig. 15d). 
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Figure 15: Loss of lincNMR causes depletion of enzymes regulating nucleotide 
metabolism 
a. Triple-label SILAC-MS: Scatter Plot shows deregulated proteins 48 h after lincNMR 
knockdown with 10 nM siPOOLs in HLE cells. Data represents log2 fold change normalized 
to negative control siPOOL from two independent replicates. Highlighted proteins 
represent key deregulated players in purine and pyrimidine metabolism according to 
KEGG pathway annotations. Color key: red = upregulated proteins; blue = downregulated 
proteins b. Western blot validation of SILAC-MS data depicting downregulation of RRM2, 
TK1 and TYMS proteins in HLE cells 72 h after lincNMR knockdown with 10 nM siPOOLs 
(n=3). Vinculin was used as a loading control c. Quantitative comparison of SILAC-MS and 
western blot results confirming consistent downregulation of RRM2, TK1 and TYMS (n=3). 
log2 fold change was calculated and normalized to negative control siPOOL d. Depletion 
of lincNMR with two independent siPOOLs (si-lincNMR-A and si-lincNMR-B) leads to 
downregulation of RRM2, TK1 and TYMS mRNAs in HLE cells at 72 h after lincNMR 
knockdown with 10 nM siPOOLs (n=3). c – d: Data represents mean and error bars 
represent SEM. Significance was calculated by unpaired, two-tailed t-test with *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. 
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5.4.8 Silencing of RRM2, TK1 and TYMS also mimics the phenotype induced by lincNMR loss 
To investigate the impact of depletion of lincNMR target genes on cellular function, I silenced RRM2, TK1 
and TYMS using siPOOLs with a knockdown efficiency in the range of 90 % - 98 % in HLE cells (Fig. 16a) 
and interestingly observed a strong induction of proliferation defect upon the loss of RRM2, TK1 and 
TYMS thus mimicking the phenotype observed after lincNMR depletion (Fig. 16b).  
 
Figure 16: Depletion of RRM2, TK1 and TYMS mimicks the phenotype induced by lincNMR loss 
a. RT-qPCR data showing knockdown efficiency of RRM2, TK1 and TYMS in HLE with 10 nM 
respective siPOOLs at 72 h post knockdown (n =3). Data was normalized to reference gene SRSF4 
and negative control siPOOL b. Depletion of RRM2, TK1 and TYMS invokes a strong proliferation 
defect 72 h after knockdown using 10 nM RRM2, TK1 or TYMS targeting siPOOLs in HLE cells in at 
least 3 biological replicates. a, b: Data represents mean and error bars represent SEM. Significance 
was calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data 
shown is normalized to negative control siPOOL. 
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5.4.9 LincNMR and YBX1 share common target genes regulating nucleotide metabolism 
Since we identified lincNMR as a regulator of the transcription factor YBX1 activity, I tested whether 
YBX1 depletion would also affect RRM2, TK1 and TYMS expression levels. Indeed, upon the loss of YBX1, 
we observed a significant decrease of RRM2, TK1 and TYMS protein levels (Fig. 17a, b) establishing the 
lincNMR - YBX1 - RRM2 / TK1 / TYMS axis in liver cancer. 
 
Figure 17: Loss of YBX1 also regulates lincNMR target genes RRM2, TK1 and TYMS 
a. YBX1 silencing inhibits the expression of RRM2, TK1 and TYMS at 72 h post transfection with 
10 nM siPOOL in HLE cells as documented by western blotting. GAPDH was used as a loading 
control b. Quantification of western blot from (a): protein fold change was calculated by 
normalizing the RRM2, TK1 and TYMS signal to loading control GAPDH and to negative control 
siPOOL (n=3). Data represents mean and error bars represent SEM. Significance was calculated 
by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
5.4.10 LincNMR target genes are regulated and associated with poor survival in liver cancer  
Next, I analyzed the clinical significance for lincNMR target genes and found RRM2, TK1 and TYMS to be 
strongly and significantly induced by about ten-, six- and four-fold respectively in liver cancer patient 
datasets from TCGA data portal compared to normal tissue (Fig. 18a, b, c).  
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Figure 18: RRM2, TK1 and TYMS are expressed and regulated in liver cancer  
a. RRM2 is expressed and regulated in liver cancer (N=normal, T=tumor; data obtained from TCGA 
data portal). LIHC=Hepatocellular Carcinoma (N=50, T=374) b. TK1 is expressed and regulated in 
liver cancer (N=normal, T=tumor; data obtained from TCGA data portal). LIHC=Hepatocellular 
Carcinoma (N=50, T=374) c. TYMS is expressed and regulated in liver cancer (N=normal, T=tumor; 
data obtained from TCGA data portal). LIHC=Hepatocellular Carcinoma (N=50, T=374) a – c: Data is 
represented as log2 RSEM. Significance was calculated by unpaired, two-tailed t-test with *, P < 
0.05; **, P < 0.01; ***, P < 0.001. 
 
Furthermore, all three lincNMR target genes, RRM2, TK1 and TYMS were also significantly associated 
with poor survival in liver cancer patient datasets (Fig. 19a, b, c).  
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Figure 19: Impact of lincNMR target genes on survival in liver cancer  
a. Kaplan-Meier plots of liver cancer patients stratified by RRM2 expression levels b. Kaplan-Meier plots 
of liver cancer patients stratified by TK1 expression levels c. Kaplan-Meier plots of liver cancer patients 
stratified by TYMS expression levels 
 
Moreover, the lincNMR expression level significantly and positively correlated with RRM2, TK1 and 
TYMS mRNA in liver cancer patient samples (Fig. 20a, b, c) further corroborating the strong link between 
lincNMR, these three regulators of nucleotide metabolism and liver cancer. 
 
Figure 20: Correlation of expression between lincNMR and its targets in liver cancer patients 
a. Correlation plot: lincNMR expression correlates with RRM2 mRNA expression in liver cancer 
patients b. Correlation plot: lincNMR expression correlates with TK1 mRNA expression in liver cancer 
patients  
c. Correlation plot: lincNMR expression correlates with TYMS mRNA expression in liver cancer 
patients  
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5.4.11 Depletion of lincNMR leads to reduced dNTP levels in liver cancer  
Since dNTP-synthesizing enzymes were downregulated by the knockdown of lincNMR, I further 
investigated whether the levels of dNTPs were also accordingly affected. Interestingly, all four dNTPs - 
dATP, dCTP, dGTP and dTTP - were significantly downregulated after lincNMR depletion in two 
independent cell liver cancer lines HLE (Fig. 21a) and FLC-4 (Fig. 21b) solidifying the role of lincNMR in 
regulation of nucleotide metabolism. 
 
Figure 21: Depletion of lincNMR leads to reduced dNTP levels 
a. Quantification of dNTP levels uncovers that the depletion of lincNMR with 10 nM siPOOLs leads to 
strong downregulation of dATP, dCTP, dGTP and dTTP in HLE cells b. Quantification of dNTP levels 
uncovers that the depletion of lincNMR with 10 nM siPOOLs leads to strong downregulation of dATP, 
dCTP, dGTP and dTTP in FLC-4 cells. a - b: Data represents mean and error bars represent SEM (n = 3). 
Significance was calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Data shown is normalized to negative control siPOOL. 
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5.4.12 Extracellular supply of dNTPs rescues the phenotype induced by depletion of lincNMR  
Interestingly, supplying exogenous dNTPs by bathing the lincNMR depleted cells rescued the impact of 
lincNMR knockdown on cell proliferation (Fig. 22a, b). This effect was found to be dose-dependent and 
statistically significant illustrating the essential role of nucleotide metabolism in the pro-proliferative 
function of lincNMR. 
 
Figure 22: Exogenous supply of dNTPs rescues the phenotype induced by lincNMR loss 
a. Schematic outline of dNTP bathing & rescue assay b. Supplying dNTPs rescues dose-dependently 
the proliferation decrease caused by lincNMR silencing determined by a BrdU incorporation assay. 
HLE cells were reverse transfected with 10 nM of the respective siPOOLs and bathed in increasing 
concentrations (0 µM to 150 µM) of extracellular pools of dNTPs 24 h post lincNMR depletion (n = 4). 
Data shown represents the results of the cell proliferation assay normalized to negative control 
siPOOL with the respective dNTP concentration. Data represents mean and error bars represent SEM. 
Significance was calculated by unpaired, two-tailed t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
Data shown is normalized to negative control siPOOL 
 
In summary, the regulation, association with survival and correlation of expression between lincNMR, 
YBX1, RRM2, TK1 and TYMS links them to liver cancer and to each other, respectively. LincNMR affects 
cell viability, proliferation, senescence and tumor growth in vivo and the interactors and targets mimic 
its phenotypes. At the molecular level, these data suggest a model in which the lncRNA lincNMR binds to 
YBX1, increases its activity resulting in the upregulation of the enzymes RRM2, TK1 and TYMS, which in 
turn govern an increase in nucleotide metabolism which can rescue the effect of lincNMR depletion. 
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5.5 Potential clinical significance of lincNMR in cancer 
5.5.1 lincNMR is induced and regulated in multiple cancer entities 
In line with the impact of lincNMR knockdown in cell lines from different tumor entities, lincNMR was 
also found to be significantly induced between tumor and normal tissues across multiple cancer types 
including breast invasive carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, bladder 
urothelial carcinoma and cervical squamous cell carcinoma (Fig. 23) suggesting broader cancer-wide 
significance.  
 
 
Figure 23: lincNMR is induced in multiple cancer entities 
LincNMR is expressed and regulated in multiple cancer types (N=normal, T=tumor; data 
obtained from TCGA data portal). LIHC = Hepatocellular Carcinoma (N=50, T=200), BRCA = 
Breast Cancer (N=105, T=150), LUAD = Lung Adenocarcinoma (N=58, T=488), LUSC = Lung 
Squamous Cell Carcinoma (N=17, T=220), BLCA = Bladder Cancer (N=30, T=252), CESC = 
Cervical Serous Carcinoma (N=3, T=196). Data is represented as log2 RPKM. 
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5.5.2 lincNMR is also expressed in multiple human cancer cell lines  
Additionally, to test whether lincNMR transcript was also expressed in other human cancer cell lines of 
diverse origins, I performed RT-qPCR in a panel of 73 different human cancer cell lines and found both 
isoforms of lincNMR to be expressed (Fig. 24) suggesting the relevance of lincNMR in multiple cancer 
types. 
 
 
Figure 24: lincNMR is also expressed in multiple human cancer cell lines 
RT-qPCR data in a panel of 73 human cancer cell lines (except IMR90, WI38, B2B, MCF10a, 1°FF, 
RPE1 = non-cancerous) showing expression of the two lincNMR isoforms (lincNMR-amp#1, lincNMR-
amp#2) across multiple cancer types (liver, lung, breast, skin, intestinal, reproductive tract, blood 
etc.). Expression data shown is normalized to an average of two reference genes SRSF4 and PPIA.  
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5.5.3 lincNMR induced knockdown and growth inhibitory phenotype is stable until 168 h 
Prior to performing in vivo xenograft experiments, I first confirmed the presence of siPOOL-induced 
lincNMR knockdown over an extended time period by checking for the knockdown efficiency and the 
presence of the growth-inhibitory phenotype. The siPOOL induced knockdown (Fig. 24a) and phenotype 
(Fig. 24b) upon lincNMR depletion were persistent until 168 h / day 7 after transfection fitting for the 
duration of the CAM assay.  
 
Figure 25: lincNMR-induced phenotype using siPOOLs is stable until day 7 after transfection 
a. Time course of knockdown efficiency determined by RT-qPCR to verify stable knockdown of lincNMR 
until seven days after transfection with 10 nM siPOOLs in HLE cells. b. Time course of BrdU incorporation 
assays in HLE cells showing induction and maintenance of proliferation defect up to 168 h / day 7 post 
lincNMR knockdown with 10 nM siPOOLs. a, b: Data is normalized to negative control siPOOL. Data 
represent mean and error bars represent SEM (n=3). Significance was calculated by unpaired, two-tailed 
t-test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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5.5.4 Depletion of lincNMR leads to decreased tumor size and growth in vivo 
To test the impact of lincNMR depletion on tumor size and growth in vivo, I performed xenograft 
experiments using the Chicken Chorioallantoic Membrane (CAM) model considering the ethical 
responsibility and aiming to replace, reduce or refine (3R) the use of animal models for research 
purposes. After seeding lincNMR-silenced or control-treated cells onto the CAM, tumors were 
harvested, measured and weighed. Tumors derived from lincNMR-depleted cells were significantly 
smaller in size as compared to the tumors derived from the control group (Fig. 26a). The tumor weight 
was also significantly reduced in lincNMR-depleted tumors in comparison to the control group (Fig. 26b). 
 
Figure 26: Loss of lincNMR leads to decreased tumor weight and size in vivo 
a. Chick Chorioallantoic Membrane (CAM) assay: Picture showing tumors harvested from the CAM 
formed from HLE cells transfected with lincNMR-targeting or control siPOOLs. Tumors were harvested 
on day six. LincNMR-depleted cells gave rise to smaller tumors. (Number of chick embryos used in total: 
si-negative control=24,  si-lincNMR-A=27, si-lincNMR-B=29) 
b. Quantification of tumors harvested from CAM assay: show decreased tumor weight in lincNMR-
depleted tumors compared to the control group. Significance was calculated by unpaired, two-tailed t-
test with *, P < 0.05; **, P < 0.01; ***, P < 0.001. 
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6. DISCUSSION 
Parts of the text and figures presented in this chapter are revised versions of the figures and text 
submitted for publication as an original research article: 
Gandhi et al., “lincNMR regulates Nucleotide Metabolism via a YBX1 - RRM2 Axis in Cancer” 
Nature Communications (manuscript under review) 
 
This is the first study to investigate and unveil the molecular mechanism of lincNMR in cancer and also 
the first report linking the involvement of lncRNA in regulation of cell proliferation through nucleotide 
metabolism pathways.  
Primary aim of my PhD project was to identify strongly deregulated novel lncRNAs in liver cancer and to 
further perform in-depth characterization of its cellular and molecular function. First, to identify strongly 
deregulated novel lncRNA candidates, a transcriptome-wide expression profiling was performed using 
publicly available RNA-sequencing dataset. LncRNA expression data was downloaded from the TANRIC 
database [164], derived from publicly available patient data from TCGA data portal. Out of 12727 
lncRNA annotations, first selection of lncRNAs was made based on their high expression and strong 
regulation in liver cancer. Primary selection lead to the identification of 217 lncRNAs, where some of the 
well-studied lncRNAs such as MALAT1, HULC, NORAD, ANRIL, CRNDE, LINC00857, TMPO-AS1, DANCR, 
ZFAS1 were found among the top deregulated candidates along with novel lncRNA transcripts, validating 
the rationale for primary selection. Second selection was made based on individually analyzing the 
attributes - novelty, coding potential, cancer-related gene neighborhood, presence of independent 
transcription start site etc. Second selection was made to ensure that only independently transcribed 
lncRNAs were selected for further steps by analyzing human promoterome dataset and also 
transcription start sites from Switchgear [173] . This led to the identification of 49 lncRNAs comprising of 
novel as well as well-studied lncRNAs. Well studied lncRNAs were included to be used as a positive 
control for further analysis. Expression analysis was performed on selected 49 lncRNAs using RT-qPCR in 
nine liver cancer cell line models of interest. Only HCC cell lines were chosen for further expression 
analysis to assist in identification of relevant and essentially disease specific transcripts. Expression 
analysis of selected lncRNAs led to the identification of nine well-expressed lncRNAs to be further 
probed for cellular function.  
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For cellular function analysis, RNAi based approach was used considering the predominant cytoplasmic 
localization of the lncRNAs in order achieve optimum knockdown efficiency. To circumvent off-target 
effects often displayed while using higher concentrations of single siRNAs, a pool of 30 single siRNAs 
called siPOOLs was used in much lower concentrations to target the gene of interest [160]. siRNA 
sequences in negative control siPOOL had no complementarity with human genome thus acting as an 
ideal negative control in further experiments. siPOOLs targeting HULC and PLK1 were used a positive 
controls pools for added confidence due to their documented impact on cell viability. Cell viability 
screen led to the identification of novel lncRNA transcript RP6-65G23.3, now named lincNMR for 
reasons discussed further below in the text. LincNMR was selected as a novel lncRNA candidate due to 
the strength of the phenotype for in-depth cellular and molecular function analysis.  
Since lncRNA lincNMR was a novel, so far uncharacterized transcript, basic characterization steps were 
performed to investigate its coding potential, subcellular localization and gene boundaries. Coding 
potential of lincNMR was analyzed using two tools, namely CPC and PhyloCSF. CPC analyzes putative 
open reading frames and assigns a score called CPC score to the transcript, where negative score 
corresponds to non-coding transcript and positive score indicates protein coding potential. A score from 
PhyloCSF algorithm determines whether alignment of multi-species nucleotide sequence is likely to 
represent protein-coding region. LincNMR was found to be a non-coding RNA using both the algorithms. 
Recently, there have been reports of micro-peptides being coded by non-coding transcripts [174, 175], 
ribosome profiling data was also analyzed for lincNMR locus through UCSC genome browser tracks to 
ensure the absence of often reported smaller open reading frames. Next, RACE experiments were 
performed in order to define the gene boundaries of lincNMR and to obtain a complete transcript 
sequence. 5’ RACE data revealed a new transcription start site with a longer 1st exon in the abundant 
lincNMR isoform, supported by independent CAGE tags and switchgear transcription start site dataset. 
Further, 3’ RACE data revealed a presence of a novel second exon in the less abundant lincNMR isoform 
however since all further experiments were performed using only the highly abundant isoform, the 
presence of new exon in less abundant isoform was duly noted and no further characterization 
experiments were performed. Next, subcellular fractionation experiments revealed a predominant 
cytoplasmic localization of the lincNMR transcript. Thus the basic characterization experiments 
confirmed lincNMR to be non-coding, predominantly cytoplasmic and independently transcribed 
lncRNA. 
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Since the cell viability screen measured the metabolic activity of the lincNMR depleted cells, the reduced 
ATP content could either come from the reduced cell numbers or reduced metabolic activity. 
Considering the role of liver cells in ATP intensive gluconeogenesis and glycogenolysis pathways [176], 
the cell proliferation assay was performed to further investigate and characterize the cellular function of 
lincNMR. For additional specificity, a second siPOOL with 30 unique siRNAs targeting lincNMR was 
ordered and used in all further experiments. The knockdown efficiency of second siPOOL was also found 
to be >95 %. Depletion of lincNMR with two independent siPOOLs invoked a strong proliferation defect 
in multiple HCC cell lines. Observation of deregulated cell proliferation in multiple cell lines after 
lincNMR silencing also confirmed the effects to be lincNMR-mediated and not cell line dependent. 
Further, cell cycle analysis after lincNMR loss revealed a cell cycle arrest in G0/G1 phase of the cell cycle 
in multiple cancer cell lines confirming the role of lincNMR in regulating cancer cell proliferation.  
Since induction of cell cycle arrest could also mean cells slipping to senescent state, β - Gal activity in 
lincNMR depleted cells was measured. And indeed, increased β - Gal activity was found in multiple HCC 
cell lines confirming the induction of senescence after lincNMR loss. Since RNAi mediated depletion of 
lincNMR is transient in nature and not every cell is guaranteed to receive siPOOLs irrespective of 
excellent knockdown efficiency of >90 %, further experimental approach could involve using CRISPR 
approach to generate lincNMR-knockout cell lines and to selective sort for senescent cells for further 
investigations, however given the strong induction of proliferation defect upon lincNMR loss, this 
approach could prove challenging in terms of remaining cell numbers for further investigations.  
Further, in order to gain a functional insight into the role of lincNMR, RNA Antisense Purification 
followed by MS was performed and YBX1 protein was identified as a direct binding partner of lincNMR. 
YBX1 is a transcription factor and has been reported several times to play diverse functional roles in 
cancer progression upon its binding to lncRNAs [177-180]. YBX1 has also been reported to drive 
tumorigenicity and invasiveness of melanoma cells and its high expression was correlated with negative 
prognosis in primary melanoma patients [181]. YBX1 expression was also shown to correlate with poor 
outcome in breast cancer patients [182]. Accordingly, in our dataset, YBX1 expression was found to 
correlate with poor overall survival in liver cancer patients. And an additional positive and significant 
correlation was also observed between lincNMR and YBX1 mRNA levels in liver cancer patient samples 
supporting the relevance of lincNMR-YBX1 interaction in cancer. 
Further, to understand the proteome-wide impact and to identify lincNMR regulated candidate proteins, 
triple-label SILAC-MS was performed. Triple label SILAC-MS assisted in circumventing technical 
 82 
 
variability and sensitivity issues normally posed in mass spectrometry experiment, especially for 
detecting smaller differences. Usage of light, medium and heavy label for metabolic labelling allowed for 
each cell line to be respectively transfected with either negative control siPOOL, or two different 
lincNMR-targeting siPOOLs whereas the mass variations in different labels allowed for sample specific 
quantification of respective proteins in the individual sample. Ratios of lincNMR-targeting siPOOL/ 
negative control siPOOL were used for further quantification and pathway enrichment analysis.  
Triple label SILAC - MS data revealed that silencing of lincNMR caused a strong depletion of key dNTP 
synthesizing enzymes RRM2 (Ribonucleotide Reductase subunit 2), TK1 (Thymidine Kinase) and TYMS 
(Thymidylate Synthetase). These enzymes have been reported to play key roles in the biosynthesis of 
dNTP pools in nucleotide metabolism pathways. Both de novo and salvage pathways lead to the 
synthesis of ribonucleotides where, the enzyme ribonucleotide reductase (RNR) performs a key 
reduction of ribonucleotides to deoxy-ribonucleotides [125, 139], a rate limiting step in nucleotide 
biosynthesis. The enzyme RNR consists of tetrameric complex with two large catalytic subunits of RRM1 
and two regulatory subunits of RRM2, where RRM2 has been shown to regulate dNTP biosynthesis 
during S-phase of the cell cycle [183]. TK1 has been shown to be essential for synthesizing dTMP, a first 
step in synthesis of dTTP whereas TYMS is known to catalyze the conversion of dUMP to dTMP, thus 
both aiding in maintaining the dTMP levels in cells.  
Since the balanced levels of dNTP pools are known to be critical for DNA replication, DNA repair of both 
nuclear and mitochondrial DNA and maintenance of genomic integrity [184], synthesis of nucleotides is 
carefully regulated during cell proliferation. Disturbances in nucleotide pools have been linked to wide 
spectrum of diseases like immunodeficiency [185, 186], aging [127, 187], kidney diseases [188, 189], 
mitochondrial pathologies [190, 191] including in cancer [192-195]. In line with the observations from 
literature, along with strong depletion of RRM2, TK1 and TYMS silencing of lincNMR also triggered 
induction of senescence in multiple liver cancer cell lines, in great concordance with multiple reports 
linking the imbalances in levels of RRM2, TK1 and TYMS with induction of senescence in cancer cells 
[130, 196, 197]. 
Consequently, all four dNTPs were also found to be depleted upon lincNMR loss in multiple liver cancer 
cell lines, consolidating the role of lincNMR in the regulation of nucleotide metabolism axis. Findings 
from this study are complemented with the previous reports where all four dNTPs were also found to be 
significantly decreased during OIS [130, 198, 199]. Importantly, bathing the cells in exogenous dNTP 
pools dose-dependently could also rescue the proliferation defect phenotype caused by lincNMR 
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knockdown in two liver cancer cell lines, which is in good accordance with previous studies stating that 
increasing dNTP levels by RRM2 overexpression or exogenous nucleoside supply overcomes aberrant 
DNA replication, DNA damage and senescence induced by oncogenic RAS or BRAF [198, 199]. It has also 
been reported that ectopic co-expression of TYMS and RRM2 suppresses OIS in normal human 
fibroblasts [198, 200]. Additionally, TYMS and RRM2 were reported to be suppressed in c-MYC-depleted 
melanoma cells undergoing OIS and that this senescent effect could be rescued by overexpression of 
TYMS and RRM2 or by addition of deoxyribonucleosides [196]. Since multiple triggers for induction of 
senescence have been reported based on the involved pathways, next step for this project could benefit 
from the experiments involving induction of senescence in cells using different approaches such as DNA 
damage inducing drug treatment, using hydrogen peroxide and overexpression of RAS and then to 
quantify the expression of lincNMR.  
To stress on the significance of this axis, these dNTP synthesizing enzymes were additionally also found 
to be strongly and significantly induced in our liver cancer patient datasets. Further stratification of 
RRM2, TK1 and TYMS using expression identified their association with poor overall survival and their 
correlation with lincNMR levels in liver cancer patients. 
Importantly, after silencing of lincNMR binding partner - YBX1, cells also mimicked the phenotype 
induced after lincNMR depletion in decreasing cell proliferation and also the RRM2, TK1 and TYMS 
levels. To further functionally understand the significance of lincNMR-YBX1 binding, lincNMR was also 
found to regulate the transactivational activity of YBX1 as identified by reporter assays – thus 
documenting a novel role for the lincNMR-YBX1 axis in regulation of nucleotide metabolism in cancer. 
Notably, depletion of lincNMR not only reduced proliferation in liver cancer but also impaired 
proliferation in multiple breast and lung cancer cell lines. Additionally, upon analysis of lincNMR 
expression in patient derived datasets of multiple cancer types, lincNMR was found to be significantly 
induced and regulated also in lung, breast, bladder and cervical cancer making it a broadly relevant 
oncogenic lncRNA. Further to validate the effects observed in cell line models and to elucidate the effect 
of lincNMR loss on tumor growth in vivo, xenograft experiments were performed using the CAM model. 
CAM model design allowed for in vitro and highly efficient knockdown of lincNMR in HLE cells, before 
being seeded in vivo onto the CAM membrane. LincNMR-depleted tumors harvested from the CAM 
membrane were found to be significantly smaller in size and weight, confirming its role in reduction of 
tumor size and growth in vivo and also implicating it as a promising target in cancer treatment.   
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Considering issues with cell lines bearing distinct genomic and transcriptomic profiles due to prolonged 
cultures, further experiments into preclinical models could be performed using patient-derived 
xenografts or patient-derived organoids to further enrich and solidify the current understanding of the 
role of lincNMR in tumor growth in vivo. Patient-derived xenografts provide for valuable tool to evaluate 
tumor growth rate or assess the therapeutic response of lncRNA targeting in vivo. Some examples 
where patient derived xenografts have been used include lncRNA HOTAIR [48, 201] and lncRNA 
SAMMSON [202]. Malat1 and MaTARs have also been depleted in mouse mammary tumor-derived 
organoids using ASO based approach to study branching morphogenesis [203, 204]. 
Targeting nucleotide metabolism has already been identified as a promising therapeutic strategy in 
cancer where the first chemotherapeutics used were cytotoxic nucleoside analogs and nucleobases like 
thiopurines and fluoropyrimidines [205]. These cytotoxic nucleoside analogs have similar structure as 
nucleosides and function via interfering in biosynthesis of DNA/RNA [206]. Gemcitabine was the first 
nucleoside analog clinically approved and still continues to be a frontline therapy against pancreatic, 
bladder and lung cancer [207] but unfortunately resistance to Gemcitabine was common through 
increase in dNTP biosynthesis or mechanism involving transport of nucleosides [208]. Ribonucleotide 
reductase (RNR) inhibitors were approved for treatment of cancer to target nucleotide metabolism axis 
[130]. Clofarabine, a purine analog targeting nucleic acid biosynthesis and ribonucleotide reductase was 
the second approved drug targeting refractory pediatric leukemia [209, 210]. A combination therapy 
with Gemcitabine, Clofarabine and Carboplatin has also been shown to significantly improve 
progression-free survival of patients with platinum-sensitive recurrent ovarian cancer [211]. Another 
successful chemotherapeutic agent methotrexate has also been reported to function via reducing the 
substrates for purine and pyrimidine biosynthesis [206, 212]. RNR inhibitor, Hydroxyurea (HU), has also 
shown promise and has been approved for use in the treatment of AML, CML and glioblastomas [213-
215].  
Several approaches have been reported to target lncRNAs for therapeutic purposes. For example, 
cytoplasmic lncRNAs could be targeted by siRNAs for argonaute mediated degradation whereas nuclear 
transcripts could be targeted using antisense oligo mediated degradation via an RNase H-dependent 
mechanism. Additional reported strategies to target lncRNAs include catalytic degradation using 
ribozymes or deoxy-ribozymes, aptamers, small molecule inhibitors, RNA destabilizing elements and 
synthetic lncRNA mimics [216-219]. The use of AntagoNAT for use in therapeutics has been investigated 
to regulate expression of sense mRNA [220]. Since depletion of lincNMR caused strong downregulation 
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of key enzymes in nucleotide metabolism pathways, targeting lincNMR could further be exploited for its 
use in cancer-wide therapeutic avenues. 
Interestingly, nucleotide metabolism pathways have also been linked to metabolism-related disorders 
such as diabetes, obesity and insulin resistance circling around mTOR signaling cascade [221-223]. mTOR 
signaling pathway has been shown not only to promote glucose uptake and protein and lipid 
biosynthesis but also to regulate nucleotide biosynthesis and uptake of nucleosides through 
transporters [224-226]. Additionally pyrimidine metabolism has been linked to fatty liver, which 
predisposes liver to HCC where a link has also been shown to be established between obesity and non-
alcoholic fatty liver disease [227, 228]. To this direction, a phosphoproteomics screen (screen data 
shown and discussed in the next chapter as: future directions for a follow up study) after the loss of 
lincNMR revealed a strong induction of UBE2O phosphorylation. UBE2O is a hybrid E2/E3 ligase shown 
to mediate monoubiquitination of target proteins [229, 230] and to negatively regulate TRAF6-mediated 
NF-kappa-B activation independently of its E2 activity [231]. UBE2O has also been reported to act as a 
positive regulator of BMP7 signaling mediated by SMAD6 in adipogenesis [229]. Additionally, UBE2O has 
been shown to regulate cytoplasmic retention of BAP1 by mediating its monoubiquitination [230]. Thus 
this dataset provides for an interesting starting point for a follow up study to further investigate the role 
of lincNMR in regulation of phosphorylation of E2/E3 ligase UBE2O.  
Taken together, this study identified a novel lncRNA lincNMR and reported a first lncRNA regulating 
nucleotide metabolism pathways. This study showed that, the lncRNA lincNMR and RNA binding protein 
YBX1 formed a complex and regulated cancer cell proliferation through modulation of key dNTP 
synthesizing enzymes RRM2, TK1 and TYMS. Moreover, lincNMR regulation of nucleotide metabolism 
could be supported by the decrease in all four dNTP levels post lincNMR silencing and the rescue of 
lincNMR mediated phenotype by bathing the cells in exogenous pools of dNTPs. In-depth analysis of 
lincNMR-YBX1 interaction revealed the functional role of lincNMR in regulating transactivational activity 
of the transcription factor YBX1. Together with the direct functional interaction, this study showed a 
common set of regulated target genes between lincNMR and YBX1, further consolidating the relevance 
of this binding in nucleotide metabolism axis.  
In summary, this study showed that loss of lincNMR lead to impaired cell proliferation, induction of a 
G0/G1 phase cell cycle arrest, deregulation of nucleotide metabolism and eventual induction of 
senescence in multiple human cancer cell lines. Thus identifying a novel tumor-promoting lncRNA - 
lincNMR - and unveiling its functional role along YBX1 - RRM2 / TK1 / TYMS axis in regulating nucleotide 
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metabolism and governing the cancer cell fate between proliferation and senescence. Importantly and 
in addition to unveiling the functional role of lincNMR, this study also discusses the avenues highlighting 
the potential of lincNMR as a potential therapeutic target in cancer. 
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7. FURTHER EXPERIMENTAL DIRECTIONS FOR THIS PROJECT 
In this study, I report the role of the novel lncRNA lincNMR in the regulation of nucleotide metabolism 
through lincNMR-YBX1-RRM2-TK1-TYMS axis as discussed in details in the previous chapter (Chapter 6. 
Discussion). Involvement of kinases in the regulation of nucleotide metabolism pathways is well 
documented, so in order to gain a deeper understanding of the role of lincNMR in the regulation of 
nucleotide metabolism, I also performed a phosho-proteomics screen using the triple-label SILAC 
approach - a methodology which I initially established in the lab (in collaboration with DKFZ Proteomics 
core facility). The methodology and schematic of the experiment is based on the initially described 
triple-label SILAC experiment to analyze the total cellular proteome after lincNMR depletion (described 
in details in the sections 4.8.1 and 5.4.6).  
 
Figure 27: Multiscatter plot for phosphoproteomics dataset as a quality control reproducibility  
Multi-scatter plot depicting deregulated phosphorylation of proteins identified across three 
biological replicates using two independent siPOOLs (si-lincNMR-A = Medium (M), si-lincNMR-B = 
Heavy (H), vs. control siPOOL = Light (L)) in triple-label SILAC-MS. HLE cell lysates were harvested 
48 h after depletion of lincNMR with 10 nM siPOOLs (n = 3). Data represents fold change 
normalized to negative control siPOOLs. Proteins identified across biological replicates and only 
with phosphorylation deregulated with both siPOOLs were selected for further analysis. Pearson 
correlation coefficient is displayed on the multi-scatter plot. 
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The experiment was performed in three biological replicates and a significant correlation was observed 
across replicates and both the siPOOLs (Fig. 27) with an average person correlation coefficient of R = 
0.938. 
 
Figure 28: Depletion of lincNMR leads to strong induction of UBE2O phosphorylation 
Scatter plot representing 222 candidates (p < 0.001) and correlation between log2 ratios 
of M/L (siPOOL-A / siPOOL Neg Ctrl) and H/L (siPOOL-B / siPOOL Neg Ctrl) where 
phosphorylation of UBE2O is strongly induced at 48 h after depletion of lincNMR in HLE 
with 10 nM of respective siPOOLs. 
Further, the analysis of deregulated phospho-proteome upon lincNMR depletion led to a significant 
strong induction of phosphorylation of UBE2O in the dataset (Fig. 28) at Ser-401. UBE2O has been 
implicated in an oncogenic role and tumor initiation [232, 233]. This phosphorylation Ser-401 has not 
been characterized in terms of its activating / inactivating role of UBE2O before and thus offers a 
promising start for the next follow-up study to investigate the role of lincNMR in regulation of UBE2O 
activity. 
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Figure 29: lincNMR levels correlates with UBE2O where UBE2O expression is linked to survival 
in liver cancer patients 
a. Correlation plot: UBE2O mRNA levels significantly correlates with lincNMR with a correlation 
coefficient of 0.558 in liver cancer patients. Log2 values plotted b. Kaplan-Meier plot of liver 
cancer patients stratified by UBE2O expression level. 
 
Moreover a significant correlation between UBE2O mRNA and lincNMR expression was observed in liver 
cancer patients (Fig. 29a). Furthermore, I also found UBE2O expression levels to significantly correlate 
with poor survival in liver cancer patient datasets (Fig. 29b). From these observations, we could propose 
that this dataset makes for a promising start for a follow up study.  
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9. APPENDIX 
9.1.1 LncRNA expression data from liver cancer patient dataset from TANRIC 
Table 15. LncRNA expression data of 217 lncRNAs with FC > 5 and p-value < 0.001 
Gene Id MED Normal MED Tumor MED Normal/MED Tumor TTEST 
ENSG00000272872.1 0.00 0.14 369.71 3.44E-14 
ENSG00000267759.1 0.00 0.04 79.50 1.70E-09 
ENSG00000259717.1 0.00 0.02 69.79 6.10E-05 
ENSG00000204832.5 0.01 0.65 61.77 3.72E-21 
ENSG00000267783.1 0.00 0.14 52.62 5.97E-07 
ENSG00000236519.1 0.00 0.03 44.19 1.09E-19 
ENSG00000224189.2 0.00 0.13 34.11 4.09E-09 
ENSG00000272137.1 0.00 0.02 33.62 1.04E-02 
ENSG00000228651.1 0.01 0.40 33.01 1.17E-14 
ENSG00000258667.1 0.00 0.01 32.08 7.50E-04 
ENSG00000237152.2 0.00 0.01 31.95 2.06E-09 
ENSG00000261039.1 0.00 0.03 28.86 3.92E-08 
ENSG00000271963.1 0.00 0.10 28.10 7.27E-08 
ENSG00000232712.2 0.00 0.00 27.72 7.98E-09 
ENSG00000240498.2 0.00 0.09 24.64 8.22E-22 
ENSG00000262952.1 0.00 0.01 24.43 1.55E-05 
ENSG00000226330.1 0.01 0.23 24.19 1.27E-22 
ENSG00000266957.1 0.00 0.04 22.60 1.23E-03 
ENSG00000215424.5 0.00 0.02 21.59 7.45E-15 
ENSG00000240710.1 0.00 0.02 21.58 6.12E-11 
ENSG00000253979.1 0.00 0.04 20.75 5.98E-04 
ENSG00000243230.1 0.01 0.15 19.84 5.00E-22 
ENSG00000245694.4 0.04 0.81 18.77 8.71E-24 
ENSG00000272068.1 0.01 0.20 17.88 3.29E-09 
ENSG00000215394.4 0.00 0.07 17.82 1.69E-17 
ENSG00000236643.1 0.00 0.04 17.27 1.76E-18 
ENSG00000237978.1 0.00 0.08 16.83 6.08E-13 
ENSG00000225210.5 0.04 0.70 16.02 2.96E-22 
ENSG00000205500.4 0.00 0.00 15.26 2.14E-02 
ENSG00000273091.1 0.00 0.03 15.16 1.80E-07 
ENSG00000206195.6 0.02 0.29 14.96 7.93E-25 
ENSG00000245812.2 0.01 0.09 14.53 1.49E-04 
ENSG00000237596.2 0.00 0.05 14.23 9.69E-05 
ENSG00000231081.1 0.00 0.03 13.96 4.45E-09 
ENSG00000235586.1 0.00 0.03 13.70 3.01E-03 
ENSG00000254233.1 0.01 0.12 12.97 4.79E-09 
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ENSG00000273257.1 0.00 0.06 12.89 8.32E-09 
ENSG00000270145.1 0.01 0.10 12.63 1.85E-21 
ENSG00000265542.1 0.00 0.01 12.58 1.66E-03 
ENSG00000270068.1 0.00 0.03 12.57 5.71E-10 
ENSG00000244306.5 0.02 0.22 12.41 7.82E-24 
ENSG00000271538.1 0.00 0.02 11.96 2.16E-07 
ENSG00000262482.1 0.01 0.07 11.96 2.65E-15 
ENSG00000230970.2 0.00 0.01 11.84 1.10E-03 
ENSG00000273424.1 0.01 0.08 11.41 3.09E-16 
ENSG00000228294.2 0.02 0.24 11.34 1.25E-16 
ENSG00000266976.1 0.01 0.09 10.90 2.50E-05 
ENSG00000228079.1 0.00 0.01 10.85 3.87E-04 
ENSG00000231439.3 0.00 0.02 10.81 4.92E-08 
ENSG00000260425.1 0.02 0.22 10.75 1.10E-17 
ENSG00000272097.1 0.00 0.05 10.51 4.30E-27 
ENSG00000265692.1 0.00 0.04 10.50 2.14E-23 
ENSG00000236434.2 0.00 0.01 10.43 2.40E-02 
ENSG00000259322.1 0.01 0.09 10.26 2.24E-08 
ENSG00000270933.1 0.09 0.91 10.24 2.58E-26 
ENSG00000224034.1 0.01 0.09 10.15 3.50E-14 
ENSG00000249816.2 0.00 0.00 10.14 1.02E-02 
ENSG00000264769.1 0.01 0.08 10.11 1.91E-05 
ENSG00000226686.3 0.00 0.04 9.98 3.56E-15 
ENSG00000262332.1 0.00 0.03 9.89 6.07E-10 
ENSG00000259887.1 0.00 0.05 9.88 2.28E-19 
ENSG00000273293.1 0.02 0.15 9.69 3.51E-19 
ENSG00000261008.2 0.00 0.02 9.62 9.73E-18 
ENSG00000228350.1 0.01 0.14 9.59 2.34E-20 
ENSG00000273002.1 0.00 0.04 9.56 2.16E-15 
ENSG00000228952.1 0.01 0.06 9.54 4.44E-07 
ENSG00000248265.1 0.00 0.02 9.52 6.02E-07 
ENSG00000267366.1 0.00 0.03 9.43 9.10E-05 
ENSG00000263412.1 0.01 0.11 9.37 9.00E-17 
ENSG00000225953.2 0.00 0.04 9.33 2.00E-20 
ENSG00000256128.1 0.01 0.06 8.96 5.88E-09 
ENSG00000253339.1 0.02 0.20 8.93 4.49E-11 
ENSG00000235612.1 0.00 0.01 8.85 2.97E-02 
ENSG00000268095.1 0.01 0.06 8.83 1.03E-06 
ENSG00000228430.4 0.00 0.01 8.70 1.22E-10 
ENSG00000246334.2 0.00 0.03 8.55 3.02E-15 
ENSG00000264188.1 0.01 0.04 8.51 5.95E-07 
ENSG00000244227.1 0.00 0.02 8.49 4.49E-04 
ENSG00000238260.1 0.01 0.11 8.44 2.56E-23 
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ENSG00000253302.1 0.00 0.04 8.43 1.76E-15 
ENSG00000238261.5 0.01 0.07 8.21 2.49E-18 
ENSG00000269560.1 0.01 0.05 8.17 1.40E-10 
ENSG00000229178.1 0.01 0.08 8.16 8.69E-13 
ENSG00000256897.1 0.00 0.03 8.12 5.64E-10 
ENSG00000258735.1 0.00 0.01 7.99 7.76E-09 
ENSG00000234245.2 0.02 0.13 7.98 1.58E-06 
ENSG00000226674.4 0.01 0.04 7.95 4.94E-14 
ENSG00000264548.1 0.00 0.04 7.91 1.65E-21 
ENSG00000253864.1 0.00 0.00 7.85 2.25E-02 
ENSG00000245614.2 0.01 0.06 7.84 2.43E-24 
ENSG00000250696.1 0.04 0.33 7.80 3.69E-18 
ENSG00000271888.1 0.02 0.19 7.74 9.77E-19 
ENSG00000259087.1 0.00 0.02 7.67 1.34E-06 
ENSG00000229832.1 0.00 0.03 7.63 2.51E-10 
ENSG00000260589.1 0.00 0.04 7.61 4.43E-23 
ENSG00000240350.1 0.02 0.16 7.59 6.22E-21 
ENSG00000227036.2 0.02 0.11 7.58 5.49E-10 
ENSG00000265688.1 0.08 0.58 7.53 4.86E-13 
ENSG00000182366.5 0.00 0.01 7.50 2.23E-05 
ENSG00000255689.1 0.02 0.14 7.47 1.87E-11 
ENSG00000230880.2 0.02 0.16 7.47 1.25E-20 
ENSG00000270557.1 0.02 0.14 7.42 1.07E-27 
ENSG00000270562.1 0.00 0.02 7.41 1.53E-14 
ENSG00000236751.1 0.02 0.18 7.40 5.00E-14 
ENSG00000259349.1 0.01 0.06 7.40 4.47E-25 
ENSG00000262412.1 0.01 0.06 7.34 7.13E-13 
ENSG00000273162.1 0.01 0.07 7.31 3.96E-16 
ENSG00000242798.1 0.02 0.13 7.27 1.73E-22 
ENSG00000273230.1 0.04 0.28 7.25 7.95E-25 
ENSG00000226673.1 0.00 0.03 7.20 1.77E-07 
ENSG00000255741.1 0.00 0.03 7.13 3.92E-05 
ENSG00000196421.3 0.01 0.10 7.13 2.40E-08 
ENSG00000233791.1 0.00 0.03 7.06 4.70E-10 
ENSG00000163364.5 0.01 0.10 7.04 2.99E-04 
ENSG00000272993.1 0.23 1.62 7.02 5.98E-30 
ENSG00000258725.1 0.00 0.03 7.01 2.36E-20 
ENSG00000226206.1 0.00 0.01 7.00 2.44E-03 
ENSG00000267715.1 0.01 0.06 6.96 1.11E-11 
ENSG00000261019.1 0.01 0.04 6.94 9.78E-19 
ENSG00000253616.1 0.02 0.13 6.90 3.13E-14 
ENSG00000272792.1 0.05 0.33 6.89 4.55E-28 
ENSG00000270195.1 0.03 0.24 6.88 8.63E-13 
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ENSG00000271762.1 0.02 0.13 6.81 3.04E-09 
ENSG00000227076.1 0.00 0.02 6.78 9.95E-06 
ENSG00000232677.2 0.07 0.49 6.77 3.19E-15 
ENSG00000234380.1 0.04 0.27 6.74 3.02E-12 
ENSG00000257596.1 0.02 0.17 6.74 9.55E-19 
ENSG00000227589.1 0.00 0.03 6.73 5.51E-06 
ENSG00000234869.1 0.01 0.04 6.73 1.27E-13 
ENSG00000267804.1 0.12 0.78 6.71 9.34E-28 
ENSG00000271151.1 0.01 0.09 6.71 6.11E-22 
ENSG00000225518.2 0.06 0.40 6.69 1.20E-24 
ENSG00000259755.1 0.00 0.01 6.68 8.83E-05 
ENSG00000273445.1 0.03 0.22 6.63 1.44E-04 
ENSG00000243224.1 0.01 0.07 6.60 3.66E-22 
ENSG00000223907.1 0.00 0.03 6.58 4.90E-09 
ENSG00000272468.1 0.03 0.21 6.57 9.20E-11 
ENSG00000237686.2 0.02 0.12 6.57 3.14E-06 
ENSG00000249395.2 0.02 0.13 6.54 9.92E-14 
ENSG00000250337.1 0.03 0.21 6.53 2.27E-13 
ENSG00000272205.1 0.02 0.15 6.53 4.46E-17 
ENSG00000228763.1 0.00 0.03 6.53 1.63E-05 
ENSG00000255050.1 0.01 0.10 6.53 6.25E-08 
ENSG00000272377.1 0.02 0.11 6.51 8.91E-19 
ENSG00000237253.1 0.01 0.08 6.50 7.37E-18 
ENSG00000271032.1 0.02 0.11 6.45 1.49E-08 
ENSG00000261840.1 0.03 0.20 6.44 3.18E-14 
ENSG00000236022.2 0.00 0.03 6.43 4.73E-04 
ENSG00000249856.1 0.00 0.03 6.43 1.48E-18 
ENSG00000232725.1 0.00 0.03 6.38 2.68E-15 
ENSG00000203849.6 0.02 0.11 6.35 1.96E-13 
ENSG00000231106.2 0.02 0.10 6.33 1.10E-03 
ENSG00000224805.2 0.13 0.80 6.29 1.43E-21 
ENSG00000236947.1 0.04 0.24 6.27 1.34E-19 
ENSG00000273249.1 0.01 0.06 6.24 3.38E-11 
ENSG00000266602.1 0.01 0.05 6.21 9.22E-10 
ENSG00000272211.1 0.00 0.01 6.20 2.17E-05 
ENSG00000261716.1 0.15 0.95 6.19 2.35E-28 
ENSG00000272953.1 0.05 0.29 6.16 4.65E-30 
ENSG00000223855.1 0.01 0.07 6.10 4.45E-10 
ENSG00000258077.2 0.00 0.01 6.04 1.76E-08 
ENSG00000271781.1 0.07 0.44 6.01 1.00E-06 
ENSG00000251556.1 0.01 0.03 6.00 1.59E-06 
ENSG00000234142.1 0.00 0.02 6.00 9.67E-11 
ENSG00000250432.1 0.01 0.04 5.98 2.49E-05 
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ENSG00000236449.1 0.00 0.01 5.92 6.01E-09 
ENSG00000172965.10 0.22 1.31 5.90 6.70E-30 
ENSG00000260942.1 0.03 0.16 5.90 6.24E-35 
ENSG00000272716.1 0.02 0.13 5.89 2.23E-19 
ENSG00000255794.2 0.00 0.01 5.88 3.16E-07 
ENSG00000260051.1 0.04 0.22 5.84 5.25E-17 
ENSG00000228022.1 0.01 0.05 5.84 2.42E-06 
ENSG00000254812.1 0.01 0.05 5.83 3.77E-14 
ENSG00000272810.1 0.02 0.10 5.82 4.06E-02 
ENSG00000259515.1 0.01 0.03 5.81 5.59E-05 
ENSG00000255142.1 0.06 0.37 5.77 6.19E-17 
ENSG00000224358.1 0.01 0.06 5.75 1.18E-16 
ENSG00000271914.1 0.02 0.11 5.75 2.00E-14 
ENSG00000232306.1 0.01 0.08 5.73 8.54E-14 
ENSG00000260988.1 0.00 0.01 5.72 1.01E-10 
ENSG00000228554.1 0.00 0.01 5.70 2.15E-06 
ENSG00000222041.6 0.78 4.43 5.66 9.31E-22 
ENSG00000256164.1 0.01 0.03 5.63 1.21E-03 
ENSG00000266236.1 0.01 0.05 5.63 3.09E-11 
ENSG00000249859.3 0.06 0.35 5.62 4.15E-20 
ENSG00000239523.1 0.07 0.37 5.60 4.44E-26 
ENSG00000260423.1 0.01 0.03 5.60 7.81E-11 
ENSG00000225278.3 0.00 0.01 5.59 1.94E-05 
ENSG00000259153.1 0.07 0.40 5.57 3.89E-20 
ENSG00000271993.1 0.02 0.09 5.54 1.73E-22 
ENSG00000260285.1 0.02 0.11 5.51 1.59E-11 
ENSG00000267583.1 0.02 0.12 5.50 1.44E-17 
ENSG00000203279.3 0.03 0.19 5.50 1.21E-17 
ENSG00000250107.1 0.00 0.01 5.50 6.90E-04 
ENSG00000233154.1 0.00 0.03 5.50 5.63E-16 
ENSG00000261342.1 0.02 0.08 5.40 1.35E-08 
ENSG00000261713.2 0.00 0.01 5.38 1.85E-05 
ENSG00000271778.1 0.01 0.07 5.35 5.34E-19 
ENSG00000232874.1 0.03 0.18 5.34 7.51E-19 
ENSG00000236743.1 0.01 0.04 5.33 6.28E-08 
ENSG00000262410.1 0.05 0.25 5.31 1.72E-23 
ENSG00000251003.3 0.02 0.13 5.30 9.41E-15 
ENSG00000235319.1 0.01 0.04 5.26 4.30E-15 
ENSG00000271327.1 0.02 0.13 5.24 2.54E-20 
ENSG00000232909.1 0.01 0.03 5.17 1.43E-15 
ENSG00000260367.1 0.02 0.11 5.16 8.47E-17 
ENSG00000226179.1 0.05 0.28 5.16 3.44E-19 
ENSG00000272301.1 0.03 0.16 5.16 1.92E-09 
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ENSG00000260495.1 0.00 0.02 5.15 2.08E-24 
ENSG00000237424.1 0.16 0.85 5.13 3.75E-23 
ENSG00000270019.1 0.00 0.01 5.13 3.10E-10 
ENSG00000262877.3 0.09 0.49 5.12 4.28E-07 
ENSG00000253264.1 0.00 0.01 5.11 1.41E-06 
ENSG00000253819.1 0.13 0.67 5.06 1.90E-13 
ENSG00000227256.1 0.01 0.05 5.05 2.98E-17 
ENSG00000260046.1 0.00 0.02 5.05 2.56E-15 
ENSG00000267197.1 0.02 0.09 5.01 3.86E-24 
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9.1.2 List of 49 lncRNAs screened for expression in 9 liver cancer cell lines 
Table 16: RT-qPCR expression data for 49 lncRNAs in multiple HCC cell lines 
 
 
  
   Gene ID Gene Symbol HLE HLF FLC-4 SNU-387 PLC/PRF15 Huh6 Huh7 SK-Hep1 HepG2 AVERAGE
ENSG00000262477.1 AC021224 18.134 18.282 16.743 17.130 18.783 17.268 20.288 18.187 18.482 18.144
ENSG00000232527.3 RP11-14N7.2 21.430 20.758 16.302 16.150 19.228 17.781 20.925 20.609 18.323 19.056
ENSG00000177410.8 ZFAS1 20.236 19.852 17.975 17.960 19.022 18.654 21.295 19.308 19.700 19.333
ENSG00000226950.2 DANCR 21.553 20.647 18.726 19.983 19.434 18.624 19.709 20.569 19.930 19.908
ENSG00000232388.2 linc00493 21.763 20.910 19.673 19.479 19.378 18.933 22.313 19.990 20.348 20.310
ENSG00000259758.1 CASC7 22.588 22.651 21.004 21.175 22.440 20.594 22.719 21.812 21.616 21.844
ENSG00000244306.5 CTD-2314B22 22.205 22.881 20.572 20.871 22.202 22.252 24.461 21.757 21.864 22.118
ENSG00000206195.6 AP000525 22.162 22.742 20.539 20.817 22.689 22.238 24.440 21.763 21.921 22.146
ENSG00000228294.2 BMS1P17 22.891 22.377 21.876 21.956 21.474 22.449 23.865 22.232 22.021 22.349
ENSG00000212978.5 AC016747 22.614 22.527 21.672 21.300 21.865 21.938 24.425 22.348 23.312 22.445
ENSG00000225210.5 AL589743 22.526 22.903 21.863 21.417 21.510 22.653 25.317 22.204 21.955 22.483
ENSG00000233137.2 RP11-220I1.1 23.530 23.388 21.921 21.539 21.502 22.281 22.373 23.202 22.786 22.503
ENSG00000188206.5 HNRNPU-AS1 24.581 23.571 22.205 22.317 22.169 22.467 22.733 22.900 22.794 22.860
ENSG00000272872.1 LL22NC03-N14H11 23.328 23.179 23.184 22.668 21.768 23.752 26.443 22.319 22.697 23.260
ENSG00000257167.2 TMPO-AS1 23.157 22.820 23.239 22.834 22.930 23.268 24.624 23.166 23.971 23.334
ENSG00000237523.1 LINC00857 22.659 22.802 23.316 22.533 22.196 21.895 24.020 23.507 27.360 23.365
ENSG00000215394.4 BMS1P18 23.573 23.579 23.026 22.850 22.696 23.446 24.920 23.276 23.286 23.406
ENSG00000225733.1 FGD5-AS1 24.356 23.921 22.597 22.304 23.192 22.835 24.613 24.249 23.815 23.542
ENSG00000215424.5 MCM3AP-AS1 24.805 24.832 23.630 24.313 23.770 24.253 23.943 23.938 24.811 24.255
ENSG00000236751.1 RP1-30G7 23.609 23.757 23.494 24.713 23.283 24.460 27.743 23.877 24.200 24.348
ENSG00000259153.1 RP6-65G23.3 (lincNMR) 26.296 25.805 22.226 23.010 24.205 22.668 25.671 23.724 25.593 24.355
ENSG00000255135.3 RP11-111M22 26.256 25.581 23.915 22.272 23.989 23.491 25.617 25.372 24.993 24.609
ENSG00000236519.1 AL773604 25.984 26.001 25.306 25.449 24.751 25.316 26.418 25.955 25.684 25.652
ENSG00000271762.1 LUCAT1 25.471 25.339 25.553 24.028 25.485 25.441 27.976 26.779 26.208 25.809
ENSG00000272761.1 RP11-572C15 25.539 26.551 25.289 23.138 28.205 28.563 26.896 22.209 28.919 26.145
ENSG00000243224.1 RP5-1157M23 26.846 26.893 26.533 26.541 24.355 25.937 27.338 26.599 25.924 26.329
ENSG00000245694.4 CRNDE 24.886 26.919 23.743 23.897 23.557 25.551 26.290 25.774 36.471 26.343
ENSG00000267296.2 CEBPA-AS1 28.867 31.729 24.946 28.528 24.189 23.002 24.528 27.501 23.995 26.365
ENSG00000204832.5 ST8SIA6-AS1 23.544 23.496 22.360 29.599 22.733 21.929 24.640 33.339 36.251 26.432
ENSG00000238045.5 AC009133 26.145 25.904 25.435 25.217 27.886 29.471 28.484 27.310 26.785 26.960
ENSG00000272097.1 RP11-421M1 26.965 26.669 27.471 25.726 26.300 27.661 28.196 26.716 27.478 27.020
ENSG00000249592.1 RP11-440L14 26.551 26.895 27.182 26.919 24.267 27.856 27.545 28.752 28.179 27.127
ENSG00000270145.1 CTD-2267D19 27.520 28.518 26.353 25.780 27.212 26.171 29.307 26.679 28.138 27.298
ENSG00000253877.1 linc01608 21.464 22.469 20.719 32.854 21.296 34.345 20.348 40.000 33.373 27.430
ENSG00000262482.1 LA16c-321D4 27.621 27.647 27.253 26.527 26.974 27.431 28.684 27.549 28.236 27.547
ENSG00000273424.1 CTA-223H9 28.619 27.930 26.774 27.148 26.930 27.196 27.722 28.642 28.375 27.704
ENSG00000253898.1 RP11-51M18 29.415 24.503 21.625 24.784 20.689 28.577 20.722 40.000 40.000 27.813
ENSG00000225383.2 SFTA1P 21.914 21.898 20.385 25.478 40.000 32.985 35.435 20.905 34.157 28.129
ENSG00000226330.1 ST8SIA6-AS1 34.923 38.028 22.823 23.769 25.310 24.945 28.202 32.575 25.492 28.452
ENSG00000285219.1 HULC 32.682 32.746 29.166 31.971 27.930 23.517 21.753 31.904 24.420 28.454
ENSG00000236643.1 RP11-175D17 31.130 29.930 27.895 28.082 27.809 27.417 27.646 29.693 27.875 28.609
ENSG00000243230.1 RP11-286H14 28.930 33.480 40.000 29.641 25.920 25.433 26.158 26.457 25.734 29.084
ENSG00000270933.1 CTD-2227E11 31.274 30.912 29.861 31.213 26.636 25.772 27.951 30.806 27.825 29.139
ENSG00000240498.2 ANRIL 24.644 24.531 24.189 40.000 25.446 30.580 25.941 40.000 33.529 29.873
ENSG00000273356.1 RP11-804H8 31.330 30.933 29.868 27.487 30.218 31.710 30.614 29.011 30.019 30.132
ENSG00000237978.1 RP11-385J1 40.000 35.877 24.603 28.930 33.224 24.271 24.804 30.318 31.899 30.436
ENSG00000240710.1 RP11-430C7 30.323 30.669 32.276 28.124 33.842 29.444 29.590 29.940 31.621 30.648
ENSG00000260032.1 NORAD 32.916 31.536 31.306 30.262 32.088 30.580 32.306 33.116 30.728 31.649
ENSG00000224034.1 RP11-445P17 35.753 39.813 31.602 26.673 30.392 30.938 31.302 33.323 31.631 32.381
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9.1.3 Genbank submission of lincNMR sequences 
Genbank accession numbers: lincNMR-001 = MK652436 and lincNMR-002 = MK652437 
Table 17: Sequences of lincNMR 5’ and 3’ RACE Clones submitted to Genbank 
>lincNMR-001 [organism=Homo sapiens] lincRNA Nucleotide Metabolism Regulator (lincNMR), 
transcript variant 1 
GAGCCTTCATTCAAACTAAAAGGCTGGAAGGGAGGCAGCTGCCTTTGTTTGCCATGGATGGGTAGGGGCTGCACT
GAGCAGCACCGGTGTTCTTCATCCGGCTGCACCCCCAACAGAGCTCTTTCTTCCCCAGATCCCTTTTACAGTTGGAT
TCTCCCTCTTGGATCTGGCTCTGCCTTAGTCCGACCTAGAGGGATCAGCTTCGCCCACGCCCACTCTCACCCGGAAC
CTTTCATCTCTTATTGAAGCCTTTTAGGCCCATTGGGATGTTCATTAGAACTCTGAAAACTACAGTTCTCCCCTTTAT
GAGGACTGCACCACAGCTCGCCCTCTCCTGGGTTCCGGTAAGAAGAGATTCCAATACCACTCTTTTTTCAGAATTCA
GAAAGGCAAGAGACCACCTTACTGAGCTTCAAACTGGGGCTGGGAACGCTGCCATGAATTGGGCTTGGTCTGTCT
GAAGGGAGCCACCTTTTCGACAATCCTTAGACTTCTTTTGCCTGTTGGAATTACACCTTGGATCGTGGCGAAGTCTA
TAGAGGTCAGATTAAGAAGAACCAAAGCAGAATAAACGTAGAACCCGATGCTGAGTTCACGAGTGAGGACGACC
TCTTCCTATATGCTTTGCTATACCCTGCGTTTTGAACATTAAGGACGAGATAGGAGGCCCATAATGTTTCTTCTTGCT
TTAATCCTGTCGTggCAACGTTGACTTCCACCTGGTTGCAGAGTGAGCCCATGGGACAGCCCTCTGAAATTATACTG
CTTACAACCATGCTGAGTCTGCAAGGACTTCGTCCAAGCCTTTCCGTCCAGGACCTCAAACAGATCCAATCACAAG
AAGAGAGATTTCAGGAAAGAGAAAATTATTCCTATCATCGGGGTTTTTGAAGAACATGAAATGACTGGGAAAATA
ATCATGTTAAGTGGAAAAAAAAAAGAAATCTATCTGTTGTAATTTTCAAATAATTTTTAAATAAATTTGAAAAATTA
AGAGAACTATATATATAA 
>lincNMR-002 [organism=Homo sapiens] lincRNA Nucleotide Metabolism Regulator (lincNMR), 
transcript variant 2 
GAGCCTTCATTCAAACTAAAAGGCTGGAAGGGAGGCAGCTGCCTTTGTTTGCCATGGATGGGTAGGGGCTGCACT
GAGCAGCACCGGTGTTCTTCATCCGGCTGCACCCCCAACAGAGCTCTTTCTTCCCCAGATCCCTTTTACAGTTGGAT
TCTCCCTCTTGGATCTGGCTCTGCCTTAGTCCGACCTAGAGGGATCAGCTTCGCCCACGCCCACTCTCACCCGGAAC
CTTTCATCTCTTATTGAAGCCTTTTAGGCCCATTGGGATGTTCATTAGAACTCTGAAAACTACAGTTCTCCCCTTTAT
GAGGACTGCACCACAGCTCGCCCTCTCCTGGGTTCCGGTAAGAAGAGATTCCAATACCACTCTTTTTTCAGAATTCA
GAAAGGCAAGAGACCACCTTACTGAGCTTCAAACTGGGGCTGGGAACGCTGCCATGAATTGGGCTTGGTCTGTCT
GAAGGGAGCCACCTTTTCGACAATCCTTAGACTTCTTTTGCCTGTTGGAATTACACCTTGGATCGTGGCGAAGTCTA
TAGAGGTCAGATTAAGAAGAACCAAAGCAGAATAAACGTAGAACCCGATGCTGAGTTCACGAGTGAGGACGACC
TCTTCCTATATGCTTTGCTATACCCTGCGTTTTGAACATTAAGGACGAGATAGGAGGCCCATAATGTTTCTTCTTGCT
TTAATCCTGTCGTggCAACGTTGACTTCCAAAACAAGGTCTCACTGTGTCACCCAGGCTGGAGAGCAGTGGCACGA
TCATAGCTCACTGATCACATGGCAGCCTCAAACTCCTGGACTCAGTGGGTCCTCCTGCCTCAGCATCCTGAGTAGCT
GGGACTACAGCCTGGTTGCAGAGTGAGCCCATGGGACAGCCCTCTGAAATTATACTGCTTACAACCATGCTGAGT
CTGCAAGGACTTCGTCCAAGCCTTTCCGTCCAGGACCTCAAACAGATCCAATCACAAGAAGAGAGATTTCAGGAAA
GAGAAAATTATTCCTATCATCGGGGTTTTTGAAGAACATGAAATGACTGGGAAAATAATCATGTTAAGTGGAAAA
AAAAAAGAAATCTATCTGTTGTAATTTTCAAATAATTTTTAAATAAATTTGAAAAATTAAGAGAACTATATATATAA 
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9.1.4 List of candidates identified in lincNMR RAP-MS 
Table 18: List of candidates from lincNMR RAP-MS 
Gene Symbol log2 FC XL vs. 
no XL 
adj. p-value XL vs. no XL 
-log10 
Survival HCC logRank-
test p-value 
Ybx1 1.076 3.13392 4.30E-08 
Cirbp 1.121 3.03594 1.10E-06 
Hnrnpcl1 2.599 3.27773 2.80E-06 
Fubp1 1.364 3.09009 5.10E-06 
Alyref 1.111 3.13392 3.20E-05 
Hnrnph1 1.272 3.13392 9.60E-05 
Srsf2 1.408 3.27773 8.40E-04 
Raly 1.031 3.04348 1.60E-03 
Srsf5 1.199 3.17046 1.90E-03 
Syne1 1.256 3.13611 2.60E-03 
Ncl 1.359 3.13392 3.10E-03 
Hnrnpm 1.100 3.11930 4.70E-03 
Ewsr1 1.544 3.13392 5.50E-03 
Srsf3 1.391 3.26192 8.40E-03 
Srsf9 1.145 3.02806 1.18E-02 
Bud13 1.098 3.09448 1.65E-02 
Hnrnpdl 1.241 3.03717 1.65E-02 
Hnrnpf 1.131 3.13392 2.20E-02 
Hnrnpc 1.852 3.27773 2.80E-02 
Ddx17 1.013 3.02811 3.24E-02 
Mfap1 2.189 3.34698 3.90E-02 
Pnn 1.029 3.03594 4.23E-02 
Elavl1 1.379 3.27773 5.30E-02 
Syncrip 1.073 3.13392 7.80E-02 
Hnrnpa2b1 1.843 3.27773 9.40E-02 
U2af1 1.464 3.13392 9.50E-02 
Hnrnpk 1.524 3.27773 1.00E-01 
Srsf7 1.305 3.23707 1.00E-01 
Rnps1 1.017 3.09448 1.08E-01 
Hnrnpab 1.264 3.11930 1.23E-01 
Thrap3 1.109 3.13392 1.30E-01 
Znf326 1.245 3.09795 1.32E-01 
Ybx3 1.076 3.13392 1.73E-01 
Taf15 1.877 3.27773 1.80E-01 
Hnrnpa0 1.018 3.02811 1.94E-01 
Pabpn1 1.322 3.11372 1.94E-01 
Zc3h18 1.261 3.04348 2.63E-01 
Fus 1.612 3.17046 3.00E-01 
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Srsf6 1.779 3.27773 3.50E-01 
Hnrnpa1 1.345 3.27773 3.50E-01 
Rbm3 1.165 3.13392 3.60E-01 
Khsrp 1.204 3.11372 4.51E-01 
Srsf4 2.177 3.27773 5.10E-01 
 
9.1.5 Proteome after lincNMR depletion 
Table 19: List of deregulated proteins post lincNMR loss (p < 0.001, data = log2 ratios)  
UniProt Names M/L 
Rep1 
M/L 
Rep2 
M/L 
Rep3 
H/L 
Rep1 
H/L 
Rep2 
H/L 
Rep3 
AVE  
H/L & M/L 
SPDLY_HUMAN -1.048 -1.446 -1.625 -2.133 -2.201 -2.424 -1.813 
CCNB1_HUMAN -1.335 -1.846 -1.533 -1.839 -2.066 -2.227 -1.808 
RIR2_HUMAN -1.295 -1.795 -1.860 -1.331 -1.694 -1.739 -1.619 
TOP2A_HUMAN -1.315 -1.885 -1.762 -1.198 -1.379 -1.343 -1.480 
SHCBP_HUMAN -0.854 -1.127 -1.489 -1.541 -1.655 -1.664 -1.388 
ANLN_HUMAN -0.837 -0.918 -1.290 -1.323 -1.441 -1.510 -1.220 
KIF11_HUMAN -0.798 -1.030 -1.069 -1.214 -1.455 -1.489 -1.176 
KITH_HUMAN -0.884 -1.167 -1.157 -1.167 -1.301 -1.260 -1.156 
KI20A_HUMAN -0.689 -0.902 -1.148 -1.287 -1.337 -1.284 -1.108 
KI67_HUMAN -1.525 -1.261 -1.072 -0.855 -1.027 -0.890 -1.105 
UBE2C_HUMAN -0.710 -0.884 -1.372 -1.024 -1.256 -1.235 -1.080 
CDK2_HUMAN -0.531 -0.926 -1.077 -1.229 -1.161 -1.289 -1.036 
PAI1_HUMAN -0.742 -1.173 -1.108 -0.841 -1.304 -1.032 -1.033 
TYMS_HUMAN -0.593 -0.890 -0.931 -0.971 -1.335 -1.366 -1.014 
FGF2_HUMAN -0.945 -0.904 -0.743 -0.896 -1.046 -1.096 -0.938 
RIF1_HUMAN -0.774 -0.946 -0.771 -0.957 -0.920 -0.973 -0.890 
TPM1_HUMAN -1.030 -0.812 -0.728 -0.900 -0.955 -0.817 -0.874 
IMA1_HUMAN -0.559 -0.781 -0.860 -0.949 -0.969 -0.946 -0.844 
CKS1_HUMAN -0.559 -0.663 -0.623 -1.058 -0.976 -1.047 -0.821 
KIF4A_HUMAN -0.440 -0.633 -0.658 -1.043 -1.000 -1.063 -0.806 
CD123_HUMAN -0.603 -0.732 -0.631 -0.682 -0.891 -1.077 -0.769 
TGFI1_HUMAN -1.099 -0.392 -0.785 -0.621 -0.564 -0.795 -0.709 
FANCI_HUMAN -0.533 -0.544 -0.553 -0.927 -0.866 -0.716 -0.690 
AN32E_HUMAN -0.789 -0.887 -0.816 -0.541 -0.513 -0.482 -0.671 
CCD86_HUMAN -0.521 -0.591 -0.892 -0.300 -0.792 -0.856 -0.659 
NAA40_HUMAN -0.731 -0.659 -0.793 -0.619 -0.461 -0.655 -0.653 
DYR_HUMAN -0.458 -0.441 -0.563 -0.782 -0.723 -0.924 -0.648 
DNMT1_HUMAN -0.696 -0.713 -0.568 -0.665 -0.610 -0.558 -0.635 
APC7_HUMAN -0.630 -0.667 -0.669 -0.920 -0.510 -0.388 -0.630 
BGH3_HUMAN -0.539 -0.380 -0.703 -0.647 -0.537 -0.850 -0.609 
LPP_HUMAN -0.763 -0.704 -0.710 -0.503 -0.390 -0.487 -0.593 
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DUT_HUMAN -0.477 -0.510 -0.542 -0.645 -0.575 -0.671 -0.570 
UFO_HUMAN -0.501 -0.621 -0.513 -0.525 -0.541 -0.661 -0.560 
PPM1B_HUMAN -0.499 -0.421 -0.416 -0.490 -0.556 -0.941 -0.554 
TMM33_HUMAN -0.433 -0.531 -0.522 -0.530 -0.653 -0.580 -0.542 
BAZ1B_HUMAN -0.643 -0.789 -0.450 -0.403 -0.439 -0.302 -0.504 
NOB1_HUMAN -0.382 -0.527 -0.301 -0.564 -0.638 -0.578 -0.498 
TXLNA_HUMAN -0.617 -0.555 -0.607 -0.468 -0.331 -0.354 -0.489 
ABLM1_HUMAN -0.571 -0.655 -0.500 -0.541 -0.350 -0.308 -0.487 
MDN1_HUMAN -0.323 -0.410 -0.406 -0.675 -0.550 -0.527 -0.482 
HN1L_HUMAN -0.537 -0.459 -0.435 -0.581 -0.432 -0.431 -0.479 
SAR1A_HUMAN -0.304 -0.356 -0.467 -0.441 -0.648 -0.632 -0.474 
OGFD1_HUMAN -0.319 -0.410 -0.446 -0.635 -0.443 -0.557 -0.468 
CHD1_HUMAN -0.306 -0.392 -0.517 -0.356 -0.583 -0.653 -0.468 
OAT_HUMAN -0.500 -0.463 -0.379 -0.453 -0.540 -0.450 -0.464 
PA1B2_HUMAN -0.492 -0.586 -0.433 -0.363 -0.572 -0.282 -0.455 
SDCB1_HUMAN -0.339 -0.453 -0.421 -0.476 -0.527 -0.513 -0.454 
CDK1_HUMAN -0.268 -0.334 -0.369 -0.656 -0.583 -0.516 -0.454 
G3BP2_HUMAN -0.344 -0.516 -0.706 -0.315 -0.465 -0.357 -0.450 
WBS22_HUMAN -0.242 -0.405 -0.469 -0.596 -0.494 -0.388 -0.432 
PNO1_HUMAN -0.483 -0.245 -0.483 -0.433 -0.470 -0.464 -0.429 
KIME_HUMAN -0.546 -0.540 -0.369 -0.514 -0.182 -0.411 -0.427 
EIF1_HUMAN -0.238 -0.370 -0.379 -0.461 -0.480 -0.547 -0.412 
CAPR1_HUMAN -0.291 -0.363 -0.390 -0.475 -0.523 -0.393 -0.406 
BZW1_HUMAN -0.278 -0.529 -0.474 -0.319 -0.421 -0.356 -0.396 
STAU1_HUMAN -0.374 -0.507 -0.531 -0.347 -0.254 -0.252 -0.377 
DDX5_HUMAN -0.213 -0.277 -0.387 -0.406 -0.448 -0.515 -0.375 
RCC2_HUMAN -0.185 -0.297 -0.330 -0.513 -0.510 -0.406 -0.374 
UCK2_HUMAN -0.305 -0.426 -0.361 -0.390 -0.402 -0.354 -0.373 
DDX47_HUMAN -0.395 -0.497 -0.514 -0.216 -0.282 -0.327 -0.372 
SMC3_HUMAN -0.231 -0.411 -0.355 -0.400 -0.407 -0.407 -0.369 
LMNB1_HUMAN -0.451 -0.413 -0.417 -0.349 -0.230 -0.314 -0.362 
WBP11_HUMAN -0.402 -0.364 -0.378 -0.317 -0.348 -0.336 -0.358 
ABCF2_HUMAN -0.323 -0.322 -0.441 -0.248 -0.423 -0.372 -0.355 
ANXA1_HUMAN -0.381 -0.322 -0.389 -0.370 -0.353 -0.298 -0.352 
IF4G1_HUMAN -0.473 -0.377 -0.341 -0.278 -0.355 -0.283 -0.351 
IQGA3_HUMAN -0.324 -0.281 -0.401 -0.390 -0.294 -0.403 -0.349 
RAB18_HUMAN -0.333 -0.415 -0.236 -0.372 -0.354 -0.348 -0.343 
HSP13_HUMAN -0.356 -0.306 -0.203 -0.523 -0.255 -0.393 -0.339 
CKAP5_HUMAN -0.361 -0.223 -0.176 -0.423 -0.475 -0.371 -0.338 
DDX3X_HUMAN -0.246 -0.294 -0.249 -0.460 -0.357 -0.365 -0.329 
CERS2_HUMAN -0.203 -0.253 -0.380 -0.420 -0.370 -0.330 -0.326 
IF4A3_HUMAN -0.154 -0.296 -0.244 -0.339 -0.467 -0.413 -0.319 
YBOX1_HUMAN -0.193 -0.276 -0.206 -0.410 -0.444 -0.365 -0.316 
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STAG2_HUMAN -0.251 -0.218 -0.322 -0.367 -0.342 -0.389 -0.315 
LRC40_HUMAN -0.260 -0.294 -0.184 -0.391 -0.273 -0.451 -0.309 
TCTP_HUMAN -0.129 -0.238 -0.316 -0.314 -0.402 -0.362 -0.293 
IPO7_HUMAN -0.234 -0.296 -0.328 -0.236 -0.350 -0.278 -0.287 
PRPS1_HUMAN -0.216 -0.431 -0.351 -0.271 -0.221 -0.214 -0.284 
BUB3_HUMAN -0.263 -0.311 -0.332 -0.220 -0.354 -0.201 -0.280 
SPT5H_HUMAN -0.333 -0.292 -0.281 -0.228 -0.225 -0.321 -0.280 
CHRD1_HUMAN -0.376 -0.236 -0.199 -0.211 -0.283 -0.342 -0.274 
SNW1_HUMAN -0.331 -0.169 -0.337 -0.279 -0.233 -0.276 -0.271 
TM41B_HUMAN -0.398 -0.184 -0.210 -0.188 -0.329 -0.311 -0.270 
RIC8A_HUMAN -0.212 -0.373 -0.348 -0.257 -0.224 -0.180 -0.266 
RAGP1_HUMAN -0.192 -0.290 -0.324 -0.267 -0.221 -0.281 -0.263 
NOG1_HUMAN -0.239 -0.299 -0.176 -0.227 -0.320 -0.304 -0.261 
ORML1_HUMAN -0.394 -0.160 -0.232 -0.211 -0.273 -0.278 -0.258 
TCEA1_HUMAN -0.271 -0.348 -0.278 -0.230 -0.190 -0.223 -0.257 
EIF3F_HUMAN -0.297 -0.214 -0.226 -0.229 -0.244 -0.294 -0.251 
IF4B_HUMAN -0.231 -0.233 -0.238 -0.240 -0.267 -0.284 -0.249 
SMC4_HUMAN -0.226 -0.167 -0.153 -0.245 -0.323 -0.379 -0.249 
PQBP1_HUMAN -0.181 -0.285 -0.156 -0.345 -0.273 -0.245 -0.248 
CBX3_HUMAN -0.234 -0.275 -0.259 -0.187 -0.174 -0.332 -0.244 
PIPNB_HUMAN -0.271 -0.273 -0.212 -0.174 -0.311 -0.215 -0.243 
CTND1_HUMAN -0.379 -0.186 -0.164 -0.168 -0.263 -0.248 -0.235 
IF4A1_HUMAN -0.130 -0.195 -0.194 -0.260 -0.323 -0.251 -0.226 
NP1L1_HUMAN -0.281 -0.258 -0.248 -0.172 -0.165 -0.139 -0.211 
RFC4_HUMAN -0.143 -0.143 -0.211 -0.210 -0.237 -0.282 -0.204 
CAND1_HUMAN -0.189 -0.183 -0.262 -0.162 -0.177 -0.204 -0.196 
ATLA3_HUMAN -0.246 -0.198 -0.240 -0.201 -0.150 -0.134 -0.195 
MCM7_HUMAN -0.110 -0.226 -0.275 -0.193 -0.198 -0.153 -0.192 
SK2L2_HUMAN -0.125 -0.192 -0.184 -0.205 -0.208 -0.236 -0.191 
PABP1_HUMAN -0.166 -0.186 -0.171 -0.194 -0.213 -0.171 -0.183 
RB6I2_HUMAN -0.216 -0.146 -0.249 -0.090 -0.182 -0.190 -0.179 
PCNA_HUMAN -0.109 -0.175 -0.154 -0.262 -0.169 -0.181 -0.175 
SNX12_HUMAN -0.176 -0.074 -0.179 -0.192 -0.229 -0.189 -0.173 
RL10_HUMAN -0.116 -0.140 -0.132 -0.197 -0.208 -0.242 -0.173 
TBB2B_HUMAN -0.213 -0.219 -0.196 -0.169 -0.163 -0.058 -0.170 
LRC59_HUMAN -0.220 -0.109 -0.105 -0.224 -0.183 -0.140 -0.163 
EIF3M_HUMAN -0.189 -0.088 -0.142 -0.134 -0.177 -0.248 -0.163 
RL40_HUMAN -0.133 -0.103 -0.138 -0.226 -0.175 -0.161 -0.156 
MCM3_HUMAN -0.103 -0.149 -0.173 -0.158 -0.136 -0.216 -0.156 
UB2V1_HUMAN -0.221 -0.187 -0.076 -0.139 -0.156 -0.147 -0.155 
FUS_HUMAN -0.172 -0.140 -0.203 -0.096 -0.151 -0.160 -0.154 
MCM6_HUMAN -0.135 -0.227 -0.201 -0.122 -0.089 -0.129 -0.151 
TBB6_HUMAN -0.099 -0.122 -0.121 -0.182 -0.198 -0.173 -0.149 
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MCM4_HUMAN -0.094 -0.195 -0.188 -0.113 -0.109 -0.135 -0.139 
EHD1_HUMAN -0.074 -0.184 -0.153 -0.164 -0.107 -0.143 -0.137 
EIF3E_HUMAN -0.118 -0.076 -0.124 -0.114 -0.214 -0.146 -0.132 
TBCB_HUMAN -0.158 -0.176 -0.101 -0.153 -0.053 -0.124 -0.127 
EF2_HUMAN -0.077 -0.109 -0.117 -0.136 -0.173 -0.115 -0.121 
EMC1_HUMAN -0.100 -0.154 -0.147 -0.065 -0.091 -0.101 -0.110 
SEPT7_HUMAN -0.072 -0.133 -0.102 -0.131 -0.110 -0.102 -0.108 
RSSA_HUMAN -0.066 -0.105 -0.107 -0.153 -0.129 -0.084 -0.107 
PSD11_HUMAN -0.106 -0.076 -0.069 -0.124 -0.139 -0.126 -0.107 
RS3_HUMAN -0.056 -0.096 -0.070 -0.111 -0.146 -0.130 -0.102 
PFKAP_HUMAN -0.025 -0.083 -0.086 -0.071 -0.060 -0.058 -0.064 
HNRC2_HUMAN 0.050 0.060 0.070 0.083 0.078 0.117 0.076 
NEUL_HUMAN 0.072 0.115 0.105 0.049 0.105 0.075 0.087 
MPCP_HUMAN 0.073 0.157 0.098 0.084 0.136 0.067 0.102 
PTBP1_HUMAN 0.074 0.118 0.109 0.105 0.148 0.095 0.108 
SYFA_HUMAN 0.088 0.158 0.095 0.160 0.079 0.128 0.118 
SPTB2_HUMAN 0.172 0.087 0.137 0.085 0.143 0.129 0.126 
PHF5A_HUMAN 0.103 0.127 0.154 0.122 0.128 0.132 0.128 
SNX3_HUMAN 0.109 0.077 0.095 0.172 0.154 0.162 0.128 
PROF1_HUMAN 0.092 0.095 0.150 0.173 0.175 0.146 0.138 
ATPO_HUMAN 0.122 0.114 0.115 0.175 0.246 0.138 0.151 
RU17_HUMAN 0.186 0.116 0.103 0.157 0.154 0.201 0.153 
PARP1_HUMAN 0.146 0.179 0.173 0.144 0.169 0.111 0.154 
ALG5_HUMAN 0.115 0.191 0.127 0.202 0.185 0.108 0.155 
HNRPM_HUMAN 0.196 0.174 0.171 0.142 0.141 0.158 0.164 
KPYM_HUMAN 0.166 0.131 0.103 0.218 0.182 0.185 0.164 
TOP2B_HUMAN 0.077 0.154 0.174 0.188 0.224 0.184 0.167 
PEBP1_HUMAN 0.187 0.227 0.220 0.145 0.071 0.171 0.170 
CAZA2_HUMAN 0.217 0.084 0.179 0.161 0.213 0.170 0.170 
NNRE_HUMAN 0.107 0.229 0.226 0.165 0.138 0.166 0.172 
RADI_HUMAN 0.103 0.136 0.132 0.193 0.224 0.245 0.172 
MOES_HUMAN 0.152 0.222 0.160 0.140 0.207 0.172 0.176 
GSHB_HUMAN 0.169 0.175 0.145 0.221 0.264 0.100 0.179 
VDAC1_HUMAN 0.137 0.222 0.232 0.089 0.203 0.218 0.184 
DHB4_HUMAN 0.109 0.205 0.149 0.176 0.214 0.250 0.184 
XPO7_HUMAN 0.128 0.278 0.226 0.210 0.118 0.173 0.189 
ECHA_HUMAN 0.150 0.161 0.164 0.186 0.230 0.252 0.191 
1433E_HUMAN 0.131 0.238 0.221 0.197 0.200 0.161 0.191 
PGRC1_HUMAN 0.089 0.183 0.208 0.232 0.207 0.237 0.193 
LSM6_HUMAN 0.119 0.201 0.261 0.155 0.174 0.248 0.193 
PTPA_HUMAN 0.116 0.219 0.148 0.297 0.220 0.178 0.196 
M2OM_HUMAN 0.197 0.271 0.214 0.166 0.221 0.113 0.197 
ARF1_HUMAN 0.184 0.206 0.252 0.141 0.225 0.176 0.197 
 108 
 
DIC_HUMAN 0.199 0.218 0.153 0.220 0.154 0.247 0.198 
RB11A_HUMAN 0.110 0.213 0.186 0.261 0.219 0.202 0.199 
ADT1_HUMAN 0.169 0.217 0.244 0.170 0.205 0.193 0.200 
ECHB_HUMAN 0.141 0.173 0.199 0.227 0.210 0.256 0.201 
SYDC_HUMAN 0.146 0.250 0.309 0.138 0.165 0.227 0.206 
TPIS_HUMAN 0.191 0.205 0.211 0.233 0.190 0.210 0.207 
UFC1_HUMAN 0.169 0.158 0.158 0.321 0.262 0.202 0.212 
ACOC_HUMAN 0.151 0.164 0.171 0.252 0.244 0.291 0.212 
AP1B1_HUMAN 0.102 0.203 0.192 0.312 0.265 0.231 0.217 
FUBP2_HUMAN 0.191 0.297 0.229 0.257 0.165 0.167 0.218 
NRBP_HUMAN 0.131 0.176 0.146 0.286 0.272 0.312 0.221 
SUMF2_HUMAN 0.198 0.344 0.152 0.135 0.246 0.259 0.222 
PYGL_HUMAN 0.221 0.133 0.196 0.333 0.195 0.283 0.227 
ILF3_HUMAN 0.137 0.305 0.239 0.241 0.233 0.217 0.229 
PDC6I_HUMAN 0.309 0.205 0.194 0.213 0.244 0.218 0.230 
STOM_HUMAN 0.316 0.191 0.092 0.232 0.298 0.260 0.232 
UCRI_HUMAN 0.106 0.231 0.318 0.283 0.207 0.267 0.236 
QCR7_HUMAN 0.133 0.202 0.266 0.281 0.266 0.268 0.236 
PGM1_HUMAN 0.191 0.286 0.199 0.222 0.233 0.295 0.238 
TM9S3_HUMAN 0.245 0.155 0.396 0.176 0.246 0.286 0.251 
AIFM1_HUMAN 0.178 0.276 0.263 0.343 0.187 0.262 0.251 
CALU_HUMAN 0.181 0.377 0.329 0.186 0.268 0.170 0.252 
MRCKB_HUMAN 0.193 0.335 0.276 0.240 0.196 0.283 0.254 
ECI1_HUMAN 0.118 0.281 0.213 0.315 0.334 0.266 0.255 
HINT1_HUMAN 0.241 0.303 0.333 0.230 0.182 0.240 0.255 
NIPS2_HUMAN 0.210 0.348 0.284 0.327 0.133 0.257 0.260 
GALT2_HUMAN 0.327 0.207 0.264 0.213 0.189 0.380 0.263 
GDIA_HUMAN 0.236 0.350 0.358 0.229 0.221 0.188 0.264 
PLIN3_HUMAN 0.313 0.203 0.197 0.331 0.243 0.301 0.265 
HNRL1_HUMAN 0.163 0.244 0.191 0.355 0.296 0.343 0.265 
1433B_HUMAN 0.151 0.258 0.251 0.302 0.297 0.346 0.268 
FUMH_HUMAN 0.270 0.251 0.289 0.240 0.339 0.219 0.268 
BAF_HUMAN 0.213 0.367 0.372 0.193 0.256 0.214 0.269 
UBA1_HUMAN 0.273 0.259 0.257 0.321 0.271 0.273 0.276 
AN32A_HUMAN 0.174 0.315 0.349 0.153 0.383 0.282 0.276 
FKB1A_HUMAN 0.299 0.296 0.380 0.279 0.234 0.171 0.277 
CHSP1_HUMAN 0.308 0.278 0.137 0.290 0.306 0.343 0.277 
1433G_HUMAN 0.207 0.409 0.284 0.196 0.343 0.248 0.281 
MIF_HUMAN 0.268 0.204 0.245 0.337 0.322 0.317 0.282 
GBB1_HUMAN 0.336 0.380 0.374 0.184 0.176 0.285 0.289 
RT34_HUMAN 0.173 0.335 0.420 0.214 0.279 0.323 0.290 
FLNB_HUMAN 0.115 0.251 0.314 0.381 0.367 0.365 0.299 
NIBL1_HUMAN 0.227 0.389 0.334 0.294 0.265 0.285 0.299 
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RBM14_HUMAN 0.274 0.299 0.376 0.232 0.344 0.309 0.306 
ETFA_HUMAN 0.210 0.455 0.367 0.220 0.301 0.289 0.307 
KAP2_HUMAN 0.268 0.450 0.383 0.226 0.352 0.187 0.311 
ABC3C_HUMAN 0.241 0.250 0.319 0.316 0.345 0.416 0.315 
PHP14_HUMAN 0.322 0.374 0.331 0.291 0.334 0.265 0.319 
PYGB_HUMAN 0.238 0.423 0.469 0.242 0.274 0.294 0.323 
PA1B3_HUMAN 0.217 0.407 0.306 0.312 0.337 0.404 0.330 
THIL_HUMAN 0.212 0.422 0.442 0.273 0.328 0.346 0.337 
TRAP1_HUMAN 0.302 0.488 0.464 0.244 0.281 0.262 0.340 
ITB6_HUMAN 0.216 0.334 0.390 0.313 0.375 0.449 0.346 
DAAF5_HUMAN 0.282 0.266 0.297 0.425 0.363 0.447 0.347 
HXK1_HUMAN 0.396 0.255 0.208 0.502 0.311 0.414 0.348 
RB22A_HUMAN 0.221 0.301 0.287 0.439 0.384 0.498 0.355 
CLIC4_HUMAN 0.163 0.408 0.334 0.375 0.418 0.435 0.356 
ARF4_HUMAN 0.378 0.283 0.308 0.352 0.439 0.402 0.360 
MYO1B_HUMAN 0.380 0.460 0.394 0.366 0.174 0.416 0.365 
ETFB_HUMAN 0.218 0.509 0.496 0.330 0.372 0.281 0.368 
HNRH2_HUMAN 0.384 0.253 0.284 0.462 0.431 0.481 0.382 
RAB5B_HUMAN 0.347 0.361 0.329 0.396 0.487 0.463 0.397 
PREP_HUMAN 0.406 0.330 0.394 0.543 0.285 0.474 0.405 
GNA11_HUMAN 0.329 0.477 0.557 0.230 0.367 0.519 0.413 
AP2A1_HUMAN 0.403 0.256 0.304 0.551 0.501 0.475 0.415 
KCY_HUMAN 0.362 0.499 0.329 0.383 0.552 0.458 0.431 
HCFC1_HUMAN 0.469 0.323 0.402 0.508 0.472 0.615 0.465 
SQRD_HUMAN 0.428 0.653 0.721 0.384 0.340 0.414 0.490 
TERA_HUMAN 0.428 0.514 0.499 0.535 0.524 0.459 0.493 
ERG28_HUMAN 0.233 0.557 0.632 0.467 0.452 0.632 0.496 
SH3G1_HUMAN 0.489 0.700 0.477 0.467 0.596 0.327 0.509 
KATL2_HUMAN 0.387 0.493 0.595 0.496 0.579 0.617 0.528 
DNPH1_HUMAN 0.469 0.568 0.528 0.721 0.482 0.475 0.541 
RFA1_HUMAN 0.600 0.747 0.665 0.395 0.539 0.413 0.560 
KPCA_HUMAN 0.662 0.599 0.477 0.548 0.540 0.631 0.576 
VPS4B_HUMAN 0.453 0.668 0.445 0.699 0.643 0.645 0.592 
RPTOR_HUMAN 0.697 0.818 0.597 0.495 0.546 0.586 0.623 
AL9A1_HUMAN 0.888 0.869 0.855 0.817 0.698 0.689 0.803 
CADM1_HUMAN 0.830 1.124 1.129 0.857 0.836 0.927 0.950 
HKDC1_HUMAN 1.146 1.275 1.158 1.113 0.678 0.796 1.028 
PDCD4_HUMAN 0.906 1.045 1.170 1.235 1.355 1.356 1.178 
SCAM1_HUMAN 1.078 1.341 1.532 1.237 1.300 1.447 1.322 
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